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ABSTRACT
Polymersomes are nano-meter sized vesicles made by the self assembly of am-
phiphilic co-polymers in water. This work presents the development of polymer-
somes as a tool for high resolution in vivo optical imaging. High resolution Intra
Vital Microscopy (IVM) was made possible by the use of the Window Chamber
(WC), a surgical procedure which allows observation of living tissues through an
optically transparent glass replacing a section of skin. WC can be used to observe
tumour growth and tumour vasculature development (angiogenesis). High resolu-
tion imaging of angiogenesis in vivo with polymersomes can give an useful insight
in mechanism of angiogenesis, tumour response to anti-angiogenic therapy and
the rationale behind the design of polymersomes for specific tumour targeting in
therapy.
In this work we optimised a number of techniques and tools to characterise
the interactions of two different polymersome formulation with three cell types
relevant to the tumour microenvironment: tumour cells Mouse Fibrosarcoma Cell
(MFC), endothelial cells Small Vessel Endothelial Cells (SVECs) and perivascular-
like cells 10T1/2. The techniques used included Reverse Phase-High Pressure Liq-
uid Chromatography (RP-HPLC), Fluorescence Activated Cell Sorting (FACS)
and optical imaging. Furthermore, a flow bio-incubator was developed to study
the effect of physiologically relevant flow rates on cellular polymersome uptake.
Finally, formulations were tested in vivo to assess suitability for optical imaging
and polymersomes distribution in tumour vasculature and stroma. Specific image
analysis tool were developed to assist the analysis.
The results demonstrated that polymersomes can be used for optical imaging
in vivo using a WC. The in vitro techniques developed allowed us to quantify the
interactions between polymersomes and cells, and the information gained can be
translated in vivo to help predict the polymersomes distribution in tumour.
Taken together, the methods and results presented here provide a set of tools
based on image analysis that allow rational design of polymersomes for in vivo
application.
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CHAPTER 1
INTRODUCTION
1.1 Cancer. General characteristics
The term tumour describes a group of cells with abnormal and uncontrolled
growth. As a tumour grows in size it compresses the surrounding normal tissue,
but is localised to a specific area of the body at this stage. Once the tumour
induces a vasculature it has the potential to escape the primary site and to induce
secondary tumours.
Cancer is a high incidence disease which is characterised by high mortality:
cancer was the second highest cause of death in UK in 2011 and it is estimated
that one in three people will develop cancer at some time in their life (Sasieni
et al. [2011]) (fig. 1.1). Furthermore, cancer accounted for the third highest ex-
penditure by the NHS after mental disorders and cardiovascular diseases, totalling
around £5.93bn, and the cost of cancer is estimated to raise to £15.3bn by 2021
(BUPA 2012 report). Thus, providing justification for additional research focus-
ing on molecular, cellular and functional aspects to identify prognostic markers
and effective treatment.
There are more than 200 different types of cancer, with names and character-
istics reflecting specific localisation (i.e. glioblastoma, fibrosarcoma, melanoma,
breast cancer etc.). Despite differences in tumour localisation and cell mutations
there are morphological features common to almost all of the tumours. A solid
tumour is characterised by the initial onset of cancer cells, defined as mutated
cells, which grow and divide in an unregulated manner. Normal apoptotic mech-
anisms are not functional. The tumour microenvironment also consists of stroma
cells including fibroblasts, immune cells, endothelial cells, and specialised mes-
enchymal cells, all playing an important role in the development of the primary
tumour (Bremnes et al. [2011], Weinberg [2013]). Finally, tumours present a
1
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Figure 1.1: Causes of death in 2011 and cancer incidence in 2010. Both data sets
are from the UK, from NHS and CRUK respectively. Data set accessed in August
2013.
necrotic, hypoxic central region and are characterised by chaotic and unstable
immature vasculature which results in continuous remodelling of the capillary
bed in a process called angiogenesis.
1.2 Angiogenesis
1.2.1 Blood vessel anatomy
Blood has an essential role in the homoeostasis of our body as it distributes
nutrients, oxygen, hormones and a number of other substances to every cell.
Furthermore, blood collects metabolic waste such as carbon dioxide and other
small substances and carries them to specialised organs (lungs, liver, kidney) for
elimination. The exchange between nutrients and oxygen and waste occurs in the
microcirculation, where the arterial system branches into smaller arterioles and
finally capillaries ('8µm diameter). The capillary bed has a much greater cross-
section surface area and the blood flow is much slower when compared to bigger
vessels (fig. 1.2). This facilitates the exchange of gases and nutrients between
blood and extracellular matrix of the tissue fed by the capillaries.
The driving motor of the circulatory system is the heart. Major arteries and
veins leave the heart and branch into smaller vessels and capillaries. Capillar-
ies then rejoin into venules and veins. Main blood vessels and first branches are
composed of three layers: tunica intima, tunica media and tunica adventitia, from
the lumen to the outside. The tunica intima is composed of a layer of endothe-
lial cells, the tunica media consists of elastic fibres and Vascular Smooth Muscle
cells (vSMCs), especially in arteries. The tunica adventitia consists of connective
tissue. Progressively smaller vessels have a much thinner wall and they are com-
posed of a layer of endothelial cells surrounded by a basal lamina, supported by
2
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a few perivascular cells. Capillaries in the brain, striated and smooth muscles,
lung and connective tissues are known as continuous capillaries as they have no
fenestration: endothelial cells form an uninterrupted wall. Other tissues such as
kidneys, pancreas and endocrine glands have fenestrated capillaries with gaps of
around 50nm-100nm. The gaps are covered with a matrix of unknown molecular
composition that regulates substances trafficking (Standring [2008]).
Figure 1.2: Properties of the vascular system with respect to size. Capillaries
have a higher surface area (green line) and lower flow velocity and pressure (red
line) than arterioles and venules.
1.2.2 Mechanisms of angiogenesis
The capillary system is mainly formed de novo during the embryogenesis by
a process known as vasculogenesis. The body has the ability to form specialised
capillaries in different organs: capillaries in the liver are fenestrated and form a
filtration system, in lungs sacks are formed to facilitate gas exchange. In adult life
the formation of new blood vessels is limited to specific physiological situations
such as menstrual cycle and wound healing. In addition, new capillaries are
formed to meet specific requirements: for example, it has been reported that
endurance athletes skeletal muscles have a more developed capillary bed compared
to sedentary people (Carrow et al. [1967], Adolfsson et al. [1981], Coggan et al.
[1992], Gielen et al. [2010]). In the human adult, new blood vessels are formed
from pre-existing ones by a process known as angiogenesis. The ability to control
vascular density based on supply/demand and the restoration of damaged vessels
is the result of a delicate balance of factors promoting (pro-angiogenic factors) and
inhibiting (anti-angiogenic factors) the formation of new blood vessels. Table 1.1
provides an overview of the factors involved in angiogenesis. Angiogenesis must
be balanced to maintain homoeostasis. A number of pathologies are associated
with unbalanced angiogenesis (see figure 1.3), either as the primary cause or as
a consequence and hallmark of the disease (fig. 1.3).
3
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Figure 1.3: Pathologies associated with unbalanced angiogenesis.
Anti-angiogenic factors Pro-angiogenic factors
TSP-1 VEGF
Angiostatin PIGF
Endostatin FGF
Tumstatin PDGF
Interferon EGF
Integrins MMP
TIMP Low pH and hypoxia
Angiopoietin
bFGF
Table 1.1: Pro- and anti-angiogenic factors. Adapted from Folkman and Kalluri
[2004].
Angiogenesis normally occurs in wound healing and menstrual cycle in re-
4
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sponse to local damage of the pre-existing vasculature. When a vessel lesion
occurs one of the first consequences is decreased oxygenation to the affected area;
this is known as hypoxia (pO2 between 5 and 10 mmHg, concentration 0.1-3%)
and is one of the initiators of angiogenesis (Moeller et al. [2004]). To form new
vessels (a) the pre-existing ones are disrupted, (b) the extracellular matrix is de-
graded, (c) endothelial and perivascular cells migrate in the direction of the new
vessels growth and finally (d) the newly formed vasculature is stabilised (Harris
[2002]). Vessel destabilisation results from the loss of cell-cell contact between en-
dothelial cells and also with perivascular cells. In response to hypoxia local NOs
concentration increases transcription of Hypoxia-inducible Factor-1α (HIF-1α)
and this up-regulates Vascular Endothelial Growth Factor (VEGF) production
by tumour (Liby et al. [2012]) and perivascular cells (Pinto et al. [2010]). VEGF
is a potent pro-angiogenic factor that was first identified by Senger in 1983 and
initially called Vascular Permeability Factor (VPF) (Senger et al. [1983]).
VEGF promotes the secretion of angiopoietin 2 from endothelial cells. An-
giopoietin 2 is an inhibitor of angiopoietin 1, which stabilises cell-cell contact
(Fagiani and Christofori [2013]). Angiopoietin 2 and VEGF, combined with
an increased expression of metalloproteases degrading the Extracellular Matrix
(ECM), promote vessels instability and increased tissue permeability(Jain [2003]).
Once pre-existing vessels are degraded and the extracellular matrix becomes less
dense, endothelial cells commence proliferation and migration in the direction of
the new vessel sprout. The migration follows a leading endothelial cell called tip
cell and is stimulated by VEGF, Fibroblast Growth Factor (FGF) and αvβ3 inte-
grins gradients (Cai et al. [2006], Monti et al. [2013], Sato et al. [2012]). Finally
the angiogenic process is switched off by the formation of tubular structures
(vessels) and cell-cell interactions, particulary endothelial cell-pericyte interac-
tions, promoted by Platelet Derived Growth Factor (PDGF) and angiopoietin 1.
Pericytes are recruited by endothelial cells secreting PDGF, angiopoietin 1 and
Transforming Growth Factor-β1 (TGF-β1) (Hellstroem et al. [1999]). Vessel sta-
bilisation is regulated by FGF, VE-cadherin, PDGF, TGF-β1 and angiopoietin 1
(Ramsauer and D’Amore [2007], Zhang et al. [2009]). Non functional vessels are
disrupted and removed in the final remodelling of the new vasculature (Ichioka
et al. [1997]).
1.2.3 Tumour angiogenesis
When angiogenesis is not initiated, tumours remain vital but do not exceed
'1mm3. When angiogenesis is initiated, tumour growth becomes exponential
(Folkman [1971]). Small, dormant in situ tumours form frequently, but do not
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evolve to invasive cancer. This concept was suggested by Folkman in 1989 and is
known as cancer without a disease. It defined angiogenesis as a hallmark for can-
cer (Folkman et al. [1989]). When the tumour grows, its centre becomes hypoxic.
Hypoxia is a major switch of tumour angiogenesis as it promotes the secretion of
angiopoietin 2 and VEGF with exactly the same mechanisms described in physi-
ological angiogenesis. It has been observed that both tumours and normal tissues
exhibit similar angiogenic mechanisms, with the crucial difference being that tu-
mours inhibit the switch off signal, maintaining the vasculature in an active state
of constant remodelling, without final maturation. This allows exponential tu-
mour growth well beyond the limit of '1mm3 reported for non vascular tumours.
Finally, cancer cells can escape the primary tumour site, enter the blood system
and colonise other tissues to establish secondary tumour. This process is known
as metastasis and it is associated with a poor prognosis (Riihimaki et al. [2013]).
1.2.4 Tumour vasculature and tumour microenvironment
Tumour vasculature
Tumour vasculature is immature and unstable. There is no well defined arteri-
oles/capillaries/venules hierarchy. Vessels are tortuous and with a heterogeneous
diameter and some are blind ended. Finally, since the vasculature is not mature,
large fenestrations (up to micrometers) exist between endothelial cells and there
is no or minimal pericytes coverage (Diaz-Flores et al. [1992]). As a result of the
large fenestrations the tumour vasculature is more leaky than normal vasculature,
a key feature in both the primary and metastatic stages of the disease. In ad-
dition, the lymphatic drainage is compromised (Matsumura and Maeda [1986]),
resulting in increased hydrostatic pressure within the tumour. The combination
of leaky vasculature and reduced lymphatic drainage produces Enhanced Perme-
ation and Retention (EPR) and is of great importance in tumour targeting. EPR
effect will be discussed in further detail in section 1.4.2.
Tumour microenvironment
The tumour microenvironment consists of the ECM, chemical factors and
a variety of cell sub-types. These include fibroblast, endothelial cells, perivas-
cular cells and immune cells which are normal cells but contribute to tumour
growth. The region around the tumour is characterised by inflammation, which
supports angiogenesis as it has been observed in wounds. This similarity be-
tween tumours and wound resulted in the definition of cancer as a wound that
does not heal (Dvorak [1986]). Fibroblasts in tumours are more specifically
named Cancer Associated Fibroblast (CAF) to distinguish them from normal
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fibroblasts. CAF are derived from normal fibroblasts, pericytes, Mesenchymal
Stem Cells (MSC), endothelial cells or epithelial cell via a transformation process
(Endothelial-Mesenchymal Transition (EndT) and Epithelial-Mesenchymal Tran-
sition (EMT) respectively) and are often myofibroblast with increased smooth
muscle actin (Fuyuhiro et al. [2011]). CAF actively contribute to angiogenesis by
secreting VEGF, PDGF andTGF-β1, all pro-angiogenic factors (see section 1.2.2-
1.2.3) (Raesanen and Vaheri [2010], Marsh et al. [2013]). Immune cells such as
Tumour Associated Macrophages (TAM) and Tumour Infiltrated Lymphocytes
(TIL) are also present in the tumour microenvironment, exhibiting reduced cyto-
toxic activity compared to their normal counterparts. The reduction of cytotoxic
activity appears to be mediated by the cancer cells (Qian and Pollard [2010],
Valenti et al. [2007]).
1.2.5 Angiogenesis as a target in cancer therapy
Angiogenesis is a hallmark of cancer. It has been highlighted how cancer
growth and survival is dependant on angiogenesis (section 1.2.3). The combi-
nation of these two factors makes tumour angiogenesis an attractive target in
cancer therapy. There are several anti-angiogenic compounds already approved
by the Food and Drugs Administration (FDA) or in clinical trial, including Beva-
cizumab, Pegaptanib (Vascular Endothelial Growth Factor Receptor (VEGFR)),
Cetuximab (Epidermal Growth Factor Receptor (EGFR)). The aim of vascular
targeted therapy is to starve tumours by interfering with the disease vascularisa-
tion. It has also been proved that traditional chemotherapeutic agents are more
effective when combined with anti-vascular agents (Ma and Waxman [2008]). The
vasculature can be compromised either by inhibiting the formation of new vessels
(anti-angiogenesis therapy) or by disrupting existing vessels (Vascular Disrupting
Agent (VDA)-based therapy).
Anti-angiognesis. The concept of anti-angiogenesis was first introduced by
Folkman in 1971 (Folkman [1971]). Perhaps the most studied anti-angiogenic tar-
get is VEGF. Initially named as VPF by Senger and co-workers in 1983 (Senger
et al. [1983]), and later renamed VEGF by Leung who also attributed angiogenic
properties to the molecule (Leung et al. [1989]). VEGF is one of the most po-
tent pro-angiogenic factors. Inhibition of VEGF results in reduced new blood
vessel formation and tumour stabilisation or regression. Vessel stabilisation has
been reported to improve drug biodistribution to the tumour in a synergistic ef-
fect of the antiangiogenesis and chemotherapy combination. Another target for
anti-angiogenesis are pericytes, a perivascular cell population controlling vessel
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stability. The rationale being that tumours having lower pericyte coverage are
more sensitive to drugs targeting the endothelial cells, such as anti-VEGF drugs
(Benjamin et al. [1998], Erber et al. [2004]). However this approach has failed
in clinical studies because of toxicity (Hainsworth et al. [2007]). An alternative
pericyte-targeted approach was proposed by Raza and colleagues, using a pro-
pericyte strategy which could be beneficial. By stimulating pericyte recruitment
blood vessels will be stabilised and new angiogenic sprouting inhibited. This
could also limit metastasis by reducing the leakiness of the vasculature (Raza
et al. [2010]).
VDAs target the differences between the tumour and normal vasculature, such
as increased fragility, proliferation and protein up-regulation. Several VDAs are
in clinical trials, including for instance combretastatin (Thorpe [2004]). Combre-
tastatin’s effect is dependent on tumour type and pericyte coverage, suggesting
again the importance of pericytes as an additional potential target in vascular
therapy. Pericyte-rich tumour models such as implanted Mouse Fibrosarcoma
Cells expressing VEGF188 isoform (MFC188) have a greater response to com-
bretastatin compared to tumours with lower pericyte coverage such as Mouse
Fibrosarcoma Cells expressing VEGF120 isoform (MFC120) (Tozer et al. [2008]).
Despite it being more than 80 years since Folkman’s anti-angiogenesis hypoth-
esis, more than 25 years since the discovery of VEGF as an anti-angiogenic target
and almost 10 years since the approval of the first anti-angiogenic drug there is
only a small amount of studies demonstrating clinical efficacy of anti-angiogenesis
therapies, even in combination with traditional chemotherapy. Progression free
survival is improved but this is not always the case for overall survival. At
the time of its approval, overall survival for the VEGF signalling inhibitor Be-
vacizumab was reported to be increased from 15 to 20 months (Hurwitz et al.
[2004]), but later trials failed to reproduce these results (Bellou et al. [2013]). The
poor outcome of anti-angiogenic therapy are likely to be due to multiple causes:
a) Endothelial cells from different tissues have a different phenotype and there-
fore are likely to have a differentiated response (Hida et al. [2004]); b) Resistance
to VEGF signalling inhibition has been reported (Bellou et al. [2013]); c) The
angiogenesis pathway has demonstrated redundancy: the inhibition of one factor
or pathway results in the increased secretion of another factor. For instance it has
been reported that VEGF inhibition can result in increased Epidermal Growth
Factor (EGF) and FGF production (Grothey et al. [2008], Batchelor et al. [2007]);
d) Vascular disruption can lead to metastatic tumours (Ebos et al. [2009], Paez-
Ribes et al. [2009]). Overall, there is no clear understanding of which patients will
benefit from anti-angiogenic therapies due to difficulties assessing the correlation
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between drugs and their effect (Ribatti [2010]). Pericytes are undoubtedly in-
volved in the response to anti-angiogenic therapies, however their role is not well
understood. As pericytes may protect endothelial cells from anti-VEGF therapy
a combination of anti-VEGF and Platelet Derived Growth Factor-B (PDGF-B)
therapy have been tested with contrasting outcomes. Some studies supported the
validity of a combined approach (Bergers et al. [2003], Erber et al. [2004]), while
in other models there was no response, or toxic side-effects were reported (Kuhn-
ert et al. [2008]). In another study using a pericyte-deficient mouse no difference
in anti-VEGF therapy response was observed when compared to that of normal
mouse, suggesting that the therapy may not be specific to the tyrosine-kinase
receptors, but may interfere with other pathways (Nisancioglu et al. [2010]).
1.3 Imaging techniques
Imaging techniques are an essential tool in research as they provide data from
direct observation of biological events. In cancer research, imaging has several
applications, including a) diagnosis, b) understanding of the mechanism of evolu-
tion and spreading and c) evaluation of treatment outcome. Techniques such as
X-ray, Positron Emission Tomography (PET) and Magnetic Resonance Imaging
(MRI) are used in clinical practice to localise cancer and evaluate size and even-
tually metastasis. MRI can also be used to obtain functional information relating
to blood flow and permeability of the tumour vasculature (Gaustad et al. [2008]).
In pre-clinical research, optical imaging techniques based on fluorescence and bio-
luminescence can be used to investigate phenomena at the cellular and molecular
level. The following sections review imaging techniques, their limitations and
strategies to overcome these limitations.
1.3.1 Techniques and limitations: an overview
There are a number of different available imaging techniques. Not all of them
can be applied to any problem, the appropriate technique should be chosen ac-
cordingly to the aim of the study. For example, Transmission Electron Microscopy
(TEM) can be used to investigate sub-cellular organelles with nanometre spatial
resolution in fixed samples, but cannot visualise the distribution of a radio ther-
apeutic agent in an animal.
The best imaging technique for a specific study should be chosen consider-
ing spatial resolution, time resolution, tissue penetration and cost. For a given
application, the ideal imaging technique should have enough spatial resolution
to visualise the structure of interest, enough tissue penetration to visualise such
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structure wherever it may be located within the body, and finally it should have
good time resolution to image events at the time scale desired. Techniques such
as X-ray, MRI, Computed Tomography (CT), PET and ultrasounds are com-
monly used to detect tumours and assess morphological properties such as size
and presence of metastasis (McDonald and Choyke [2003]). Since the original ap-
plication of the techniques, spatial resolution has been greatly improved. Micro-
and nano- bubbles improved spatial resolution of ultrasound from millimetres
to micrometers (Lindner [2004], Yin et al. [2012]). Similar improvements have
been achieved for MRI, by refining imaging acquisition and processing technique
(Brindle [2008]). Thanks to such improvements it is possible to obtain more de-
tailed functional information from MRI. As an example, Brindle and co-workers
were able to detect cell death in a tumour by specifically targeting the delivery of
the contrast agent gadolinium to apoptotic cancer cells (Krishnan et al. [2008]).
Others applications include detection of tumour hypoxia, blood volume and vas-
culature permeability (Pacheco-Torres et al. [2011], Roberts et al. [2000], Cha
et al. [2000], Law et al. [2004]).
Optical imaging such as confocal imaging offers great spatial resolution. In
angiogenesis imaging, wide field analysis allows visualisation and quantification
of morphological parameters such as tortuosity and Micro Vessel Density (MVD),
both important parameters correlated to tumour severity. Improved spatial res-
olution and 3D mapping are possible with Confocal Laser Scanning Microscopy
(CLSM), where the use of a pinhole allows elimination of out of focus light, im-
proving signal to noise ratio. When the focus plane is moved through the specimen
a 3D image can be reconstructed (Pawley [2006]). In Multi Photon Microscopy
(MPM), fluorescence is generated when two or more photons with total energy
equal to the one required by single photon fluorescence excitation are adsorbed
by the fluorophore at the same time. This is an unlikely statistical event to occur,
therefore the beam of light must be highly focused. As a result, only a restricted
plane of focus is generated and no pinhole is required to eliminate out of focus
light (Denk et al. [1990]). The main advantages of MPM over CLSM are greater
tissue penetration (from '60µm of CLSM to a few hundreds of micrometers) and
reduced photobleaching and phototoxicity (Lunt et al. [2010]). Despite MPM
being achieved with any number of photons, in practical applications MPM is in
fact dual-photon. However, recently a tri-photon application has been reported
to achieve great spatial resolution and tissue penetration in a mouse brain model
(Horton et al. [2013], Howard et al. [2013]). Spatial resolution can be further
increased using techniques such as Stochastic Optical Reconstruction Microscopy
(STORM) and Stimulated Emission Depletion (STED) (Denk and Webb [1990],
Hell and Wichmann [1994], Rust et al. [2006]) in Intra Vital Microscopy (IVM).
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Technique
Tissue
Resolution
Acquisition
penetration time
Intravital microscopy 400-800µm 1µm Seconds
Bioluminescence Imaging cm mm Minutes
FMT <10cm 1mm Minutes
PET No limit 1mm Minutes
Ultrasound cm 50µm Seconds
CT No limit 50µm Minutes
MRI No limit 10-100µm Minutes
Table 1.2: Imaging techniques comparison by spatial and time resolution and
tissue penetration. Data from Weissleder and Pittet [2008].
In traditional optical imaging spatial resolution is estimated with the Abbe equa-
tion for the diffraction limit D = λ/2 ·NA where D is the diffraction limit, λ is
the wavelength used and NA is the objective numerical aperture. STORM and
STED microscopy bypass the diffraction limit and structures 10nm apart can
be resolved. Despite achieving remarkable progress in tissue penetration, optical
imaging in vivo without further modification can only be applied to study an-
giogenesis in the retina, where the eye provides a natural transparent window to
access the specimen (Wright et al. [2012]).
1.4 Nanocarriers
1.4.1 Background
Cancer targeting for therapy or imaging requires specific extravasation which
is controlled by the size of the vessel fenestration. Moreover, especially in therapy,
some of the most potent drugs are poorly water soluble and have severe side
effects. The combination of the these problems (targeting, solubility, side effects)
has lead to the development of nanometre sized carriers.
1.4.2 Targeting tumour with nanocarriers: basic princi-
ples
To take full advantage of any imaging technique or cancer therapy based on
nanocarriers, it is critical to maximise the delivery of contrast agents or drugs to
the tumour site, while minimising distribution to other organs. This operation
is known as targeting. In cancer applications, targeting can be divided into two
subsequent mechanisms: passive targeting and active targeting. Passive targeting
takes advantage of the irregular anatomy of the tumour micro-vasculature, while
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active targeting requires specific nanocarrier/cell recognition within the tumour
microenvironment.
Passive targeting
Tumour microvascular anatomy has been described previously (sect. 1.2.4).
Tumour blood vessels have fenestrations up to micrometres, while healthy tissue
vasculature has no or little fenestration, with the exception of specialised struc-
tures such as hepatic sinusoids where fenestration as large as 150nm have been
described. Tumour vasculature fenestrations lead to increase vascular leakiness.
Moreover lymphatic drainage is compromised. The sum of the two factors is
known as the EPR effect and it was first described by Maeda (Matsumura and
Maeda [1986]). The EPR effect represented a revolution in tumour therapy and
cancer targeting Delivery agents have been engineered to effectively extravasate
into tumours. Using the same mechanisms imaging techniques have been im-
proved too. For instance MRI imaging of tumour is enhanced by contrast agent
extravasation and accumulation (i.e. gadolinium) and ultrasound imaging can be
enhanced by the accumulation of nanobubbles (Xing et al. [2010]). Unfortunately,
increased leakiness and reduced lymphatic drainage cause increased hydrostatic
pressure. When intra tumour pressure is higher than intra-capillary pressure,
gradient driven diffusion of molecules from the vasculature to the tumour is re-
duced. In this case diffusion is dependent only on the concentration gradient and
the diffusion coefficient, which is inversely correlated to the radius according to
the Stokes-Einstein equation D = kbT
6piηR
, where kb is the Boltzmann’s constant,
T is the temperature, η is the viscosity and R is the particle radius. Diffusion
is a slower process compared to convection. However, since the first description
of EPR almost 25 years ago, countless of proofs have been collected in favour of
particle accumulation in tumours due to such effect. Delivery systems exploiting
the EPR effect include a huge heterogeneity of chemistries, ranging from quan-
tum dots to liposomes, bioconjugates, micelles and polymersomes (Moghimi et al.
[2001]). In imaging, passive targeting is useful to reveal the presence of tumour
mass. For techniques aiming at higher spatial resolution passive targeting is not
enough and specific tumour features should be targeted. This second level of
targeting is known as active targeting.
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Figure 1.4: EPR effect. Tumours blood vessels are characterised by large fenestra-
tion that allows nano-particles to extravasate. Furthermore, lymphatic drainage
is reduced therefore nano-particles are not rapidly cleared by the interstitial cel-
lular flow. In normal tissues there are no or smaller fenestrations, therefore
nano-particles will not extravasate.
Active Targeting
By the EPR effect nano-metre sized particles can passively accumulate within
tumours. When a therapeutic or imaging agent is delivered specifically to the cell
of interest within the tumour the term active targeting is used. Active targeting
of nanocarriers is achieved by functionalisation with moieties that can recognise
specifically a cell type. Active targeting has been extensively researched in ther-
apy (see Moghimi et al. [2001] for an extensive review). Limiting the subject to
imaging, as more relevant to the work presented in this thesis, the most remark-
able achievements have been reported when active targeting is coupled to high
resolution optical imaging such as CLSM or MPM. An extensive review of nano-
carriers and different targets can be found at (Brannon-Peppas and Blanchette
[2012]).
1.4.3 Nanocarriers pharmacokinetics
The body is highly compartmentalised: organs are confined and separated
from each others, normally communicating via the circulatory system. Compart-
mentalisation is found also at the cellular level, where different organelles are
separated from each others by lipidic membranes. Nanocarriers in vivo will have
to travel through a number of different barriers in order to reach the desired site
of accumulation. The number and type of barriers depends on both the adminis-
tration site and the localisation of the target. The fate of any molecule or carrier
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in the body is traditionally studied in terms of the Administration, Distribution,
Metabolism, Excretion (ADME) profile.
Nanocarriers administration Typical administration routes are Intra Mus-
cular (i.m.), Intra Peritoneal (i.p.), Intra Venous (i.v.) and Sub Cutaneous (s.c.).
i.m., i.p. or topical administration are useful in local delivery. However, i.v.
administration is more common and it is referred to as systemic administration,
as the injected substances will be spread to the whole body via the circulatory
system. Local delivery is useful to maximise the concentration of the delivered
agent at the delivered site, and normally release from cargo is slow and sustained,
compared for instance to systemic delivery where nanocarrieres are challenged by
the Reticuloendothelial System (RES) which can quickly clear them from the
circulation. The term RES or the equivalent Mononuclear Phagocyte System
(MPS) refers to phagocytic cells which are part of the immune system. These
include macrophages and monocytes, but also hepatic Kupffer cells. Therefore,
the RES represents the first barrier that must be overcome to avoid fast blood
clearance of nanocarriers.
Nanocarriers distribution Nanocarriers delivered systemically will circulate
in the blood and distribute to different organs. The profile of distribution is dic-
tated by their size, shape, and charge. Most of the polymeric nanocarriers are
cleared by the RES (also referred to as MPS) after opsonisation. Opsonisation
is the recognition by a group of plasma protein known as opsonin which includes
specific immunoglobulins and complement proteins. Opsonisation is a fast pro-
cess: it only take seconds. Opsonised nanocarriers are recognised by phagocytic
cells and accumulate in liver and spleen, but also lung and kidney. The ideal
nanocarrier size for tumour accumulation and MPS is below 100nm (Alexis et al.
[2008], Perrault et al. [2009], Petros and DeSimone [2010]). Nanocarrier shape
also affect clearance. It has been reported that tubular micelles exhibit bet-
ter pharmacokinetic profile than spherical vesicles, probably because elongated
shapes are easily up-taken by phagocytic cells (Geng et al. [2007]).
Chemical composition of the nanocarrier is important because it affects recog-
nition by MPS. For this reason many formulations have a protective brush of
Polyethylene Oxide (PEO). Another strategy to prolong particle half life is coat-
ing with molecules recognised as self by the MPS. An example has been reported
by Discher and co-workers when they coat microbeads with CD47, a marker of
self normally found on the surface of red blood cells (Tsai and Discher [2008]).
At the tumour site, nanocarriers will need to leave the blood stream to enter
the tumour and release their cargo. Size is critical in the extravasation step.
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Nanocarriers should have smaller size than the pore size cut-off of vascular fenes-
tration in tumour sites, but bigger than fenestrations in normal tissues. Diffusion
from the vessels to the tumour is inversely correlated with particle radius (Dreher
et al. [2006]). Charge is also a critical factor in diffusion. Cationic particles diffuse
faster and further than neutral or anionic counterparts (Dellian et al. [2000]). Fi-
nally, using beads functionalised with quantum dots and targeted to HER2, Tada
and co-workers were able to visualise accumulation of the beads in the target cells
and by tracking their trajectories they extrapolate extravasation kinetic param-
eters, including an average travelling speed of 1-4µm/s, characterised by a stop-
and-go movement most likely caused by a cage effect of the dense extracellular
matrix (Tada et al. [2007]).
At the tumour site, nanocarriers release their cargo either extra-cellularly or
intra-cellularly. Extra-cellular release can be achieved by exploiting tumour mi-
croenvironment specific features such as low pH ('6) or high temperature (Kratz
et al. [2008]). Cellular up-take mechanisms can occur by phagocytosis only in a
few specialised cells. The most common mechanisms of up-take include pinocy-
tosis and endocytosis, mediated or not by receptor-ligand interactions. For an
extensive review on nanocarriers endocytosis see Canton and Battaglia [2012].
As biodistribution, cellular uptake is controlled by size, shape, chemical prop-
erties and topology of the vesicles, however in some cases ideal biodistribution
parameters do not match ideal cellular uptake conditions. For instance, cellular
uptake is higher for positively charged nanocarriers because of the interactions
with the negatively charged proteoglycans expressed at cellular surface. Unfor-
tunately this is also true for the cells of the MPS, therefore positively charged
particles have poor biodistribution. Considering nanocarriers size, it is interest-
ing to notice that the same size that in flow escape the MPS (radius6100nm) is
also a good size for cellular uptake: smaller particles are up-taken faster in static
in vitro endocytosis assays which can resemble to a condition of very low flow at
the tumour level. In more detail, cellular uptake requires the cellular membrane
to bend to engulf around the nanocarriers. This process requires energy and
there is a theoretical minimum radius that particles should possess to facilitate
the process : Rmin =
√
2·k·A
E·kB ·T where k is the membrane bending modulus, A is
the membrane surface area, E is the binding energy (e.g. chemical energy per
ligand-receptor pair), kB is the Boltzmann constant, and T is the temperature
(Chaudhuri et al. [2011]). Finally, nanocarriers topology affects cellular uptake.
In polymeric vesicles it has been found that mixtures of different co-polymers
creates domains in the nanocarriers membrane and brush. Such domains affects
kinetics uptake (Massignani et al. [2009], LoPresti et al. [2011]).
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Nanocarriers metabolism Metabolism depends on the nanocarrier chemistry
and size. For polymeric vectors, biodegradable polymers can be broken down and
the monomer can be recycled in the body’s metabolic pathways or eliminated by
the kidney or the GI (Mehvar [2000]). Small non biodegradable polymers are se-
creted by the kidney, provided they are below the glomerular threshold. Glomeru-
lar threshold for PEO has been measured to be 30KDa ('680 monomers) with
elimination rate inversely correlated to molecular weight (Webster et al. [2007]).
If the co-polymer is non biodegradable and below the glomerular threshold it may
be secreted with the faeces, however accumulation in the body is a concern and
more studies are required to elucidate the fate of polymers, especially concerning
chronic administration and renal or liver accumulation.
1.4.4 Nanocarriers self-assembly
Nanocarriers can be made by a number of different chemicals, ranging from
lipids to polymers to metals. An important classification can be made on the basis
of the type of interaction between the components. Systems such as silica beads,
quantum-dots, carbon nanotubes and dendrimers are all characterised by strong
covalent bonds between the components. Another class of nanocarriers is char-
acterised by weak interaction between the components based on supramolecular
forces, such as the hydrophobic effect, hydrogen bonding, coulomb interaction
and aromatic forces. Micelles, liposomes and polymersomes belong to this second
class. A key difference between the two classes is represented by the synthetic
process. Strong bonds are usually generated via chemical synthesis, while weak
interactions mimic self assembly of natural components in water, such as biolog-
ical membranes, proteins and nucleic acids.
Self-assembly processes involve the aggregation of molecules to form defined
structures. As a general rule, this process is concentration dependant, where at
low concentrations, the different building blocks are molecularly dissolved and as
the concentration increases, they start to interact and self-assemble. This concen-
tration is known as Critical Aggregation Concentration (CAC). Self-assembly can
be triggered by several supramolecular interactions that depend on the chemical
structure of the components of the carrier and the solvent. Amphiphilic molecules
contain a part that is able to interact with water molecules hence is water soluble
and a part that are is water repellent and hence is insoluble. The balance between
water attracting and water repelling parts will dictate the final structures formed
and it is known as packing factor, p, defined as
p =
v
a0 · d
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where v is the volume occupied by the packed hydrophobic block, a0 is the
surface area per molecule defined at the hydrophobic chain-water interface, and
d is the length of the hydrophobic block (Nagarajan [2002]). Amphiphilies with
packing factor smaller than 1
3
will generate spheres (micelles), if p is between 1
3
and
1
2
cylindrical micelles will be obtained and finally if the packing factor is between 1
2
and 1, bilayers (vesicles) will be formed (fig. 1.5) (Bates and Fredrickson [1990],
Matsen and Bates [1996b], Matsen and Bates [1996a], Fredrickson and Bates
[1996]).
Figure 1.5: Geometrical parameters governing the self-assembly. If the packing
factor p is higher than 1
2
the co-polymers self assemble in bi-layer, if p is between
1
3
and 1
2
the resulting geometry will be tubular micelles, if p is lower than 1
3
the
favoured shape is spherical micelle.
A common example of self-assembled nanocarriers is the liposome. Such
spherical vesicles are made by phospholipids. Phospholipids arrange in water
in a way that the hydrophobic tails are packed together excluding water, while
the polar heads are at the interface between the water and the hydrophobic tails.
The result is a bilayer membrane. Since the membrane cannot extend indefinitely,
it will enclose into a spherical vesicle with an hydrophilic lumen.
Liposomes without any further modification, however, have poor plasma half
life as they are rapidly cleared by the RES. PEO is a synthetic polymer that
has been extensively used in bioconjugation to improve half life of drugs and
proteins in vivo. The application of PEO to liposomes technology gave raise to a
class of liposomes known as stealth liposomes, in which a percentage of the total
phospholipids is conjugated with PEO. The construct showed a prolonged half life
compared to the previous generation of liposomes, however it had stability issues.
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The introduction of a highly hydrophilic chain of PEO of molecular weight typ-
ically ranging from 2000-5000Da dramatically altered the packing factor toward
values < 1
3
, therefore favouring a micellar shape. For this reason only about 5%
of the total lipidic composition was conjugated to PEO, and a 100% conjugation
was not possible. To be able to use 100% PEO it is was necessary to replace the
phospholipid with an amphiphilic co-polymer (1.6).
Figure 1.6: Critical aggregation concentration (CAC). In Liposomes, free phos-
pholipids and aggregates exists in equilibrium. Functionalisation with PEO in-
creases the value of CAC of the phospholipids, therefore the equilibrium is shifted
towards free PEO-phospholipids. As a result the stealth properties are lost over
time. Polymersomes, made of 100% PEO-copolymer, have CAC close to 0, there-
fore their stealth properties are not lost over time.
1.4.5 Polymersomes
Polymersomes are nano/micro-metre sized, spherical vesicles characterised by
hydrophilic lumen. Polymersomes can be generated by the self assembling of
diblock co-polymers, generally referred to as Am-Bn, where A and B are the
hydrophilic and hydrophobic blocks, m and n represent the number of monomer
in A and B respectively, a critical parameter in the determination of the packing
factor. Multi-block co-polymers can also be used to form polymersomes, allowing
extra-control on the assembly process, surface and membrane topology (see fig
1.7) (LoPresti et al. [2009]).
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Figure 1.7: Examples of assembly of multi-block co-polymers. Hydrophobic block
are always segregated into the membrane, but the co-polymers chain arrangement
is dependant on the number and order of the blocks. Adapted from LoPresti et al.
[2009].
Polymersomes size, membrane thickness and length of the hydrophilic brush
are also dependant of the size of the co-polymers used. Polymersomes in the range
100-200nm made with diblock co-polymers based on PEO have been reported to
have a membrane ranging from 8nm to 21nm, with power relation d ' MW bA
to increasing PEO chain length from 2KDa to 20KDa (Discher and Ahmed
[2006]). This increase in membrane thickness was also correlated to membrane
permeability and to circulation half life in vivo. For PEO-PBO polymersomes
permeability was reported to be inversely correlated to membrane thickness, while
circulation half life was improved with thickness of at least 16nm (LoPresti et al.
[2009]).
1.4.6 Polymersomes applications
Polymersomes can be engineered to deliver hydrophilic moieties encapsulated
in the hydrophilic lumen and/or hydrophobic molecules intercalated in the mem-
brane. If a contrast agent such as gadolinium or fluorescent dyes are encapsulated
or linked to the co-polymers they can be used in imaging applications, both in
vitro and in vivo.
In vitro applications include the intracellular delivery of antibodies and lipids
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for live cell imaging (Massignani et al. [2010]). pH sensitive polymersomes made of
Poly(2 - methacryloxyethyl-phosphorylcholine)-poly( 2 -(diisopropylamino)ethyl
methacrylate) (PMPC-PDPA) were reported to escape endosomes and to suc-
cessfully deliver functional probes intracellularly (Canton et al. [2013]).
In vivo applications include therapy and imaging practices. In cancer therapy,
tumour regression has been reported after i.v. administration of doxorubicin
and taxol co-encapsulated in PEO-PLA polymersomes (Ahmed et al. [2006]).
Other therapeutic applications include the delivery in vitro of the anti-cancer
drug gemcitabine to pancreatic tumour cells via PEO-PCL polymersomes (Sood
et al. [2013]) and the use of PMPC-PDPA polymersomes in oral squamous cell
carcinoma (Murdoch et al. [2010]).
Figure 1.8: Advantages of the polymersomes. Polymersomes can be loaded with
hydrophilic molecules because of the hydrophilic core, they can also incorporate
hydrophobic molecules in the membrane, including phospholipids. Finally, they
can be functionalise for active targeting or with imaging contrast agent (Christian
et al. [2009b], Ahmed et al. [2006], Massignani et al. [2010], Lomas et al. [2010]).
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1.4.7 Co-polymers for in vivo applications
Blood is a fluid densely packed with cells (eg. erythrocytes, leukocytes and
other circulating cells), nanoparticles (i.e. lipoproteins), proteins (albumin, fer-
ritin), immunoglobulin, small molecules (lipids, sugars, salts). As a result, the
free space available for circulating nanocarriers is limited and interactions be-
tween them and blood components occur. When circulating proteins interacts
and get adsorbed by the nanoparticle the opsonisation process starts, which leads
to recognition by phagocytic cells and rapid blood clearance. Alternatively, the
nanocarrier might presents superficial features directly recognised by the MPS
which increase the rate of particle elimination from blood. In both scenarios,
short blood half life of nanoparticles is likely to result in insufficient accumula-
tion in the target organs.
The circulation half life of nanoparticles, specifically polymersomes, can be
altered by choosing a hydrophilic co-polymer that prevents polymersome interac-
tion with other blood components. Protection from fast clearance from the blood
is a combination of chemical and physical protection. Highly hydrophilic poly-
mers are characterised by a large volume of water molecules acting as a shield.
However, charged polymers cause high disturbance of water structure normally
given by weaker hydrogen bonds. Moreover, positively charged polymers strongly
interact with proteins, which are mostly negatively charged. As a first general
rule, the protective hydrophilic polymer should have no charge and should inter-
act with water without disturbing its structure, for example the polymer PEO.
PEO is not charged and the oxygen atoms separated by two methylene groups
interacts with water via hydrogen bounds. A molecule such as protein or lipid
should replace water to interact with the polymer, and this event is energetically
not favoured. This chemical protection is however relatively weak and alone is not
sufficient to prevent interactions between blood components and the nanocarrier.
In polymersomes, the hydrophilic polymers are packed close to each other, in
brush-like conformations and stretch from the hydrophobic membrane towards
the exterior (see fig 1.7), generating a physical protective barrier (Vonarbourg
et al. [2006]).
In this work, all co-polymers used had the same hydrophobic block (poly(2-
(diisopropylamino)ethyl methacrylate) (PDPA)), but different hydrophilic brush:
PEO, poly(oligo(ethylene glycol) methacrylate) (POEGMA) and
Poly(2 - methacryloxyethyl - phosphorylcholine) (PMPC).
PEO is one of the mostly studied stealth polymers. It is non charged, highly
hydrophilic, and its molecular geometry allows optimal interaction with water via
hydrogen binding. This strong hydrophilicity is one of the bases of the stealth
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properties of the polymer. It was introduced in bioconjugation to prolong circu-
lation half life of molecules in the late 70s.
POEGMA is another hydrophilic and non charged polymer. It is chemically
related to PEO, however, it is not made by a single long chain of −CH2CH2O−,
but of a backbone of poly(methyl ether methacrylate) in which all monomers can
be functionalised with short chains of PEO. The resulting polymers is still not
fouling (Lee et al. [2009], Stetsyshyn et al. [2013]). Non fouling is an important
property because it means that blood proteins do not accumulate at the surface
of the nanocarrier. Protein accumulation is critical as it leads to recognition by
the RES and rapid blood clearance. Another advantage of POEGMA over PEO
is that it presents more chemical groups available to functionalisation: PEO only
has two ends, one of which is already linked to the hydrophobic membrane, while
the other end is usually methoxylated to reduce fouling.
PMPC is hydrophilic and zwitterionic: the monomer has a both a positive and
a negative charge, therefore it has no total charge, and it can interact with water
to form a chemical barrier to opsonisation. Due to its non fouling properties
it is widely used in biological applications such as contact lenses and coronary
stents. However, it has been found that polymersomes made of PMPC have
hydrophilic blocks that are prone to quick internalisation by almost any cell type
(Lomas et al. [2010], Massignani et al. [2010], Pegoraro et al. [2014]). Later studies
found that PMPC is recognised by scavenger receptors class BI (SR-B1), normally
receptors for oxidized low density lipoproteins. This class of receptor is expressed
by many cells and it is responsible for the rapid internalisation of PMPC based
polymersomes. It should be noted that this mechanism of internalisation occurs
when polymersomes directly interact with the cellular receptor SR-B1, and it
does not affect its efficacy as non-fouling material in film coatings (Colley et al.
[2014]).
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Figure 1.9: The chemical structures of PEO, PMPC and POEGMA. Note how
PEO and POEGMA have no charge, while PMPC is zwitterionic. Moreover,
POEGMA is characterised by chains of PEO linked to the backbone of the poly-
mer.
1.4.8 Nanocarriers in in vivo imaging
Polymersomes have been used in medical imaging due to their capability to
accumulate in tumours. In one study Lecommandoux and co-workers exploited
the flexibility of polymeric nanocarriers to functionalised PTMC-b-PGA vesicles
with a targeting antibody to HER-2. The same vesicles were labelled with a
fluorescent tag for in vitro cellular uptake study and Ultrasmall Superparamag-
netic Iron Oxide nanoparticles (USPIO) were encapsulated in the hydrophobic
membrane. This approach allowed them to validate the targeting effect of the
functionalisation in vitro using Fluorescence Activated Cell Sorting (FACS) and
to confirm the in vivo accumulation within tumour by MRI (Pourtau et al. [2013]).
In another study Tsourkas and colleagues encapsulated gadolinium conjugated to
PAMAM dendrimers into polymersomes of PEO-PBD mixed with the biodegrad-
able PEO-PCL. Polymersomes accumulates into tumour by EPR effect and then
partial degradation of polymersomes improves water flux trough the membrane.
The increased hydration of gadolinium has a positive effect o its relaxation time
increasing the signal-to-noise ratio, a common limitation ofencapsulated gadolin-
ium. Because gadolinium was conjugated to PAMAM dendrimers its escape from
polymersomes and signal dispersion was prevented (Cheng et al. [2009]). PEO-
PBD NIR-polymersomes were imaged in vivo using optical imaging , allowing
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precise localisation and measuring of the tumour size in 3D in vivo (Ghoroghchian
et al. [2005]). The same formulation was further developed to target dendritic
cells in vivo by conjugation with the Tat peptide. Dendritic cells were exposed
to the polymersomes and then injected in mouse and tracked with an optical
imaging set up ( eXplore Optix MX2 system) (Christian et al. [2009b]). Another
possibility was explored by Battaglia and co-workers by labelling PMPC-PDPA
and PEO-PDPA polymersomes with rhodamine, a fluorescent dye that was later
tracked in vivo with a macroimaging system (Murdoch et al. [2010]).
Polymersomes have also been used in theranostic systems. In this field of re-
search a drug and an imaging reporter are co-encapsulated. For example, PTMC-
PGA polymersomes loaded with both the drug doxorubicin and maghemite γ-
Fe2O3 which provides contrast for magnetic resonance. The magnetic properties
were also used to drive the polymersomes to the tumour site using an eternal
magnetic field (Sanson et al. [2011]). The anticancer drug paclitaxel and MRI
contrast agent super paramagnetic iron nanoparticles have been co-encapsulated
into polymersomes to simultaneously deliver the anticancer drug and visualise
the tumour response in vivo (Muthiah et al. [2013]).
1.5 Aims
Polymersomes are nano-sized carriers successfully developed for in vitro and
in vivo applications, including low resolution optical imaging in vivo. However,
information on pathological disease at the sub-tissue level requires higher spatial
resolution. This can be achieved using confocal microscopy. Because of poor
tissue penetration of light, confocal microscopy in vivo is not possible at depths
greater than a few micrometers. To overcome this limitation, it is possible to
use a surgical procedure known as Window Chamber (WC), in which part of
the tissues obstructing the light pathway are replaced with optically transparent
glass.
An interesting application of high resolution optical imaging in vivo is in tu-
mour microvasculature imaging. Tumour microvasculature development (tumour
angiogenesis) is a key step in tumour and metastasis progression. Imaging of
the vasculature at high resolution using polymersomes can provide useful insight
into the mechanisms governing the diffusion the nanoparticles in the tumour en-
vironment, which in turn could be used to increase the fundamental body of
knowledge required to design formulations specifically targeted to the tumour
microenvironment or specific cell types present.
The aim of this work is to investigate the use of polymersomes in in vivo
optical imaging coupled with a WC set up. To do so, it will be necessary to
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develop a number of screening techniques to test polymersome interactions with
cells in vitro, and analyse their distribution in vivo in the tumour microenviron-
ment. During the in vivo screening, efforts will be made to improve the analysis
throughput.
Specifically, the in vitro development will include quantification of uptake of
two different rhodamine labelled polymersome formulations (poly(oligo(ethylene
glycol) methacrylate)-poly( 2 -(diisopropylamino)ethyl methacrylate) (POEGMA-
PDPA) and PMPC-PDPA) by three cell types representative of the tumour mi-
croenvironment: tumour cells Mouse Fibrosarcoma Cell (MFC), endothelial cells
Small Vessel Endothelial Cells (SVECs) and pericytes in vitro precursor 10T1/2.
The quantification will be conducted both in cells growing in static conditions
and in cells growing under flow. Polymersome uptake in flow will be assessed
using a specifically developed flow bio-incubator.
In vivo applications will focus on the analysis of distribution of polymersomes
in the vasculature via image analysis. The analysis aims to highlight the differ-
ences between the two polymersome formulations PMPC-PDPA and POEGMA-
PDPA in terms of circulation half life and tumour accumulation. These are useful
parameters in the rationale design of polymersomes for imaging and therapeutic
applications in cancer research.
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Figure 1.10: Aim of the work. Different polymersome formulations will be
screened in vitro for uptake by different cell lines (10T1/2, MFC188, SVECs.
In vitro screening will be performed under flow conditions. Following the in
vitro screening,formulations will be tested in vivo using Dorsal Skinfold Chamber
(DSC).
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METHODS
2.1 Polymersomes
2.1.1 Copolymers synthesis
All co-polymers were synthesized by Prof. Steve Armes’ group, Chemistry
Department, University of Sheffield, UK.
PMPC25-PDPA70 Copolymer synthesis
PMPC-PDPA copolymer was synthesized by Atom Transfer Radical Polymeri-
sation (ATRP) as previously reported (Du et al. [2005]). ATRP is a polymerisa-
tion technique characterised by synthess of copolymers with low polydispersity.
Briefly, 2-methacryloxyethyl-phosphorylcholine (MPC) (1.32g, 4.46mmol) and
CuBr (25.6mg, 0.178mmol) were added with 2ml of a deoxygenated (30min with
bubbling N2) methanol solution of bpy (55.8mg, 0.358mmol) and ME-Br (50.0mg,
0.178mmol). The reaction was conducted for 65min at 20°C in N2 saturated en-
vironment. A 3ml solution of 2-(diisopropylamino)ethyl methacrylate) (DPA)
(2.67g, 12.5mmol) was injected into the flask and allowed to react for 48h. The
final reaction mixture was diluted with 200ml isopropanol and purified from the
catalyst using a silica column.
Rhodamine-PMPC25-PDPA70 Copolymer synthesis
Rhodamine labelled (Rhd)-PMPC-PDPA copolymer was synthesized by ATRP
as previously reported (Madsen [2009]). Briefly, MPC (1.20 g, 4.05mmol) was
solubilised in 0.75ml of anydhrous methanol inside a round bottom flask. An in-
house prepared rhodamine 6G-based initiator (83.8mg, 0.135mmol) was added
to the solution and the flask was washed with 0.75ml anhydrous methanol. bpy
27
2. Methods 2.1. POLYMERSOMES
(42.17mg, 0.171mmol) and CuBr (19.37mg, 0.135mmol) were added to the reac-
tion after degassing with N2 for 30min. The reaction was conducted for 40min
at 20°C in N2 saturated environment. DPA (1.73g, 8.10mmol) dissolved in de-
oxygenated methanol (2ml) was injected into the flask. After 48h, the reaction
solution was diluted by addition of methanol (about 70ml) and opened to the
flask. The reaction considered complete when turned green. It was then added
of chloroform (200ml) and purifired form the catalyst using a silica column. bpy
was removed by 3days dialysis against a solution 3:1 chloroform:methanol. The
solution was changed daily. After dialysis, the product of the reaction was desic-
cated, dispersed in water, freeze-dried. Traces of organic solvents were removed
by desiccation in a vacuum oven at 80°C for 48h.
PEO113-PDPA70
PEO113 conjugated with the polymerisation macro-initiatior Br was dissolved
in methanol degassed with N2 for 30min. bpy and DPA were added to the solution
and the mixture was heated to 50°C before adding the catalyst CuCl. After 16h
an aliquot was analysed by 1H-NMR and the reaction was considered concluded
when less than 0.1% of monomer was detected. The reaction was stopped by
exposing it to air. The reaction mixture was then dissolved in Tetrahydrofuran
(THF) and purified from the catalyst using a silica column. The product was
then purified from unreacted bpy by dialysis against water for 7days followed
by dialysis against methanol for 2days. After purification, the product of the
reaction was desiccated and characterised by 1H-NMR.
2.1.2 Polymersomes synthesis
Polymersomes formulations were prepared by pH switch or film hydration.
Both methods can be used to obtain polymersomes, however they differ in prepa-
ration time and condition. pH switch is faster, as it can produce milliliters of
samples in few hours, while film hydration requires at two weeks of constant stir-
ring. However, because of the faster kinetic pH switch method is characterised
by a lower polymersomes yield as micelles formation is favoured. Furthermore,
pH switch method requires solubilisation of co-polymers at pH=2, which is not
compatible with protein stability and could compromise chemical the binding be-
tween co-polymers and functionalising moieties, such as biotin. For this reason
the pH switch method was employed in routine preparation of rhodamine la-
belled formulations, while film hydration was choose in the preparation of biotin
labelled polymersomes to prevent hydrolisis of the biotin/co-polymer link. The
composition of all the polymersomes formulations used is reported in table 8.9.
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Film hydration
Co-polymers were dissolved in chloroform:methanol (2:1 solution) in a sterile
glass vial at the concentration of 2mg/ml. The organic solvent was evaporated
under vacuum in a desiccator for at least 24h in order to obtain a thin film of
co-polymer on the vial wall. The co-polymer film was rehydrated with 2ml of
Phosphate Buffer Saline pH 7.4 (PBS7.4) and the vial was left under constant
magnetic stirring for 2 weeks.
pH switch
20mg of co-polymers were dissolved in a 7ml bijoux with 2ml of Phosphate
Buffer Saline (PBS) acidified to pH=2 with Hydrochloric Acid (HCl) 1N . The
solution was filtered into a new 7ml plastic bijoux through a 220µm filter. The
solution was kept under constant agitation using a magnetic stirrer and a pH
meter was used to continuously monitor the pH. 220µm filtered Sodium Hydroxide
(NaOH) 0.5N was added to the solution through a programmable pump to ensure
slow and constant delivery (18µl/min). The pump was stopped at pH=7.4. All
steps were performed at room temperature. Sterile polymersomes were prepared
inside a class II cabinet.
Figure 2.1: PDPA pH sensitivity. At pH<pKa the tertiary amino group is proto-
nated. The polymer is charged and hydrophilic. At pH>pKa the aminogroups are
deprotonated: the polymer becomes hydrophobic.
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2.1.3 Polymersomes purification
Polymersomes were purified by Gel Permeation Chromatography (GPC) us-
ing 4B Sepharose resin. 500µL of samples were loaded to the head of a 15cm
column. Samples were collected in fractions and fractions were characterised
by Dynamic Light Scattering (DLS). Fractions containing polymersomes of 100-
200nm were joined together. Samples were then concentrated by centrifugation.
1ml was transferred into a 2.0ml eppendorf and centrifuged for 20min at 2000rcf
for 20min. The supernatant was transferred to a new 2.0ml eppendorf and cen-
trifuged at 20000rcf for 20min. The supernatant was then discarded and 500µl
of sterile PBS7.4 was used to re-suspend the pellet.
The suspension was sonicated for 20min to ensure complete re-suspension of
the polymersomes. Polymersomes concentration was measured by fluorometer or
Reverse Phase-High Pressure Liquid Chromatography (RP-HPLC) for function-
alised polymersomes and the final concentration was adjusted to 10mg/ml with
sterile PBS7.4
2.1.4 Polymersomes characterisation
Dynamic Light Scattering (DLS)
Size distribution was determined by DLS analysis. Small particles in solu-
tion scatters light in all directions. The scattered light at a specific angle can be
measured and its fluctuations correlated with time. The intensity of scattered
light fluctuates because particles undergo Brownian motion, and smaller parti-
cles have higher diffusion coefficients compared to big particles, according to the
Stokes-Einstein equation:
D =
kb T
6 pi η R
where kb is the Boltzmann’s constant, T is the temperature, η is the viscosity
and R is the radius of the particle.
DLS analysis assumes that particles are spherical. The DLS used was equipped
with a He-Ne laser 633nm and was measuring scattered light at an angle of 173°.
Briefly, a small aliquot ('50µl) of polymersome was diluted 1:20 with 220µm
filtered PBS7.4, placed into a clean small volume plastic vial and analysed using a
Malvern Zetasizer Nano set to 20°C, PBS dispersant and latex beads as particle
type. Results are expressed as intensity number against size distribution (fig.
2.2).
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Figure 2.2: Typical DLS results for PMPC-PDPA and POEGMA-PDPA synthe-
sised by pH switch. Both formulations have average hydrodynamic diameter of
'150nm.
Transmission Electron Microscopy (TEM)
Size distribution and morphology of polymersomes were characterised by TEM.
TEM is a microscopy technique in which a beam of electron is focused through
a thin specimen. In order to achieve optical contrast it is necessary to have
electrondense specimens. In our experiments contrast is achieved with Phosph-
tungstenic acid (PTA) positive staining. PTA stains the ester bonds present
in PDPA and PMPC polymersomes membrane (Gedde [1996]). Polymersomes
suspension were diluted to 0.5mg/ml with 220µm filtered PBS7.4. 400 meshed
copper carbon coated grids were charged using a glow charger to allow hydrophilic
polymersomes to attach to the grid. 5µl of polymersomes were allowed to settle
on the grid for 1min and the excess of liquid was removed using filter paper. 5µl
of 0.75%w/v PTA were added to the grid and allowed to stain for 5s. Excess
of liquid was removed using filter paper and compressed air. Grids were imaged
using a FEI Tecnica Spirit microscope with maximal working voltage of 120KV
and equipped with Gatan1K MS600CW CCD camera (fig. 2.3).
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(a) PMPC-PDPA (b) POEGMA-PDPA
Figure 2.3: Typical TEM results for PMPC-PDPA and POEGMA-PDPA synthe-
sised by pH switch. Polymersomes are visible as rounded features of '150nm of
diameter.
2.1.5 Polymersomes concentration
Fluorometer
Rhodamine labelled polymersomes were prepared including in the formula-
tion 10% w/w of rhodamine labelled copolymer prepared as described in section
2.1.1. Te concentration of the rhodamine labelled copolymer was quantified us-
ing a fluorometer equipped with a 96 well plate reader. An aliquot ('20µl) of
polymersomes were diluted 20 times with Phosphate Buffer Saline pH 2 (PBS2).
The solution was transferred to a 96 well plate and the concentration of rho-
damine labelled copolymer was determined against a calibration curve. Because
the polymersomes were prepared starting with 10% molar ratio of rhodamine
labelled copolymer the final concentration of polymersomes was calculated by
multiplying the fluorometer result by 10.
RP-HPLC
In this work a C18, 150X4.60mm, 5µm, 300A˚ column was used. The flow ratio
was always 1ml/min, the eluents milliQ water and methanol, both acidified with
0.05% of Trifluoroacetic Acid (TFA). The different gradients used are reported
in table 2.1 and figure 2.4. An aliquot of 100µl of sample was placed into a RP-
HPLC vial and acidified with 2µl of TFA. 80µl of sample were injected and the
concentration was determined against a calibration curve.
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Gradient Analyte Wavelength [nm] Retention
time [min]
POLY Rhodamine labelled copolymers
UV 220
11.3
EX/EM 540/565
AB
Rhodamine labelled copolymers
UV 220
7.8
EX/EM 540/565
Antibody
UV 280
28.0
EX/EM 270/300
Table 2.1: RP-HPLC settings used.
(a) Gradient for polymersomes (b) Gradient for antibody
Figure 2.4: Gradients used in RP-HPLC analysis. a) Gradient POLY, b) gradi-
ent AB. Eluent A was milliQ water acidified with 0.05% of TFA, eluent B was
methanol acidified with 0.05% of TFA.
2.1.6 Polymersomes functionalisation
Biotin/streptavidin
Biotinylated polymersomes were prepared by film hydration. Composition is
available in table 8.9. Polymersomes were then added with streptavidin (1:1 molar
ratio with biotinylated copolymer) and kept stirring for 2h at room temperature.
Reaction mixture was purified by GPC. The purified reaction was added with
biotinylated antibody to Platelet Derived Growth Factor Receptor-β (PDGFR-
β) or biotin-TexasRed (1:2 molar ration with streptavidin). The reaction was left
stirring for 2h at room temperature. Reaction mixture was purified by GPC and
the product was characterised by DLS, TEM and RP-HPLC.
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Figure 2.5: Biotin Streptavidin functionalisation. Biotinylated polymersomes
were added of streptavidin. The excess of streptavidin was removed by GPC.
Biotinylated antibody was added. The excess of antibody was removed by GPC.
Maleimide reaction
The reaction was carried out to functionalise polymersomes with Immunoglob-
ulin of the class G (IgG), acting as a model for targeting antibody. A generic
rabbit IgG was used instead of a specific antibody to contain costs during the
optimisation of the reaction. Composition is available in table 8.9. All liquid
reagents were purged with bubbling N2 for 15min for every millilitre of solution.
Weighted copolymers were dissolved in PBS2 to a final concentration of 10mg/ml.
pH was slowly increased to 7.4 as previously described (2.1.2), but in this case
the reaction mixture was kept under bubbling N2 to avoid maleimide inactivation
by atmospheric oxygen. IgGs were added 1:2 molar ratio with PMPC-PDPA-
Mal and the reaction was performed 2h room temperature. Excess of IgG was
removed by GPC. Reaction mixture was purified by GPC and the product was
characterised by DLS, TEM and RP-HPLC.
Pol N
O
O
+ IgGHS N
O
O
SPol
IgG
2h, RT
N2
Figure 2.6: Maleimide reaction. Maleimide reacts with thiol groups in IgG.
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2.2 Tissue culture
2.2.1 Routine subculture of Murine Fibrosarcoma cells
MFC cells expressing single iso-form of VEGF were kindly provided by Prof.
Tozer Group, Oncology Department, University of Sheffield. The development of
the cell lines is described elsewhere (Shima et al. [1996], Greco and Dachs [2005]).
Briefly, primary fibroblast were isolated from 13.5 days post-coitum Swiss mouse
embryo. The cultured fibroblast cultures were genotyped for VEGF-A isoform
expression. Finally, retrovirus SV40 was used as vector to immortalise the fibrob-
lasts and oncogenically transform them via H-Ras activation. MFC were main-
tained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10%
Fetal calf serum (FCS), G-418 600µg/ml and puromycin 2µg/ml. Sub-confluent
cells were washed with 10ml PBS, treated with 5ml trypsin and incubated 5min
5% CO2 at 37°C. Detached cells were counted using a Neubauer improved hemo-
cytometer and subdivided into cell culture flasks and 10ml of fresh media was
added. Cells were sub-cultured every 3-4 days at a ratio of 1:15
2.2.2 Routine subculture of SVECs
SVECs were maintained in DMEM supplemented with 10% FCS, 1% peni-
cillin/streptomycin and 1% fungizone. Sub-confluent cells were washed with 10ml
PBS, treated with 5ml trypsin for 5min and centrifuged. The pellet was resus-
pended in DMEM and incubated 5min 5% CO2 at 37°C. Detached cells were
counted using a Neubauer improved hemocytometer and subdivided into cell cul-
ture flasks and 10ml of fresh media was added. Cells were sub-cultured every 3-4
days at a ratio of 1:10
2.2.3 Routine subculture of C3H/10T1/2
C3H/10T1/2 were purchased from American Type Culture Collection (ATCC).
Cells were maintained in Basal medium eagle (BME) supplemented with 10%
FCS, G-418 600µg/ml and puromycin 2µg/ml. Sub-confluent (below 70% con-
fluency) were washed with 10ml PBS, treated with 5ml trypsin and incubated
5min 5% CO2 at 37°C. Detached cells were counted using a Neubauer improved
hemocytometer and subdivided into cell culture flasks and 10ml of fresh media
was added. Cells were sub-cultured every 3-4 days at a ratio of 1:10.
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2.2.4 Differentiation of 10T1/2
10T1/2 differentiation into pericytes was stimulated using TGF-β1. In this
work the effect of different concentration and time exposure to TGF-β1 was
assessed. In every experiment the desired concentration of TGF-β1 was obtained
by diluting the stock solution (R&D system) in fresh 10T1/2 media, and then
incubating the cells with the TGF-β1 enriched media for the 24h, 48h or 72h at
37°C, 5% CO2. The effect of conditioned media was assessed as well. In these
studies 10T1/2 were incubated with media obtained from a flask of MFC188 or
SVECs cultured for 72h. TGF-β1 was diluted into the conditioned media before
incubation with 10T1/2 cells.
2.2.5 Fibronectin coating
Fibronectin coating of wells was used to assess the effect of different growing
substrates in 10T1/2 differentiation and in flow studies to guarantee adhesion
of cells under flow. Wells were coated with 5µg/cm2 of fibronectin dissolved in
PBS7.4. 200µl of fibronectin solution were deposited in a well (24 well plate) and
allow to dry at room temperature for 60min. Coated plates were stored at 4°C
until use and for no longer than 72h. Wells were rinsed with media before cell
seeding.
2.3 Pericyte markers expression quantification
2.3.1 Immunocytochemistry (ICC)
10T1/2, MFC188 or SVECs were seeded at 5000cell/well in dark 96 well plate
and incubated 24h at 37°C,5% CO2. TGF-β1 was added to 10T1/2 by replacing
the growth media with fresh media added with the desired concentration of TGF-
β1. Cells were placed back in the incubator for the desired exposure time.
Conditioned media was obtained from sub-confluent T75 flasks of MFC188 or
SVECs cultured for 96h.
At the end of the experiment cells were washed 3 times with PBS7.4 and fixed
with 3.6% formaldehyde for 10min. Cells were washed 3 times for 5min with
PBS7.4. To assess α-Smooth Muscle Actin (α-SMA) expression cells were per-
meabilised with 0.1% triton X-100 for 10min and then washed with PBS7.4 for
5min This step facilitate the penetration of the primary and secondary antibody
inside the cell, where α-SMA is located. Non specific reactions between primary
antibody and cells component other than α-SMA were prevented by incubating
cells at room temperature for 1h with blocking solution (5% Bovine serum albu-
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mine (BSA) in PBS7.4). Primary antibody was dissolved in blocking solution and
incubated with cells overnight at 4°C. Cells were washed 3 times for 5min with
PBS7.4. Secondary antibody was diluted in blocking solution and incubated with
cells for 2h at room temperature. Cells were washed 3 times for 5min with PBS7.4,
DAPI diluted 1:100 in PBS7.4 was added tot he cells and the plate were stored at
4 °C until imaged. A list of the primary and secondary antibodies used is given
in table 8.4. Nerve Glial antigen 2 (NG2) and PDGFR-β were detected using the
same protocol, but without the permeabilisation step as they are located on the
external cell surface, therefore there is no need to facilitate the penetration of the
primary and secondary antibodies inside the cell.
2.3.2 Western blot
For Western Blot (WB) analysis cells were cultured in T75 flasks. Cells were
washed carefully with PBS7.4, excess of liquid was removed and the proteins
were extracted by lysis with 500µl of RIPA buffer for 10min at 4°C. The lysate
was transferred to a 2.0ml eppendorf and aggregates were mechanically broken
using a syringe equipped with a 30G needle by 10 cycle of aspiration/injection.
The lysate was then centrifuged at 4°C for 20min at 10000g and the precipitate
was discarded. Protein concentration in the samples was measured using the
Bicinchoninic acid assay (BCA) assay, samples were stored in 50µl aliquot at
-80°C for further analysis.
BCA is a colorimetric assay used to quantify the protein concentration. It is
based on a two steps reaction. In the first step cupric acid is added to the sample,
and Cu2+ is reduced to Cu+ at a rate proportional to the protein concentration.
In the second step each newly formed Cu+ ion chelate with with two molecules of
bicinchoninic acid. The product of the reaction can be detected by quantifying
its optical density at 562nm.
In this work, the BCA assay was used to normalise the loading of all the
samples analysed in western blot experiments. Cell lysate were added with the
BCA reagents as indicated by the kit supplier for a 96 well plate assay. Samples
were incubated 40min at 37°C and optical density was measured at 562nm. Pro-
tein concentration was calculated from a calibration curve obtained with a BSA
standard.
Samples preparation Protein loading was normalised by total protein con-
centration and loading volume. 20µg of total proteins were loaded in a volume of
40µl. The volume of diluent (RIPA buffer) was calculated as VX = 26− VS were
VS is the volume of stock sample containing 20µg of proteins and VX is the volume
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of RIPA buffer to add. All volumes in µl. The solution obtained was added of
4µl of sample reducing buffer 10X and 10µl of sample buffer 4X. Samples were
then denatured at 95°C for 5min and 35µl, and 30µl were loaded into the gel.
One channel was reserved for molecular weight ladder.
Western blot gel preparation The composition of all gels and buffers is
reported in table 8.8. Running gel was poured into a 0.75mm 9 lines template,
the template was filled with 2-butanol and the gel was allowed to settle at room
temperature for 60min. Excess of 2-butanol was removed and the stacking gel
was added on top of the running gel. The system was closed with a template to
allow the formation of 9 loading channels. Stacking gel was allowed to settle for
60min at room temperature. The gel was then placed into the running support
and loaded into the running tank filled with running buffer.
Western blot run Samples were run for 15-20min at 100V to allow uniform
sample loading at the top of the running gel. Once samples entered the running
gel, voltage was increased to 180V and samples were run until the ladder corre-
sponding to the molecular weight of the protein analysed run for about 2/3 of the
high of the gel. This usually took 120min for PDGFR-β and 150min for NG2.
When the separation was over, the gel was plased into a semi-dry membrane
transfer cassette to transfer the proteins from the gel to a Polyvinylidene fluoride
(PVDF) membrane suitable for chemoluminescence staining staining. Transfer
was performed at 100V for 60min.
Membrane blotting After transfer the membrane was blocked for 1h at room
temperature with blocking solution (5% non-fat milk in milliQ water). The pri-
mary antibody diluted 1:500 in blocking solution was left on the membrane over
night at 4°C. After washing 5 times for 4min with PBS7.4 the secondary antibody
diluted 1:10000 in blocking solution was added for 1h at room temperature. The
membrane was then washed 5 times for 4min with PBS7.4. The Enhanced chemi-
luminescence (ECL) solution was added (1ml/membrane) and allow to react for
5min at room temperature. Excess of ECL was removed and the membrane was
developed using photographic film.
Membrane development Photographic film development was carried out in
a dark room. The PVDF membrane was placed into a development cassette. A
photographic film was cut to size and placed on top of the PVDF membrane.
Exposure time was optimise every time, but it was usually between 30sec and
5min. The photographic film was then placed for a few seconds in developing
38
2. Methods 2.3. PERICYTE MARKERS EXPRESSION QUANTIFICATION
solution, washed with tap water and the development was then fixed with fixing
solution for '30sec. The film was washed with tap water and dried at room
temperature. The film was scanned and the digital image was used to quantify
bands intensity using the Gel Analyser Tool available in ImageJ-64bit v1.47.
Results are expressed as ratio of band intensity between the sample and the
control (10T1/2 cells not treated with TGF-β1).
2.3.3 Quantitative size-based protein assay
Quantitative size-based protein assay was performed using a Protein simple
equipment commercially known as Simon. This machine automates the process
of protein separation and quantification aiming to remove user-dependant vari-
ables, to make the quantification faster compared to western blot and to reduce
costs by reducing the volume of reagents required. This is achieved by a full
automation of the process. The user is required to prepare the protein samples
and to load them into the machine together with all the other required materi-
als: running and stacking gels, primary and secondary antibodies. When the run
starts, the machine automates the process of preparing the gels and to load the
samples. Furthermore, reaction with primary and secondary antibody, gel imag-
ing and quantification of protein is also automated by the machine. A schematic
of the working principle of Simon is given in figure 2.7. Samples are prepared as
described for traditional western blot (section 2.3.2), but only 5µl are required
for the final analysis. A 384 well plate is prepared by loading a maximum of
12 samples, separation matrix, primary and secondary antibodies and internal
standard. The machine automatically loads running capillaries with the reagents
and runs the samples according to the specified parameters. In this work samples
were run at 300V for 46min, matrix was diluted 80% v/v with antibody diluent.
All the other parameters are used as default. All reagents are provided by the
equipment producer, except RIPA buffer and primary antibodies. Data were nor-
malised with the internal standard and antibody signal peak was integrated using
Simon dedicated software. Results were expressed as ratio of signal integration
between the sample and the control (10T1/2 cells not treated with TGF-β1).
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Figure 2.7: Automated western blot work-flow. Samples are loaded into a capil-
lary containing a separation gel. Separation occurs because of proteins different
molecular weights and charge as in traditional WB (a voltage is applied to the
capillary). At the end of the run the proteins are cross-linked with UV and im-
munoprobed using a primary antibody and a HRP-labelled sundry antibody. Signal
coming from the HRP probe is finally quantified.
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2.4 Polymersomes in vitro
2.4.1 Static culture cells treatment
For a typical uptake study, MFC and SVECs cells were seeded on a 24 well
plate at a density of 50·103 cells density. 10T1/2 cells were seeded at 25·103
cell/well and treated for 48h with 2ng/ml of TGF-β1 prior exposure to polymer-
somes. This different seeding density is required to avoid confluency of 10T1/2,
which can inhibit further differentiation and proliferation (Reznikoff et al. [1973b],
Reznikoff et al. [1973a]). 500µl of media containing 1mg/ml of polymersomes
were then added, cells were incubated at 37°C and 5%CO2 and uptake was quan-
tified at defined time-points for up to 24h.
2.4.2 Cytotoxicity
Cytotoxicity was assessed by (3 - (4,5 - Dimethylthiazol - 2 - yl) - 2,5 -
diphenyltetrazolium bromide (MTT) assay, a colorimetric method that exploits
the ability of living cells to metabolize MTT into a purple formazan salt (see
figure 2.8). MFC and SVECs cells were seeded on a 24 well plate at a density
of 50·103 cells density. 10T1/2 cells were seeded at 25·103 cell/well and treated
for 48h with 2ng/ml of TGF-β1. 1mg/ml polymersomes dispersed in cell me-
dia were incubated with cells at 37°C, 5% CO2 for 24h cells were washed with
3 times with PBS7.4. 500µl of MTT 0.5mg/ml were added to each well in a 24
well plate. Cells were incubated 40min at 37°C and 5% CO2. MTT solution was
removed and 300µl of isopropanol acidified with HCl (25µl of concentrated HCl
for 20ml of isopropanol). This will solubilise the formazane salts. 150µl of the
solution were transferred to a 96 wells plate and the optical density was measured
at 540nm (referenced at 630nm). The optical density measure correlates linearly
with the cell viability and results are expressed as percentage of viability with
respect of a control (cells treated with PBS7.4, the polymersomes diluent). In in
flow studies the 100% viability control was defined as the viability of the same
cell line cultured in static conditions.
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Figure 2.8: MTT reaction. Yellow water soluble MTT is converted by cell mito-
chondria in non water soluble purple formazane salts.
Figure 2.9: MFC188, SVECs and 10T1/2 viability after 24h exposure to 1mg/ml
of polymersomes. Viability express as percentage with respect to the same cell
type treated with an equal volume of only PBS.
2.4.3 FACS
Cells were detached using a Tripsin/EDTA (TE) cell scraper, transferred to
a eppendorf tube and centrifuged at 1000rcf for 5min. From now on every
step was performed keeping the cells at 4°C. The pellet was washed with 1ml
of ice cold 220µm filtered PBS7.4 and cells were centrifuged again. This step
was repeated 3 times. The pellet was then re-suspended with 200µl of ice cold
PBS7.4 and analysed using a BD FACSArray equipment. Cells were gated for size
and granularity and for fluorescence intensity using untreated cells as a negative
control.
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2.4.4 RP-HPLC
RP-HPLC was used to quantify the amount of polymersomes internalised
by cells. Because the polymersomes used were 10% rhodamine labelled it is
possible to use this chromatography technique coupled with a fluorescent detector
to accurately quantify the amount of copolymer present in the sample. To use
this technique, it is essential to extract the internalised polymeric material from
the cells and solubilise it in a solvent compatible with the RP-HPLC equipment
used. This section presents the method optimised to extract the co-polymer
from the cells and to quantify it by RP-HPLC. The RP-HPLC gradient used
is reported in figure 2.11. After polymersomes treatment cells were washed 3
times with PBS7.4 and excess of liquid was carefully removed. Cells were then
left at -20°C for 24h. This step cause cell lysis because of the formation of
water ice crystals. 200µl of PBS2 were added to the well and using a 200µl tip
as a scraper cells were mechanically broken and the suspension was transferred
to a 2.0ml eppendorf. The liquid was centrifuged for 30s at 20000rpm. 150µl
of supernatant were transferred into a RP-HPLC vial and 80µl were injected
for quantification. RP-HPLC settings are reported in figure 2.11. The work-
flow of the method is illustrated in figure 2.10. The recovery efficiency, critical
to accurate quantification, was assessed to be > 95% with respect of maximal
theoretical recovery when a known amount was incubated for 24h at 37°C with
cell lysate (see fig. 2.12).
Figure 2.10: Work-flow of polymersomes extraction from cells for RP-HPLC anal-
ysis. Cells are lysate by incubation at -20°C for 48h. The co-polymer is recovered
by solubilisation in PBS2.
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Figure 2.11: RP-HPLC gradient and chromatogram for rhodamine labelled poly-
mersomes. The insert represents the gradient. Free rhodamine and rhodamine
labelled co-polymer were resolved in sharp peaks.
Figure 2.12: Recovery of RhdPMPC-PDPA from cells. Rhd-PMPC-PDPA was
efficiently recovered (yield>95%) form cells incubated with the co-polymer (treat-
ment) compared to the theoretical 100% total recovery derived from the calibration
curve.
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2.5 In flow uptake studies
2.5.1 Flow modelling
The flow chamber was developed based on the geometry of a 24 well plate.
The flow was delivered using a peristaltic pump Watson Marlow 205S connected
to the well with a marprene tube, 0.8mm bore. The rotation speed of the rotor
of the pump can be tuned to obtain different flow rates. The rotation speed and
flow rate were calibrated by collecting different volumes of liquid from the outlet
at different time points. The flow inside the chamber was simulated using a fi-
nite element approach and COMSOL Multiphysics, Computational fluid dynamic
(CFD) module. Different design parameters such as depth of inlet and outlet and
the use of a shield to protect cells from direct perpendicular flow were tested in
silico using such approach. General simulation settings are reported in table 2.2.
General boundary condition No slip, u = 0
Density ρ 1000kg ∗m−3
Pressure p 101325Pa
Temperature T 310.15K
Inlet conditions
Laminar flow
Lentr = 0m
Lentr∇t · [−pentrI + u(∇tu+ (∇tu)T )], ∇t · u = 0
Outlet conditions
Laminar flow
Lexit = 0m
Lexit∇t · [−pexitI + u(∇tu+ (∇tu)T )], ∇t · u = 0
Initial flow Flow inlet=Flow outlet, 2 · 10−8m3 ∗ s−1
Fluid Newtonian fluid, non compressible
Table 2.2: In silico parameters.
COMSOL shear rate φ output was converted to shear stress τ assuming the
media as a newtonian fluid: τ = µ · φ. The shear stress and velocity magnitude
were analysed at the level of cellular growth (bottom of the well).
2.5.2 Device sterilisation and preparation
The well plate was replaced with a new one for every experiment. The outer
part of the tubing and the lid were routinely sterilised using azo-wipe. The inside
of the tubing and the lid were sterilised by submersion in 70% Industrial Methy-
lated Spirit (IMS) over-night, followed by 2h of slow flow when submerged in
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trigene. Finally, the trigene was substituted with 70% IMS for 1h and eventually
with sterile PBS7.4 for 1h. The PBS7.4 was changed every 15min. At this point
the device, already kept inside a class II cabinet, was ready to be used. Prior
inserting the tubing in the wells the system was equilibrated with cell media for
30min.
2.5.3 Cell seeding
MFC188 and SVECs were seeded in 24 well plate at a density of 50·103 cel-
l/well 24h before incubation in flow. 10T1/2 were seeded at a density of 35·103
cell/well and 24h after media was replaced with fresh media added with 2ng/ml
of TGF-β1 and incubated for 48h before applying flow. Flow was increased to
the analysis flow rate at a rate of increased of '3.5µl/s every 60min. The two
cell lines were seeded at different densities because 10T1/2 are sensitive to con-
fluency, which should be avoided. Therefore they were seeded at a lower density
compared to SVECs.
2.6 Polymersomes in vivo
2.6.1 DSC
Animals
Experiments were performed on male SCID mice weighing 30±3g obtained
from the University of Sheffield Field Laboratories and held in the animal facil-
ity for at least 1 week before experimentation. Prior to surgery, animals were
housed in pairs on sawdust, in Perspex cages in a holding facility maintained at
21.5±1.5°C, 40-65% relative humidity, with a 12/12 hour light/dark cycle. Food
in the form of standard pelleted commercial diet and tap water were available ad
libitum. All procedures were performed under the Animal Scientific Procedures
Act (1986).
Spheroids preparation A tumour was implanted in the window of the dorsal
skinfold chamber in the form of a spheroid obtained from MFC188. Sub-confluent
cells were detached from a flask and counted using a Neubauer counting chamber.
Cells were re-suspended to a concentration of 150·103 cells/20µl and 20µl drops
were deposited on the lid of a 3cm Petri dish. Cells were then incubated 48h at
37°C 5% CO2 to allow spheroids to from in the drops. Humidity was assured by
putting 2ml of media at the bottom of the Petri dish.
46
2. Methods 2.6. POLYMERSOMES IN VIVO
Figure 2.13: Spheroid of MFC188 cells growing in drops placed on the lid of a
Petri dish. 2ml of media at the bottom of the dish assured humidity and avoid
that drops drained out. One spheroid is highlighted by a black dotted circle. Bar
7.5mm.
DSC Surgery
Immediately prior to surgery the warming pad and the site of the surgical
preparation were sprayed with Trigene. The chambers, nuts, screws and spacers
were sterilised by autoclave. The window chamber was custom made by the
University Workshop, University of Sheffield. The parts of the chambers are
pictured in figure 2.14. The frame is made of titanium and weights '2g.
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Figure 2.14: Parts of the custom made window chamber. The two black frames
holding the flap of skin are visible, together with the bolts and the clip holding
the optical glass. Bar 7mm.
Anaesthesia Animals were anaesthetised with a i.p. injection of a mixture of
Hyponorm, 1 part of Hypnovel and 2 parts of injectable water. 100µl per 30g
animal were used.
Shaving All the steps of the surgery were performed with the animal lying on a
hotplate heated at 37°C. The animals dorsal area was shaved from hip to shoulder
and around the edge of the ventral area using shaving clippers. Remaining fur
was removed with Veet shaving cream applied for 5min and removed with dH2O
and gauze swabs. Skin was sterilised with hibi-scrub and alcohol gauze pad. The
area where the chamber sits was marked using a sterile marker pen.
Placement of the chamber A flap of skin was sutured with 4/0 Ethilon su-
ture to a C-clamp to keep the skin evenly tensioned before applying the chamber.
6 evenly spaced suture points were used. Using a template, the position of the
3 screws and the glass window was marked with a sterile marker pen. A 0.5cm
circle of tissue (epidermis, dermis, subcutis, muscle and subcutaneous fat) cor-
responding to the area of the glass window was removed, leaving blood vessels
exposed. Tissue drying was prevented using saline. Finally, the two frames of
the chamber were sutured on the two sides of the flap of skin using ethibond
suture. Tumours were implanted by placing one spheroid in the middle of the
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exposed vasculature of the window. A glass coverslip was placed in the chamber
and secured with a spring grip.
Post operative care and husbandry Aureomycin ointment was applied to
the chambers frames edges, 100µl of Vetergesic (buprenorphine 30µg/ml) were
administered i.p. and 1ml of dextrose/saline was given subcutaneous to aid
recovery. Animals were kept in individual cages in a 30°C cabinet. Animals were
monitored daily for signs of infections or distress.
Intra vital microscopy (IVM) Imaging sessions started when tumour grow
to cover around 80% of the chamber and developed a visible vasculature, typically
7 days post surgery. 80µl of 10mg/ml rhodamine labelled polymerosmes were
injected i.v. into the tail vein. Animals were restrained but not anaesthetised
during imaging sessions. One imaging session lasted '15min. Imaging sessions
were performed routinely for up to 24h after injection. Images were acquired
using a Zaiss confocal microscope equipped with a 10X objective and a Nikon
epi-fluorescence microscope equipped with a 2.5X and a 20X objective.
2.7 Statistical analysis
All in vitro experiments were performed at least in triplicate (N =3). Sta-
tistical analysis and comparisons of groups were performed in MATLAB using
the Statistical Analysis Toolbox. Experimental error is expressed as standard
deviation. Statistical comparisons between groups was performed with a Mann-
Whitney U test. This non-parametric test is a strong test for difference in mean
between two independent set of data non-normally distributed. For normally dis-
tributed data, it is comparable to the parametric Student t-test. Therefore, as
data were not assessed for normality, the Mann-Whitney U -test was preferred to
the Student t-test. Significance level was set to p<0.05.
In vivo experiments were performed in N =1 for PMPC-PDPA imaged at
the confocal, N =2 for POEGMA-PDPA imaged at the confocal and N =2 for
POEGMA-PDPA imaged with the epifluorescence microscope. Error was calcu-
lated as error = |animal1−animal2
2
| when N =2. Because of the small sample size,
animal experiments should be considered as pilot experiments, and no statistical
significant conclusion can be inferred from the results.
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CHAPTER 3
IMAGE ANALYSIS
Abstract
Quantification of polymersomes uptake in vitro and intra-tumour distribu-
tion in vivo relies on dedicated fluorescence image analysis tools capable of high
throughput. Such methods are based on image segmentation to identify Regions
of interest (ROI)s such us cell cytoplasm or nucleus, regions of a well correspond-
ing to flow parameter, blood vessel or tumour stroma. The spatial information
relative to a specific ROI must finally be correlated with the relative fluorescence
signal intensity. The following chapter will focus on the development of such
analytical tools.
3.1 Introduction
The large amount of images to analyse requires automation of the method
to make the analysis faster and more reliable. Of the many possible alternatives
in image analysis, such as ImageJ, R or other commercially available software,
MATLAB was chosen as the developing platform. This because MATLAB has a
strong Image Analysis toolbox and it is highly customisable through the integra-
tion of a number of scripts and functions.
All the software developed are based on segmentation: the extraction of par-
ticular ROI from the rest of the image. The segmentation process can be imple-
mented with a number of algorithms, all of which are targeted for enhancing the
contrast between the ROI and the background. The algorithms applied and the
order they are applied in is highly dependent on the original image. A good con-
focal image can be segmented using a simple threshold approach: only regions
with pixel intensity higher than the threshold are considered. Other images,
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such as vasculature images here analysed, do not have enough contrast to use a
thresholding masking. In this case, other filters should be applied to facilitate
segmentation. Such filters usually operate in multi-step, first blurring the image
to eliminate noise, then enhancing the contrast at the edges of the ROI and finally
restoring the original sharpness.
In this work, several different pictures (Immunocytochemistry (ICC), up-take,
vasculature in vivo) have been acquired using different microscope set-ups (epi-
fluorescence, confocal, different magnification). As a result, the analysis tool
should perform the same task (segmentation and intensity-based analysis) using
a flexible approach, to allow satisfactory results in different conditions. This
result was obtained by implementing different segmentation tools into a software
with Graphic user interface (GUI) that allows flexible interaction of the user with
the masking algorithms.
3.2 Image segmentation
3.2.1 Thresholding masking
The thresholding masking is the simplest approach in segmentation problems.
In good confocal or epi-fluorescence images, the background has signal intensity
close to 0, while the feature of interest is characterised by brighter regions. When
a thresholding masking is applied, the ROI is identified by all the areas having
intensity value higher than the threshold. In the software GUI, this was imple-
mented by a slide bar that the user can move to adjust the threshold. A limitation
of this approach is that the background should be highly homogeneous and there
should be enough contrast between background and ROI, otherwise it is impossi-
ble to discriminate the two area. In the analysis here performed, this was achieved
only in nuclear DAPI staining, where nucleus are homogeneously stained and the
contrast DAPI/background is relatively high (see fig. 3.1). Images characterised
by weaker signal and lower contrast, such as low polymersomes uptake or blood
vessels, were segmented using different algorithms.
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(a) Original image (b) Mask
Figure 3.1: Example of intensity thresholding masking on epi-fluorescence image
of nucleus stained with DAPI. Pixel values with intensity higher than the threshold
are considered as ROI and highlighted in white on the right image. Bar 13µm.
3.2.2 Difference of gaussians (DoG)
DoG algorithm is a form of band-pass filter (Marr and Hildreth [1980]) com-
monly used to detect edges. Its operating principle is that Gaussian blurring of
an image only excludes high frequency spatial information: noise. By applying
to the original image two different Gaussian blurring with different standard de-
viation and subtracting the two blurred images from each other, it is possible to
remove noise, and identifying the area of the images corresponding to the lower
difference of Gaussian (minimum of the function) allows to accurately identify
the edges of the ROI. In MATLAB, a Gaussian convolution kernel is generated
with
gauss ian = f s p e c i a l ( ’ Gaussian ’ , hs i z , s i g ) ;
Where hsiz define lowpass filter size, and sig define the standard deviation of
the Gaussian. The difference between two kernel is obtained using
dog = gauss ian1 − gauss ian2 ;
Finally, the original imnage is convoluted with the DoG filter using
d = conv2 ( double ( I ) , dog , ’ same ’ ) ;
The minimum in the resulting d matrix represents the regions of the image
to be analysed. The DoG algorithm is implemented in MATLAB using two slide
bars that allow the user to define the standard deviation of each of the two
Gaussian, and a third slide bar to define the hsiz parameter, common between
the two gaussians. Note that the DoG is not an absolute value: inverting the
values of sig1 and sig2 generates the negative of the mask, i.e. identifies the
background rather than the ROI. Figure 3.2 report an example of the application
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of the DoG algorithm. Note that the image refers to a micrograph acquired with
a 20X objective, which was the most difficult to segment because of the poor
background. However, the segmentation analysis did allow to correctly identify
the blood vessels. A limited amount of wrongly assigned pixels can be seen around
the micrograph edges, but those areas can be excluded by the analysis applying
one the filters provided with the developed software.
(a) Original image (b) Mask
Figure 3.2: Example of DoG application on a vessel image acquired in bright
field using a 20X objective. The original image on the left has poor contrast and
cannot be segmented by simple intensity thresholding. DoG algorithm was capable
of correctly identifying vessels (right image, in white). Bar 70µm.
3.2.3 Local threshold entropy (LTE)
The LTE algorithm was used to segment some of the in vivo images. It was
proposed by Fan and co-workers (Thitiporn and Guoliang [2003]), and it was here
slightly modified to meet the specific requirements of the analysis. LTE is a two
steps algorithm. The first step is a matched filtering, followed by local entropy
thresholding. Matched filtering is an enhance filter that enhances contrast of blood
vessels by detecting linear segments in the image (vessels) and assuming Gaussian
distribution of intensity at the edges. Once the contrast has been enhanced
at the edges of the ROI using the matching filtering, the LTE automatically
detects the optimal thresholding for vessel extraction. This is done locally on
small regions of the image by assuming that the intensity values are spatially
correlated and not pixel-position independent: the ROI is a contiguous region of
space characterised by a local homogeneous distribution of intensity values. This
is different to the intensity thresholding approach as two different images with
the same overall signal intensity but different spatial pixel distribution will have
different threshold. A critical parameter is the size of the matching filter, which
is correlated to the size of blood vessels. In early versions of the segmentation
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software the user was given the possibility to tweak the parameter, however it was
later found that results were not better or faster than DoG filtering. The only
exception was in segmentation of vessels images acquired with the 2.5X objective.
Those images were effectively masked by the algorithm proposed by Fan using
the same size of the match filter, most likely because of the resemblance with the
images analysed in the cited work, at least regarding blood vessels pixels size.
(a) Original image (b) Mask
Figure 3.3: Example of LTE. An image of blood vessels acquired with a 2.5X
magnification was effectively segmented using the LTE algorithm. Extracted vas-
culature on the right, in white. Bar 800µm.
3.2.4 Mask post-processing
Post-processing intensity thresholding Regardless of the segmentation pro-
cess used, the mask generated was not perfect. It could contain some noise given
by isolated bright pixels or in some pixels the signal intensity was out of scale
(saturated pixels, intensity=255 in an 8bit image). All those values can nega-
tively interfere therefore they should be removed. Saturated pixels were removed
by applying a thresholding filter on the mask, and the threshold level was set by
the user as previously described. There was also the possibility to remove very
dark pixels, an option useful in the clean up process of in vivo images, where
some dark pixels occasionally generated unwanted ROI.
Size-filtering post-processing Isolated pixels or small groups of isolated pix-
els (noise) can be removed by applying a size filter to exclude regions smaller (or
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bigger) than a defined size limit. This feature is based on the internal MATLAB
function regionprops and its optional argument Size. The regionprops command
accepts as input a binary image (mask), where white represents the ROI and
black the background. The function identifies separate ROIs defined as continu-
ous, uninterrupted regions of white, and store their size values separately. The
size filter then check for the size values and excludes ROI outside the size bound-
aries. T size filter is implemented in the GUI with the use of two side bars that
allow to interactively fix the size threshold (upper and lower limit).
(a) Original image (b) Cleaning mask, 1st step
(c) Cleaning mask, 2nd step (d) Final mask
Figure 3.4: Original picture (a) was segmented. The mask obtained (b) was
cleaned by eliminating high intensity values (c) and small, isolated pixels (d).
Bar 22µm.
3.3 Pericyte markers image analysis
Images were segmented using the specifically developed software. The work-
flow of the analysis and a segmentation example is reported in figure (3.5). Nu-
clear mask was subtract from the cell mask to exclude any cross-talk between the
channel by excluding the nuclear ROI from the cell mask. To be able to compare
different sets of experiments, the ratio of the average intensity in samples over
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the control was used rather than the absolute intensity value. An example of
such operation for 10T1/2 treated with 0, 2 or 5ng/ml of Transforming Growth
Factor-β1 (TGF-β1) is reported in figure 3.5-3.6.
Figure 3.5: Work-flow of image analysis for ICC experiments. Cells were seg-
mented using the antibody channel (A, C) to identify the cells and the DAPI
channel (B, D) to identify the nucleus. The nucleus masks (F, H) were subtracted
to the respective cell masks (E, G) and the average intensity was measured in the
resulting ROI (I, J). Bar 22µm.
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Figure 3.6: Average intensity in selected ROI was measured for control and sam-
ples. The average intensity of the sample over the control gave the ratio used to
compare expression between different concentrations and samples. Bar 30µm.
3.4 Image analysis for uptake in static condi-
tions
Uptake quantification was performed by quantifying the average intensity of
cells detected by the segmentation software and plotting the result as a variation
of the average intensity over time. To be able to easily compare results between
different cell lines, data were expressed with respect of the maximal uptake, fixed
as a 100%. The maximal uptake is here defined as the maximal value of intensity
recorded for the analysis, which correspond to the uptake of rhodamine labelled
Poly(2 - methacryloxyethyl-phosphorylcholine)-poly( 2 -(diisopropylamino)ethyl
methacrylate) (PMPC-PDPA) polymersomes from the tumour cell type Mouse
Fibrosarcoma Cells expressing VEGF188 isoform (MFC188) at t=24h. An ex-
ample of this application using modified pictures used in the testing phase is
reported in figure 3.7.
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(a) t=0h (b) t=1h (c) t=2h (d) t=3h (e) t=4h
(f) Analysis report
Figure 3.7: Example of time analysis. The top row represents an ideal set of
five pictures of increasing intensity, such as the ones that could be obtained in an
uptake study from t=0 to t=end. The bottom plot shows the variation on average
intensity recorded in the ROI identified in the segmentation analysis versus time.
As expected, the software report an increase of intensity over time, reflecting what
can be seen in the picures. Bar 30µm.
3.5 Image analysis for uptake in flow conditions
This analysis aimed to correlate physical flow parameters in specific area of
cell in the imaged plate with polymersomes uptake. Images of different areas of
a 24 well plate were imaged and the measured uptake was correlated to shear
stress or velocity magnitude in the same area.
3.5.1 BD Pathway 855 microscope set-up
The analysis depends on accurately mapping the imaging area of the 24 well
plate. Because the BD Pathway 855 does not natively support 24 well plate the
well was manually mapped and the imaging positions were saved into the micro-
scope settings as xy offsets from defined positions. The mapping was performed
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by accurately drawing a grid on the bottom of the well and using the intersec-
tion of the grid as guideline for setting the offset. The grid also allowed us to
accurately identify the position of the inlet and the outlet (see fig 3.8).
Imaging a full 24 well plate and all the well used in one analysis required a long
amount of time, which was not compatible with cell viability in the microscope.
Cell fixation also proved to not be an option, as the fixation severely compromised
rhodamine signal (see fig. 3.9) To overcome this limitation, a lower resolution
objective was used (10X) three representative areas were imaged instead of the
whole well.
(a) Reference grid (b) Well mapping
(c) Overlay with shear stress
Figure 3.8: Mapping a well. Using a well with marked position as a reference (a)
images were taken and then a well was reconstructed saving on the microscope
software the xy offset (b). Finally, the shear stress mapping obtained from Comsol
MultiPhysics simulation was overlaid (c). Bar 3mm.
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(a) Fixed sample (b) Non fixed sample
Figure 3.9: Effect of fixation on rhodamine labelled polymersomes signal in cell
imaging. After fixation (left) the intensity signal from rhodamine labelled poly-
mersomes up-taken is severely compromised compared to live cell imaging (no
fixation, right picture). Bar 2mm.
3.5.2 In silico well mapping segmentation
In silico simulations was used to quantify shear stress and velocity magnitude
at the cell level. Because COMSOL is based on finite element analysis, it divides
the volume to be analysed (the well) into a finite mash, and when asked for
the value of shear stress or velocity magnitude at the cell level it only gives the
values at the intercept between the mesh and the plane of cell growth. Depending
on the size of the meshing this can be a rather sparse matrix. To obtain a
detail reconstruction of the well mapping the data were passed to MATLAB
and the function meshgrid was called to interpolate missing data to the tenth
of micrometer resolution, significantly higher than the resolution achievable with
the 10X objective used in later imaging. The resulting map was stored as grey
scale image and used for segmentation. The range 0-255 was then divided into
8 ROI each one of step 32, so that the first area had intensity 0-31, the second
32-63 etc. Because it is a grey scale 8bit image, the intensity values will range
from 0 to 255, corresponding to low and high values of shear stress and velocity
magnitude. Knowing the corresponding values it is possible to directly correlate
the intensity value to the actual shear stress or velocity magnitude. For instance,
if the range 0-255 corresponds to a range of velocity 0-80µm/s, then it can be
derived that intensity value of 32 will correspond to velocity 80·32
255
' 10µm/s (fig.
3.10)
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(a) Shear stress mask (b) Shear stress mask
(c) ROI 1 (d) ROI 2 (e) ROI 3 (f) ROI 4
(g) ROI 5 (h) ROI 6 (i) ROI 7 (j) ROI 8
Figure 3.10: Segmentation of the flow parameter. The reference well with the
analysed z-plan is displayed in (a). In this example the shear stress is considered.
The original range of grey intensity 0-255 (b) was divided into 8 ROIs, showed
in different colours in picture (c-j). Every ROI has intensity range of 256
8
= 32.
The corresponding full range of shear stress was 0-12dyn ∗ cm−2, therefore every
ROI correspond to a range of shear stress of 12
8
= 1.5dyn ∗ cm−2.
3.5.3 Image analysis
After image acquisition, the images were carefully overlayed with the well
mapping of a defined flow parameter (shear stress or velocity magnitude). Av-
erage signal intensity of cells growing in area with a specific flow parameter was
finally correlated with the flow parameter itself, to identify a correlation between
up-take and shear stress or velocity magnitude (see fig 3.11).
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(a) Shear stress distribution (b) ROIs 1-4
(c) Signal intensity-ROI correlation
Figure 3.11: Image analysis method. The first four of the total eight ROIs cor-
responding to the lower values of shear stress are highlighted in the figure (top
right), from dark blue to pale green. A micrograph is placed on the appropriate
xy position of an entire well and the 8 ROIs are overlaid to the micrograph (the
red lines represents the edges of the single ROI. Intensities of the areas belonging
to a ROI are averaged and a new well-uptake image is reconstructed based on the
average value).
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3.6 Image Analysis for in vivo experiments
3.6.1 Masking
In vivo image analysis had the aim to quantify and localise signal intensity of
rhodamine labelled images of tumour vasculature. This is a segmentation prob-
lem as it requires identification of at least two ROIs in every image: vasculature
and stroma. The identification of these two ROIs in confocal pictures is not an
easy task, mostly because of the very variable and weak signal, especially at later
time points. However, the confocal microscope used can acquire simultaneously
a transmitted light image of the vasculature, where the vessels are always clearly
visible in black over brighter tumour stroma. The simultaneous acquisition to-
gether with imaging in different areas of the tumour over-time eliminates the need
for registration. Tumour images were segmented using a software specifically de-
veloped. First of all, the tumour area to analyse was manually chosen (this option
included the possibility to analyse the whole as well), finally intensity threshold,
LTE and DoG algorithms were implemented to allow vessel segmentation. Dif-
ferent images were segmented better with different algorithms, depending on the
image characteristics (see fig 3.12).
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(a) 20X objective, transmitted light (b) 20X objective, mask
(c) 2.5X objective, transmitted light (d) 2.5X objective, mask
(e) 10X objective, transmitted light (f) 10X objective, mask
Figure 3.12: Mask generation in different pictures. Images of vasculature acquired
using transmitted light in an epi-fluorescence microscope (20X (a), 2.5X (c)),
and in a confocal (10X (e)). Images (a) and (b) were both segmented using DoG
algorithm. Image (c) was segmented using LTE algorithm. For all images, vessels
were correctly identified. Bar (a) 70µm; (c) 800µm; (e) 200µm.
As in ICC and uptake image analysis, masks were further processed to reduce
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noise by size filtering. A crucial difference between the ICC and uptake image
analysis software and the in vivo image analysis software is the introduction of a
third ROI in the latter. This third ROI correspond to the perivascular region and
it is therefore located between the vessel mask and the stroma mask. There are
two main reasons to justify the introduction of this third mask. First of all, in low
resolution images such as 2.5X images, it can be used as a safe zone, to exclude
pixels which cannot be assigned to the vessel or the stroma mask because of the
low resolution. The second reason is that, in higher resolution images, it can
be used to assess the distribution of polymersomes in perivascular region, where
pericytes are normally located, and also to evaluate the diffusion of polymersomes
into the tumour by measuring the average intensity in this region, which can be
dynamically expanded (fig. 3.13).
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(a) Original image, transmitted light (b) Original image, fluorescence
(c) Transmitted light and mask (d) Fluorescence and mask
Figure 3.13: Masking blood vessels. Original images on top(a-b), masks over-
lay at the bottom (c-d). Masks were created on transmitted light images (a-c)
and then transferred to rhodamine images (b-d) The tumour area was identified
manually and is shown as coloured RGB overlay. Vessels were identified auto-
matically by the proposed segmentation algorithm. Vessels in red, stroma in blue
and perivascular region in green. Bar 210µm.
3.6.2 Vessel mask segmentation: Isolating vessels to de-
termine vascular diameter and diffusion profile
To correlate diffusion of nanoparticles with vessel diameter and travelled dis-
tance it is necessary to separate all the vessels identified with the vascular mask.
This was achieved by reducing the vasculature mask to its skeleton using the
MATLAB built in function bwmorph
s k e l e t o n v e s = bwmorph( ves , ’ ske l ’ , i n f ) ;
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The skeleton mask is a binary mask were the vessel has value 1, the non-
vessel has value 0. Considering the vessel a linear sequence of 1s, vessels ends
and branching points can be easily identified as the only one surrounded by 1
or 3 1s respectively (see fig 3.15). By subtracting the branching points from the
skeleton mask a new mask will be created where the continuity of 1s sequence is
interrupted at the branching level. The regionprops function can be called at this
point as it will identify every different ROI, where ROI is defined as a continuous
region of space completely surrounded by 0s.
l i s t v e s s e l s=reg ionprops ( ske l e ton ves new , . . .
’ P ixe l IdxL i s t ’ , ’ Area ’ , ’ P ix e lL i s t ’ ) ;
Note that since it is a skeleton mask running from vascular node to vascular
node, the Area corresponds to the vessel length. Finally, the function bwdist can
be called on the negative of the vessels mask to calculate the Euclidean distance
between every pixel of the vessel and the closest pixel belonging to the tumour
stroma:
edtImage = 2 * bwdist (˜ ves ) ;
Note that the multiplicative factor of 2 will directly give the diameter of the
vessel. For every vessel, the diameter calculated in the middle of the vessel was
stored.
Finally, the Euclidean distance of every pixel of the tumour stroma from the
closest vessel is calculated in a similar way:
[ d i s tance s , l a b e l ] = 2 * bwdist (˜ stroma ) ;
For every pixel belonging to the tumour stroma, its coordinates were used to
store simultaneously the distance from the closest vessels and its rhodamine signal
intensity. The label option of the bwdist command allows to correlate the distance
measured to the corresponding vessels, and therefore to retrieve its diameter. All
data are stored in a matrix correlating pixel by pixel the rhodamine intensity, the
distance from the closest vessel and the vessel diameter. The function griddata
was used to produce a meshed grid of data useful to produce a surface plot of
vessel diameter against distance, with the pixel intensity represented in a colour
map (3.14-3.15):
x l i n=l i n s p a c e (0 , max diam , max diam *10 ) ;
y l i n=l i n s p a c e (0 , max dist , max dist *1 0 ) ’ ;
zg=gr iddata ( vess diam , d i s tance , i n t e n s i t y , x l in , y l in , ’ l i n e a r ’ ) ;
s u r f ( zg , ’ Edgecolor ’ , ’ none ’ )
67
3. Image analysis 3.6. IMAGE ANALYSIS FOR IN VIVO EXPERIMENTS
(a) Transmitted light (b) Full vessel mask
(c) Skeleton mask (d) Detailed skeleton mask
Figure 3.14: Identification of vessels and branching points. From the transmitted
light image (a) the full mask vessel was obtained (b). The skeleton mask (c)
showing only the vessels central line was computed from the vessels mask. Finally,
vessel ends (green), vessel branching points (red) and vessel centre (blue) were
identified as reported in fig. 3.15. Bar 210µm.
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Figure 3.15: Identifying vessels, ends and branching points in a binary mask.
Pixels belonging to the middle of the vessel have sum of surrounding pixels of 2.
Branching points have sum of 3 and ends have sum of 1.
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(a) Transmitted light (b) Full vessel mask
(c) Skeleton mask
Figure 3.16: Computation of vessel diameter. The tumour stroma mask was used
to compute Euclidean distances from the vessels (shown in (c) as grey scale image,
with brighter points representing points far from vessels). By correlating the pixel
position in the distance map and in the original image it is possible to correlate
signal strength with distance from vessel. 300µm.
3.7 Automatisation of image analysis
Automatisation of image analysis allows faster image processing and higher
throughput. Image analysis automatisation was implemented with the develop-
ment of two GUI softwares using MATLAB GUIDE toolbox. One software is
dedicated to in vitro image analysis (3.17), the second one to in vivo image anal-
ysis (3.18). Both softwares store images in a database for batch processing and
allow the user to categorise images using a tag system. The tag system is used to
recall images from the database an to perform analysis on data sub-sets, i.e. pro-
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cess only images acquired with a specific microscope or from cell treated with a
specific polymersomes formulation. A panel allows to test different algorithm and
post-processing mask settings in order to identify the ideal conditions for segmen-
tations. The settings can be then applied to the entire database or to a sub-set
specified by the tag system. Segmentation results can reviewed individually for
further refinement. In vitro GUI was optimised to perform intensity based stud-
ies such as calculation of average intensity on specific ROIs, either in relation to
specific growing condition (i.e. TGF-β1 concentration) or over time (i.e uptake
studies). The software can also perform co-localisation (Pearson and Manders
coefficient). In vivo GUI was optimised to identify the three ROIs blood vessel,
vessel edges and tumour stroma and to measure the relative average intensity.
Figure 3.17: GUI of the software used to analyse ICC and Immunohystochemistry
(IHC) images. The interface is divided in panels to group different stages of
the analysis: data input, data retrieval, mask creation, combination of masks,
analysis and plotting. On the right, the chosen picture is always displayed. During
batch analysis, the right picture box provides feedbacks on the analysis status (i.e.
on-going, finished, errors).
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Figure 3.18: GUI of the software used to analyse tumour vasculature images.
The interface is divided in panels to group different stages of the analysis: data
input, data retrieval, mask creation, analysis and plotting. On the left, the chosen
picture is always displayed along with the different masks obtained.
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CHAPTER 4
POLYMERSOME UP-TAKE
Abstract
Fluorescently labelled polymersomes can be detected in cells using a vari-
ety of techniques, including Reverse Phase-High Pressure Liquid Chromatogra-
phy (RP-HPLC), Fluorescence Activated Cell Sorting (FACS) and microscopy.
Of these, the latter is the most sensitive, being capable of resolving uptake at
the single cell level. It is also the quickest one to perform routinely in a high
throughput screening context, as it does not involve extraction or preparation
steps: cells can be imaged live. In this part of the work, the use of fluorescence
microscopy to quantify cellular uptake was validated through comparison with
consolidated quantitative (RP-HPLC) and semi-quantitative (FACS) techniques.
Furthermore, the analytical system was complicated by the introduction of an in
house developed flow bio-incubator to assess the effect of shear stress and fluid
velocity on cellular uptake.
The polymersomes used had hydrophilic brush composed of Poly(2 - methacry-
loxyethyl - phosphorylcholine) (PMPC) or poly(oligo(ethylene glycol) methacry-
late) (POEGMA), known to interact with cells in different ways: PMPC based
polymersomes were expected to be internalised quickly, while POEGMA based
polymersomes were expected to have a significant slower uptake kinetic. The tu-
mour microenvironment was replicated in vitro by studying the uptake in three
cell type characteristic of the disease: tumour cells (Mouse Fibrosarcoma Cells
expressing VEGF188 isoform (MFC188)), blood vessel endothelial cells (Small
Vessel Endothelial Cells (SVECs)), and perivascular cells (10T1/2). MFC188
cells can originate a more vascularised and pericytes rich tumour when used in
vivo in Dorsal Skinfold Chamber (DSC) preparation (Tozer et al. [2008]). This
will facilitate vascular imaging in vivo in later experiment presented in this thesis.
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For this reason MFC188 cells were chosen as a model of tumour cell for both in
vitro and in vivo studies.
4.1 Introduction
4.1.1 Uptake and in vitro screening
A comprehensive understanding of the mechanism and parameters regulating
uptake of polymersomes by cells is at the basis of a clever design of nanoparticles
for a specific application.
Direct quantification of the vector up-taken in vitro is strongly dependent on
the properties of the vector itself. Delivery of radioactive marked nanocarriers
can be quantified by measuring the radioactivity signal (Penate Medina et al.
[2010]). This is a very sensitive technique and it is also useful to determine the
metabolic fate of the carrier, however it is a costly technique and it requires
specific equipment and working spaces. Fluorescently labelled carriers represent
a valid alternative (McDonald and Choyke [2003], Beerling et al. [2011]) both in
vitro (Massignani et al. [2010]) and in vivo (Christian et al. [2009a]), a routine
step of pre-clinical development. Fluorescently labelled particles can be detected
in a number of way. In vitro, the most commonly used techniques for detection
of fluorescently labelled vectors in cells are RP-HPLC, FACS and cell imaging.
RP-HPLC is a quantitative technique capable of separate solute according
to their charge and molecular weight, and to quantify their concentration when
coupled with a detector, typically a UV-VIS spectrophotometer or a fluorometer
(Horvath et al. [1967], Gerber et al. [2004]). In drug development and discovery
it has been used to detect a number of different molecules, from peptides to anti-
cancer drug (Carr [2002], Tekade et al. [2013]). In this study, RP-HPLC was
used to quantify the amount of polymersomes, specifically of rhodamine labelled
colpolymer, up-taken by the cell.
FACS is a technique capable of sorting every cell in the cell individually on
the basis of its size and granularity/complexity. As a result, FACS allows to
separate (sort) different cell type in a sample as they will have different size and
granularity (Dittrich and Gohde [1973], Kiziltepe et al. [2012], Lee and Tung
[2011]). Furthermore, every cell is analysed for fluorescence intensity at a given
wavelength. This aspect is of importance for this work as it allows to obtain in-
formation regarding the amount of rhodamine labelled polymersomes internalised
by cells (Massignani et al. [2009]).
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Live cell imaging , specifically coupled with fluorescence detectors, is a com-
monly used technique to assess cellular uptake of fluorescent labelled moieties.
Traditionally capable of micrometer spatial resolution, it is now possible to break
the diffraction limit and to resolve at the nanometer scale (Hell and Wichmann
[1994]). Fluorescence microscopy can record intensity of emission from fluorescent
material uptaken by cells, and the signal strength is proportional to the amount
of material uptaken (Canton and Battaglia [2013], Kim et al. [2009], Discher et al.
[2008]).
4.1.2 Static and flow in vitro cell growth
In vitro study of cells in every day laboratory practice is mostly performed
on a plastic Micro well plate (MWP). MWPs are a confined environment fully
controlled by the researcher, making them ideal to increase reproducibility of the
analysis and to study impact of single variables on cellular phenomena. However,
cells in the body are subjected to a much more complex environment given by
interactions with other cells types, different chemicals and mechanical stimuli.
One of the determinants of the local concentration of chemicals is blood flow, as
it is responsible for mass transfer. Blood flow affects cells also because of direct
mechanical stimuli, to the point that some cells have specifically evolved to sense
flow and to adapt phenotype in response to variation of flow. An example of such
cells include endothelial cells, the cells that constitute the wall of blood vessels.
An interesting study on the effect of shear stress on endothelial cells (HUVEC)
was performed by Khan and Sefton. Using a specifically designed microchip that
recreates a number of obstructions and channels of different sizes they were able
to recreate several different shear stress and flow streamlines within the same
chip. They then investigated the changes in expression of VE-cadherin and other
adhesion molecules to show a clear effect of the flow on the expression of such
molecules and the phenotype of the cells (Khan and Sefton [2011]).
4.1.3 Effect of flow on cellular uptake
It is easy to speculate that flow can affect cellular uptake, especially by cells
specialised to sense flow such as the endothelial cells. Despite this there is a sur-
prisingly lack of literature supporting this statement, most uptake studies being
still conducted in static conditions in MWP. A recent study performed by Volkov
and co-workers correlates uptake of positively and negatively charged quantum
dots and SiO2-NPs by endothelial cells (HUVEC) under different shear stress
stimulation. Surprisingly, they reported no uptake in static in 20min despite
one of the formulation being significantly toxic at the same exposure time. Fur-
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thermore, they showed maximum uptake at low shear stress (0.05Pa) for all the
formulations tested, and then a decrease of up-take that reflects the increase in
shear stress, even if the trend was not statistically relevant (Samuel et al. [2012]).
In another study Discher and co-workers investigated the effect of flow on up-take
of filomicelles of different lengths. They reported how immobilised macrophages
under flow rates similar to the ones measured in spleen in vivo can recognise and
uptake small spherical vesicles, but the flow forces the filomicelles in a stream-
lined conformation, and as a results a small fragment of the tip can be detached
and up-taken, but the majority of the mass of the filaments is rapidly taken
away from the cell by the flow therefore prolonging its circulation time in the
device. This in vitro data was confirmed in in vivo results showing circulation
half time proportional to filament length (Geng et al. [2007]). To date, no studies
have been published providing a comprehensive correlation of uptake for a given
polymersomes formulation and cell line with shear stress.
4.1.4 Flow devices
Several devices have been designed to overcome static tissue culture limita-
tions. Such devices tend to be application specific and custom made, not com-
mercially available. Examples includes reproduction of blood vessels (Miyakawa
et al. [2008], Leong et al. [2013], Samuel et al. [2013]), heart valves (Dumont et al.
[2002]), liver (Powers et al. [2002]) and bones (Kim and Ma [2012]). An interest-
ing exception is represented by the flow bio-incubator developed by Mazzei and
collaborator, (Mazzei et al. [2010]), and commercialised with the name Quasi-
Vivo® by Kirkstall, a company based in Sheffield. The system resembles a 24
well plate and has a modular nature which allows interconnecting of chambers to
recreate cross-talking between organs, an approach they describe as organomics.
An important classification of flow bio-incubator is based on sized. Most of
the devices cited above have chambers at least millimetre-sized. Another popular
type of devices is known as micro-fluidic devices. These have the great advan-
tages of being highly reproducible because of the precise manufacturing process
and to minimise the requirements of cells, media and other reagents. However,
their small size is also their main limitation. Because of the limited number
of cells used they cannot be representative of big and complex tissues (Tingley
[2006]). Furthermore, because of their geometry they have a big edge/surface
ratio (Lundholt et al. [2003]).
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4.1.5 Aim
RP-HPLC, FACS and live cell imaging are all techniques suitable for quanti-
fying polymersomes uptake. In routine screening for uptake the technique giving
the most accurate results should be used, and that technique should ideally be
fast and easy to set-up. Here the three techniques were compared and inte-
grated in the study of uptake of different formulations by different cell type. The
aim was to validate the use of live cell microscopy as a semi-quantitative tech-
nique to screen polymersomes uptake by tumour-relevant cell types: tumour cells
(Mouse Fibrosarcoma Cell (MFC)), endothelial cells (SVECs) and perivascular
cell (10T1/2). Furthermore, the analysis protocols will be applied to in flow
uptake studies, to elucidate the role of shear stress and fluid velocity on cellu-
lar uptake. This is critical as polymersomes will be administered in vivo Intra
Venous (i.v.), therefore they will be subjected to flow dynamics.
4.2 Results
4.2.1 Static conditions
Quantification of uptake with RP-HPLC, FACS and live cell imaging
The technique of choice in this work is imaging, therefore almost all uptake
data collected will be based on image analysis. Comparison with established
analytical techniques RP-HPLC and FACS was used to validate the method.
MFC188 cells were treated with 1mg/ml of rhodamine labelled
Poly(2 - methacryloxyethyl-phosphorylcholine)-poly( 2 -(diisopropylamino)ethyl
methacrylate) (PMPC-PDPA) polymersomes and the uptake was quantified with
RP-HPLC, FACS and live cell image analysis. All three methods showed very
similar uptake profile (fig. 4.1).
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Figure 4.1: RP-HPLC, FACS and live cell imaging comparison. All uptake re-
fer to 10% rhodamine labelled PMPC-PDPA polymersomes, 1mg/ml, MFC188
cells. All data were normalised with respect to the maximal uptake for the relative
quantitative technique, corresponding to the uptake at t=24h. All techniques have
similar uptake profile. N=3, ±SD.
Once confirmed the validity of the method, live cell imaging analysis was used
to compare uptake of rhodamine labelled PMPC-PDPA and poly(oligo(ethylene
glycol) methacrylate)-poly( 2 -(diisopropylamino)ethyl methacrylate) (POEGMA-
PDPA) polymersomes from MFC188, SVECs and 10T1/2. All cells were treated
for up to 24h with 1mg/ml of rhodamine labelled polymersomes. For any of the
three cell types, uptake of PMPC-PDPA polymersomes was higher compared to
POEGMA-PDPA (p<0.05) (fig. 4.2). This was observed both in FACS and image
analysis. MFC188 had higher uptake compared to SVECs or 10T1/2, especially
for PMPC-PDPA polymersomes.
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(a) FACS
(b) Image analysis
Figure 4.2: Quantification of uptake of rhodamine labelled PMPC-PDPA and
POEGMA-PDPA polymersome by 10T1/2, MFC188 and SVECs. Uptake was
quantified by FACS (a) and image analysis (b). PMPC-PDPA uptake was greater
than POEGMA-PDPA, and MFC188 had greater uptake compared to SVECs
or 10T1/2, with the only exception of uptake of POEGMA-PDPA measured by
FACS. N=3, ±SD.
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Figure 4.3: Representative images of PMPC-PDPA uptake in live cells imaging
from 10T1/2 (A, B, C, D), MFC188 (E, F, G, H) and SVECs (I, J, K, L).
Images were acquired at 0h, 1h, 6h and 24h. Cells cultured in static conditions.
Uptake in MFC188 is greater than uptake in 10T1/2 or SVECs. Bar 70µm.
Figure 4.4: Representative images of POEGMA-PDPA uptake in live cells imag-
ing from 10T1/2 (A, B, C, D), MFC188 (E, F, G, H) and SVECs (I, J, K, L).
Images were acquired at 0h, 1h, 6h and 24h. Cells cultured in static conditions.
Uptake in MFC188 is greater than uptake in 10T1/2 or SVECs. Bar 70µm.
4.2.2 Flow bio-incubator
Flow bio-incubator optimisation
The flow bio-incubator developed here was based on the 24 well plate geom-
etry for easy translation of existing experimental protocols to the new device.
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COMSOL Mutliphysics was employed to assess shear stress at the cellular level
and to optimise the design to deliver a homogeneous flow. From the first simula-
tions run a clear problem emerged: the inlet and outlet positioned perpendicular
to the cell plane generated a high local peak of shear stress. Furthermore, this
design was difficult to assemble in a reproducible manner: the tubes were sub-
jected to movement that deviated from the simulated perpendicular angle (see
fig. 4.5).
To protect the cells from perpendicular flow a shield was introduced, so that
the liquid was entering the well parallel to the cell surface. This was achieved
using L-shaped elbow connectors attached to the tubing. The elbow connectors
had several advantages. Their bulk volume substituted liquid volume in the well,
reducing the amount of media needed. Furthermore, the inlet and the outlet
shield provided stability to the tubing reducing movement. As with the previous
design, the position of the tubing was optimised using in silico modelling. Results
from the simulations are reported in figure 4.6-4.7. When inlet and outlet are too
close to the cells (H=1mm) there is almost no flow at the cell level (velocity and
shear stress close to 0). At medium high (H=4mm) the situation improved, and
finally at H=7mm the flow was higher, but less parallel to the horizontal plane.
Regarding the relative position of inlet and outlet it was found that if they are
located close to the edge the flow profile was irregular with localised peaks of
shear stress and velocity close to the wall edges. If the tubes are located close to
the centre the profile was more homogeneous. Considering the in silico results,
the model chosen was with inlet and outlet located at the edges of the well and at
4mm from the cell level. This model was the easiest to assemble in a controlled
way, and it gave a good balance between homogeneous flow at the cellular level
and shear stress-velocity magnitude range in relation to the peristaltic pump
set-up. Positioning the tubing further away from the cells would have caused
loss of accuracy at lower rpm and flow rate, which are the critical parameter to
use when simulating low flow rates such as those characteristic of the tumour
microenvironment.
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* * *
***
* * *
Position 1 Position 2 Position 3
Figure 4.5: Flow device models. The three proposed flow device models. The first
model (top row) had no shield. The second and third models (second and bottom
rows) had a shield orientating the flow parallel to the cell plane. The difference
between the two models is in the relative position of the inlet and the outlet. In
the second model they are close to the well wall, in the third model they are located
close to each other. In silico simulations were run positioning the tubing at close
to the bottom of the well (left column, Position 1), in the middle of the well
(middle column, Position 2) or far from the cell level (right column, Position 3).
Flow= 20µL/s. ∗ Identifies the inlet. Scale bar 7mm.
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Position 2 Position 3
dyn/cm2
Mean
Position 1
47 14 14
5 7 5
2 3 3
Mean
Mean
*
*
*
* * *
***
* * *
Figure 4.6: Shear stress distribution across the three models. The coloured disc
represent the plane of cell growth (bottom of the well). When no shield is present
(top row) there is high heterogeneity between different areas of the well depending
on their location with respect to the inlet or the outlet. When a shield was used
(second and third rows) the shear stress distribution was more homogeneous. How-
ever, when the shield was too close to the bottom of the well (Position 1) there was
almost no flow (shear stress '0dyn ∗ cm−2 under the shield itself. Mean refers to
the mean shear stress generated 5µm from the bottom of the well. Flow= 20µL/s.
∗ Identifies the inlet. Scale bar 7mm.
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Mean 191 74 79
8 40 27
13 18 19
Mean
Mean
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Position 2 Position 3Position 1
Figure 4.7: Velocity distribution across the three models. The velocity considered
here is the total absolute velocity parallel to the cell plane. The coloured disc
represent the plane of cell growth (bottom of the well). The general observations
reported for shear stress in figure 4.6 are confirmed for the velocity profiles here
presented. Mean refers to the mean velocity generated 5µm from the bottom of
the well. Flow= 20µL/s. ∗ Identifies the inlet. Scale bar 7mm.
(a) a (b) b
Figure 4.8: Flow device overview. The wells are connected with 0.8mm bore
tubing to a peristaltic pump. In (a) the elbow connectors are made visible by
sectioning the well plate. In (b) the lid used is visible. The white circles are self-
sealing membrane pierced with a 30G needle when injecting polymersomes into
the system.
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Cell viability
Cell viability was measured as described previously (sec. 2.4.2), and cell
viability of cells growing in static was compared to cell viability of cells growing
under flow. The flow rate chosen for this analysis was 30µl/s because this value is
50% higher than the maximum value planned to be used in the uptake experiment,
and it was assumed that if cells have no significant decrease in viability at this
flow rate, then any lower flow rate could have been used without compromising
cell viability. Cell viability was assessed for MFC188, SVECs and 10T1/2 treated
with Transforming Growth Factor-β1 (TGF-β1). Results are reported in figure
4.9. No significant decrease in viability was observed for any of the cell lines
(p>0.05).
Figure 4.9: Cell viability in flow, (3 - (4,5 - Dimethylthiazol - 2 - yl) - 2,5
- diphenyltetrazolium bromide (MTT) assay. Cell viability was assessed for
10T1/2, MFC188 and SVECs. No significant decrease in cell viability was ob-
served for any of the cell type used with respect of the same cell type cultured in
static condition: 100% viability (U-test, p>0.05). Flow rate was 30µL/s. N=3,
±SD.
Cellular uptake
In this study we compared uptake at 20µl/s with uptake in no flow condi-
tions. We compared PMPC-PDPA and POEGMA-PDPA, MFC188, SVECs and
10T1/2. Uptake was quantified by FACS and live cell image analysis. Results
from both analysis showed higher uptake of polymersomes in static compared
to in flow conditions. Furthermore, uptake of PMPC-PDPA polymersomes is
higher than uptake of POEGMA-PDPA. Cell imaging allowed for better resolu-
tion, probably due to a better sensitivity. Analysis of cell imaging data revealed
that in flow conditions the difference in uptake kinetics between the two formu-
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lations is minimal compared to the difference of uptake in static conditions. For
example, uptake of PMPC-PDPA at 24h from SVECs is double compared to the
uptake of POEGMA-PDPA, while in flow there was no significant difference. It
is also interesting to notice that the difference between different cell types is min-
imal in flow compared to static, where mfc188 showed the greater uptake and
10T1/2 the lowest. Image analysis and FACS results are reported in fig. 4.11.
FACS data expressed as percentage of cells positive for rhodamine over time are
reported in section 9.2, figure 9.5-9.7.
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(a) 10T1/2
(b) SVECs
(c) MFC188
Figure 4.10: Uptake of PMPC-PDPA (b, f) and POEGMA-PDPA (d, h) from
10T1/2, MFC188 and SVECs in static and in flow (20µl/s). Images a, c, e, g
are bright field images showing cells distributions in the well. Uptake in static
conditions is greater than uptake in flow, and uptake of PMPC-PDPA is grater
than uptake of POEGMA-PDPA. In static condition uptake from MFC188 is
greater than uptake from SVECs or 10T1/2, while in flow conditions there is
little difference between the three cell types. Bar 170µm.
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(a) 10T1/2, FACS (b) 10T1/2, Imaging
(c) SVECs, FACS (d) SVECs, Imaging
(e) MFC, FACS (f) MFC, Imaging
Figure 4.11: Quantification of uptake in static (solid lines) and in flow (dotted
lines) conditions with FACS (a, c, e) and imaging (b, d, f). Uptake was quantified
for PMPC-PDPA (red lines) and POEGMA-PDPA (blue lines) polymersomes.
10T1/2 (a, b), SVECs (c, d) and MFC188 (e, f) cells were compared. Uptake in
static conditions is greater than uptake in flow, and uptake of PMPC-PDPA is
grater than uptake of POEGMA-PDPA. In static condition uptake from MFC188
is greater than uptake from SVECs or 10T1/2, while in flow conditions there is
little difference between the three cell types. N=3, ±SD.
Image analysis and well mapping
In the developed device, shear stress and velocity magnitude at the cell growth
level is not perfectly homogeneous (see fig. 4.6-4.7). This is generally regarded
as a disadvantage, especially compared to commercially available flow macro-
chamber (i.e Ibidi IV0.4 chamber slides) or microfluidic devices. In those bio-
incubators the flow delivered is perfectly homogeneous across the whole observa-
tion chamber. However, in this study this can be used as an advantage. First of
all, it can reproduce heterogeneous flow in tumour microenvironment, but it can
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also be used to obtain uptake data in different flow conditions from the same well.
In this situation the only variable is the flow rate at the cell level, as the rest of
the well is exactly the same (same cells, same formulation, same pH and temper-
ature). In order to correlate uptake with different areas of the well characterised
by different shear stress, parallel (horizontal) or perpendicular (vertical) velocity
the microscope was programmed to acquire images in different areas of the well,
and the well was divided into eight regions having different flow properties. This
was of interest because it was hypothesised that cells exposed to different flow
rate, therefore to different shear stress and flow velocity, could not only exhibit
altered phenotype, such as elongated shape as already reported for endothelial
cells (Khan and Sefton [2011]), but also different uptake. The analytical method
here reported will allow quantify uptake in relation to flow parameter in the same
well, therefore in cells otherwise identical. This approach will also increase the
throughput of the analysis by allowing multiple data collection (i.e uptake vs
flow) in the same well. The process of dividing the well into different areas char-
acterised by different flow properties is described in section 3.5.2-3.5.3. Details
of the different Regions of interest (ROI)s with corresponding physical proper-
ties are reported in table 4.1-4.3. This analysis was performed for PMPC-PDPA
polymersomes up-taken by MFC188.
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10[µl/s] 20[µl/s]
ROI Shear stress range [dyn ∗ cm−2]
0.00/0.75 0.00/1.50
0.75/1.50 1.51/3.00
1.60/2.25 3.01/4.50
2.26/3.00 4.51/6.00
3.10/3.75 6.01/7.50
3.76/4.60 7.51/9.00
4.70/5.25 9.01/10.50
5.26/6.00 10.51/12.00
Table 4.1: ROI segmentation for shear stress. Shear stress in dyn ∗ cm−2. Data
for flow rate of 10µl ∗ s−1 and 20µl ∗ s−1. Data refers to division of ROI from
Position 2, shield located near walls, reported in figure 4.6. The resulting well
segmentation with all eight different ROI is reported.
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10[µl/s] 20[µl/s]
ROI Velocity range [µm ∗ s−1]
0.00/3.00 0.00/6.00
3.01/6.00 6.01/12.00
6.01/9.00 12.00/18.00
9.01/12.00 18.01/24.00
12.01/15.00 24.01/30.00
15.01/18.00 30.01/36.00
18.01/21.00 36.01/42.00
21.01/24.00 42.01/48.00
Table 4.2: ROI segmentation for horizontal velocity magnitude. Velocity in
µm ∗ s−1. Data for flow rate of 10µl ∗ s−1 and 20µl ∗ s−1. Data refers to division
of ROI from Position 2, shield located near walls, reported in figure 4.7. The
resulting well segmentation with all eight different ROI is reported.
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10[µl/s] 20[µl/s]
ROI Velocity range [µm ∗ s−1]
-6.00/-4.50 -12.00/-9.00
-4.49/-3.00 -8.99/-6.00
-2.99/-1.50 -5.99/-3.00
-1.49/0.00 -2.99/0.00
0.01/1.50 0.01/3.00
1.51/3.00 3.01/6.00
3.01/4.50 6.01/9.00
4.51/6.00 9.01/12.00
Table 4.3: ROI segmentation for vertical velocity magnitude. Velocity in µm∗s−1.
Data for flow rate of 10µl ∗ s−1 and 20µl ∗ s−1. Data refers to division of ROI
from Position 2, shield located near walls, reported in figure 4.7. The resulting
well segmentation with all eight different ROI is reported.
Images recorded by the epifluorescence BD-Pathway 855 microscope equipped
with a 4X objective were analysed as described previously (sections 3.5.2-3.5.3) to
correlate average fluorescence intensity with any specific flow parameter. Results
are reported in figure 4.12-4.14. Analysis revealed higher uptake (p<0.05) in
static compared than in flow, as already seen in FACS and single image analysis
(section 4.11). Furthermore, it can be observed that uptake at 10µl ∗ s−1 is
higher than uptake at 20µl ∗ s−1, particularly at the t=24h time point. However,
the relative small difference seems to indicate that in the range of flow rates
studied there is no significant difference of uptake (p>0.05): there is a significant
difference compared to static conditions, but once flow is applied the difference
is minimal across the range 10-20µl ∗ s−1. Shear stress and horizontal velocity
magnitude had a peak of uptake generally located in the middle of the well,
corresponding to average values and more horizontal fluid streamline (see fig. 4.5).
Vertical velocity showed a higher correlation of increased uptake with increased
velocity magnitude, with higher uptake in areas with higher velocity.
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Figure 4.12: Mapping of rhodamine intensity in the eight different ROI for shear
stress. The average intensity measured in the area of a given ROI, identified as
described in figure 3.10 is represented in colour code from blue (low intensity) to
red (high intensity). Intensity is proportional to polymersomes uptake. Analysis
refers to PMPC-PDPA polymersomes uptake by MFC188. In static condition
(bottom row) uptake was homogeneous across the well. Uptake in flow at 20µl/s
and 10µl/s was similar and uptake in the center of the well was greater than on
the ROI corresponding to the inlet (white asterisk) and the outlet (black asterisk)
region.
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Figure 4.13: Mapping of rhodamine intensity in the eight different ROI for shear
stress. The average intensity measured in the area of a given ROI, identified as
described in figure 3.10 is represented in colour code from blue (low intensity) to
red (high intensity). Intensity is proportional to polymersomes uptake. Analysis
refers to PMPC-PDPA polymersomes uptake by MFC188. In static condition
(bottom row) uptake was homogeneous across the well. Uptake in flow at 20µl/s
and 10µl/s was similar and uptake in the center of the well was greater than on
the ROI corresponding to the inlet (white asterisk) and the outlet (black asterisk)
region.
94
4. Polymersome up-take 4.3. DISCUSSION
Figure 4.14: Mapping of rhodamine intensity in the eight different ROI for shear
stress. The average intensity measured in the area of a given ROI, identified as
described in figure 3.10 is represented in colour code from blue (low intensity) to
red (high intensity). Intensity is proportional to polymersomes uptake. Analysis
refers to PMPC-PDPA polymersomes uptake by MFC188. In static condition
(bottom row) uptake was homogeneous across the well. Uptake in flow at 20µl/s
and 10µl/s was similar and uptake in the center of the well was greater than on
the ROI corresponding to the inlet (white asterisk) and the outlet (black asterisk)
region.
4.3 Discussion
In this work, polymersomes will be engineered to image the tumour microen-
vironment. Before screening different formulations in vivo, polymersomes were
tested in vitro for uptake kinetics in three tumour relevant cell types: tumuor
cells (MFC188), endothelial cells (SVECs) and perivascular cells (10T1/2). These
three cell types were specifically chosen as they represents an in vitro model of
the tumour that was implanted in in vivo experiments, obtained from MFC188
spheroid. This specific cell type is known to form tumours well vascularised and
rich on perivascular cells (Akerman et al. [2013]). 10T1/2 are in vitro precursors
of perivascular cells.
Two different polymersome formulations were tested: PMPC-PDPA and POEGMA-
PDPA. The two formulations chosen were expected to have different uptake ki-
netics, with PMPC-PDPA having faster uptake compared to POEGMA-PDPA.
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The kinetic of uptake of fluorescent labelled polymersomes can be monitored
using RP-HPLC, FACS and cell imaging. RP-HPLC and FACS are commonly
used quantitative techniques, however they are less suitable to fast and sensitive
screening than live cell imaging because of longer sample preparation. RP-HPLC
is useful to quantify the exact amount of fluorescent labelled polymersomes de-
livered to the whole cell population. FACS analysis can sort cells in co-culture
systems and analyse intensity at the single cell level. FACS cannot exactly quan-
tify the amount of polymersomes delivered to the cells. Live cell imaging is the
most sensitive technique as it allows to monitor uptake at the subcellular level.
Like FACS, image analysis cannot quantify the exact amount of polymersomes
up-taken, however it is a faster technique and it allows continuous monitoring of
the same group of cells for the entire analysis, limiting the amount of materials
required to perform the analysis. These characteristics make live cell imaging the
ideal candidate for high throughput screening.
The image analysis method reported in section 3.4 was validated through
comparison with RP-HPLC and FACS. The validation was performed studying
uptake of 10% rhodamine labelled PMPC-PDPA polymersomes from MFC188.
This formulation was chosen as it is known to have fast and high uptake from
many cell type, especially cancer cells (Massignani et al. [2010], Pegoraro et al.
[2014], Colley et al. [2014]). Results showed a very similar uptake profile in the
time of analysis considered (up to 24h, fig. 4.1). Following experiments were
therefore performed analysing uptake preferentially with optical imaging, and
using FACS for confirmation. RP-HPLC was abandoned as it was considerably
more time consuming and not suitable for high throughput set-up.
Uptake kinetics analysis showed a faster uptake for PMPC-PDPA compared
to poly(2-(diisopropylamino)ethyl methacrylate) (PDPA), and a greater uptake
from MFC188 compared to SVECs or 10T1/2. These findings are consistent
with the reported mechanism of uptake of PMPC-PDPA, which is mediated by
scavenger receptor SR-B1 (Colley et al. [2014]). POEGMA-PDPA uptake is not
receptor mediated, therefore it was expected to have slower uptake. Further-
more, it has already been reported that PMPC-PDPA polymersomes have faster
uptake compared to Polyethylen Oxide-poly(2-(diisopropylamino)ethyl methacry-
late) (PEO-PDPA) polymersomes (Murdoch et al. [2010]). The hydrophilic block
POEGMA used here is a chemically related to Polyethylene Oxide (PEO), as it
is essentially made by short PEO chains linked to a polymeric backbone. Fi-
nally, the cited work of Colley and co-workers (Colley et al. [2014]) reported how
tumour cells have greater expression of scavenger receptors compared to normal
cells. Further experiments confirming the validity of the statement for MFC188
could explain the greater polymersomes uptake observed in this cell type com-
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pared to SVECs and10T1/2.
Uptake studies performed in static tissue culture conditions are a laboratory
standard. However, cells in the natural environment are growing in completely
different conditions, caused by different surrounding (i.e. other cell lines present in
proximity), extracellular matrix and shear stress. This latter one can be mimic in
vitro by using a flow bio-incubator. There are several flow chambers commercially
available, however most of them are developed to mimic specific environments,
such as coronary vessels, or to be used in conjunction with specific techniques,
usually live cell imaging.
Considering that a number of protocol for RP-HPLC, FACS and live cell
imaging analysis of uptake have been developed in the first part of the work, it
was decided to develop a flow bio-incubator that allowed easy transfer of pre-
existing protocols. The device was based on the geometry of 24 well plate. In
silico modelling was used to optimise the design of the device so that the flow
delivered was as uniform as possible and to make sure that the shear stress and
flow rate delivered were comparable to the physiological ones at the capillary
level: τ = 100dyn · cm−2, U = 10− 100µm · s−1 (Decuzzi and Ferrari [2006]). It
should be noted that for the flow rates used in the final experiments (10-20µl/s)
the corresponding fluid velocity velocity was well within the indicated range,
while the shear stress was '8 times lower. However, tumour microvasculature is
characterised by irregular flow compared to healthy capillaries, therefore it could
be that the stated value of 100dyn · cm−2 is lower in tumours. Furthermore, the
experimental set-up used media, a Newtonian fluid with viscosity significantly
lower than blood. Further development of the device will be focused on the use
of more viscous media, for instance by adding dextran to the media.
Whole-well analysis of uptake kinetics were performed by FACS and cell imag-
ing. The two analysis methods showed significant decrease of uptake for all cell
lines under flow compared to static uptake. Furthermore, the difference of of up-
take between the two polymersome formulations PMPC-PDPA and POEGMA-
PDPA was significantly reduced. This could be explained considering that uptake
is a dynamic event requiring interactions of polymersomes with specifical cellular
structures, such as scavenger receptors SR-B1 for PMPC-PDPA. When polymer-
somes are administered under flow, they are carried away from the cell surface
by the flow. This is likely to reduce the interaction time between polymersomes
and the receptors, and therefore to decrease the uptake rate. Furthermore, by
limiting the receptor mediated uptake, the difference between PMPC-PDPA and
POEGMA-PDPA observed in static are likely to be reduced consequently.
A close observation of the shear stress and velocity magnitude profile at the
cell level (fig. 4.5-4.7) revealed areas characterised by different flow parameters.
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This could be seen as a disadvantage of the device developed, which is unable to
deliver perfectly homogeneous flow. However, live cell imaging unique capability
to focus on different areas of the plate can be used to obtain uptake data of cells
growing in slightly different conditions, but still on the same well. Potentially,
this can considerably decrease the amount of materials and experiments needed
to characterise uptake and flow correlation, with a positive impact on analysis
throughput.
Cell growth area was divided in 8 different ROIs corresponding to 8 areas
characterised by different horizontal or vertical velocity magnitude or shear stress.
Fluorescence intensity of cells growing in one of the 8 ROI was use to map the
uptake intensity in the area vs the corresponding physical parameter. For this
analysis uptake in static (control) was compared to uptake at 10µ/l and 20µ/l.
For the development and testing of the method the same combination of cell type
and polymersome formulation used to validate imaging was chosen: MFC188 and
10% rhodamine labelled PMPC-PDPA.
Data showed a small but not significant (p>0.05) difference between uptake at
10µl · s−1 and 20µl · s−1. However, there is a clear decrease of uptake between no
flow and 10µl · s−1. A comprehensive study on the effect of flow on nanopraticle
uptake has not been reported yet. In 2012, Samuel and co-workers (Samuel et al.
[2012]) reported a decrease in uptake of negatively charged quantum dots with
increasing shear stress from 0.1Pa to 5dyn/cm−2, a behaviour similar to the find-
ings here reported. However the two studies cannot be directly compared because
of different experimental set-up. Samuel and coworkers used negatively charged
quantum dots of 50nm of diameter, while we used 120nm neutral polymersomes.
The uptake was studied for up to 20min after exposure in the cited work; in our
experiment the uptake was analysed for 24h, with the first time point recorded
after 30min. Finally, the average shear stress used in our system is up to 10 fold
higher.
It should be noiced The inverse correlation between uptake rate and shear
stress was confirmed in this work, however the two systems cannot be directly
compared because of the different nanoparticles used: negatively charged 50nm
quantum dots and non-charged 120nm polymersomes. Furthermore, in the cited
work the uptake was monitored for 20min, in our experiment it was monitored
up to 24h, with the earliest time point recorded after 30min.
Considering the segmentation of flow parameters, it was observed that for
both shear stress and horizontal velocity magnitude there is an higher uptake
in the region corresponding to the middle of the well, characterised by an inter-
mediate parameter magnitude. This suggested a relatively low impact of shear
stress or velocity on uptake in the range considered. Perhaps a wider range
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would reveal a correlation between the physical parameter and uptake, but this
correlation cannot be confirmed by the data reported. A correlation was ob-
served between vertical velocity and uptake, with uptake higher at the higher
vertical velocity (near the outlet) and lower at lower vertical velocity (near the
inlet). A low uptake with low (negative, inlet) vertical velocity was expected,
as it was the region were polymersomes were moving faster pushed away from
the inlet. However, a high uptake at the outlet was not anticipated, as it is a
region characterised by particles moving away from the cells towards the outlet
of the chamber. Further investigation on polymersomes distribution in the well
will clarify the role of vertical velocity and uptake, particularly with respect of
local particles concentrations. Such results can be obtained by integrating the in
silico simulation performed with the COMSOL Multiphysics CFD module with
the module particle tracking.
In conclusion, different methods have been developed to assess polymersomes
uptake under static and flow conditions. Protocols can be used to quickly screen
several different formulations in combination with different cell types. Results
obtained will be useful in the optimisation of polymersomes for imaging the tu-
mour microenvironment, as it was found that PMPC-PDPA polymersomes are
up-taken preferentially by tumour cells, while POEGMA-PDPA polymersomes
have generally lower uptake, but less affected by flow dynamics in perivascular-
like cells (10T1/2). Furthermore, PMPC-PDPA polymersomes fast uptake will
likely correlate with fast clearance in vivo, while the other two formulations are
expected to have longer circulation time in blood. This could result in an im-
proved accumulation within the tumour via Enhanced Permeation and Retention
(EPR) effect. Finally, uptake under flow conditions analysis revealed a strong
effect of capillary-like flow rates on uptake, with significant reduction of uptake
kinetic, especially for PMPC-PDPA. Further studies will better elucidate the
correlation between uptake and different flow parameters, however preliminary
results suggested that uptake by cells at the vascular and perivascular level will
not be significantly shifted towards a specific cell line, as flow minimised the
differences between cell types and polymersomes formulations.
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CHAPTER 5
IN VIVO IMAGING
Abstract
Dorsal Skinfold Chamber (DSC) allows detailed visualisation of tumour phys-
iology in real time in vivo. Fluorescent labelled polymersomes have been success-
fully used in in vitro and in vivo imaging, however their use in a DSC chamber
set-up has not been reported yet. The aim of this work is to assess the suitabil-
ity of fluorescent labelled polymersomes for in vivo optical imaging using DSC.
Poly(2 - methacryloxyethyl-phosphorylcholine)-poly( 2 -(diisopropylamino)ethyl
methacrylate) (PMPC-PDPA) and poly(oligo(ethylene glycol) methacrylate)-poly(
2 -(diisopropylamino)ethyl methacrylate) (POEGMA-PDPA) rhodamine labelled
were injected Intra Venously (i.v.) into a mouse tail bearing a DSC. Preliminary
results showed intravascular distribution of polymersomes at the early time point
(1h) for both formulations, but at the later time point (15h) PMPC-PDPA was
not detected in tumour vasculature or stroma, while POEGMA-PDPA was seen
to extravasate and accumulate within the tumour. These finding will set the ba-
sis for future further development of polymersomes aimed at imaging the tumour
microenvironment in vivo.
5.1 Introduction
5.1.1 Window chamber
In vivo optical imaging, and particularly high resolution Intra Vital Mi-
croscopy (IVM), is affected by poor tissue penetration of light. To negate this
limitation the layers of tissues between the objective and the plans of focus can
be removed and replaced with an optically transparent material. This approach
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is adopted in the preparation known as the Window Chamber (WC). WC was
first introduced in a rabbit model in 1924 (Sandison [1924]), adapted for mice in
1943 (Algire [1943]) and developed for application to the hamster cheek pouch in
1947 (Fulton et al. [1947]) before being optimised for angiogenesis studies in the
mouse DSC in 1993 (Lehr et al. [1993]).
When applied to the back of the animal (DSC) a skin layer and associated
connective tissue and fat are surgically removed from the dorsum to provide
optical clarity. A chamber holds the skin away from the mouse body exposing
the vascularised layer of muscle and skin on the opposite side of window. The
preparation is then closed with a thin optical glass coverslip. Before closing the
chamber, a tumour fragment or tumour cells are implanted (Koehl et al. [2009]).
In a few days, the tumour starts to vascularise and angiogenesis can be imaged.
Applications of IVM, an umbrella term including WC, have been extensively
reviewed by Fukumura and co-workers (Jain et al. [2002]). Some of the most
significant ones are reported in the next paragraph. The WC can be used to
monitor molecular, cellular, anatomical and functional parameters. As Laschke
defined, it is a ’window into the dynamic interaction of biomaterials with their
surrounding host tissue’ (Laschke et al. [2011]).
The WC preparation may be used to study a number of different parameters
in vivo, at different levels of spatial resolution. Such parameters can be classified
into molecular, cellular, anatomical and functional parameters.
Molecular parameters Molecular parameters include monitoring pH and pO2,
expression of receptors and molecular pathways (Helmlinger et al. [1997]). Mon-
itoring such parameters require the use of probes that change optical properties
according to the concentration of the molecule to test. An example of such
probe that meay be useful in measuring pH in vivo has been recently reported
by Madsen and co-workers. They synthesised a copolymer linked to a dye that
changes emission spectra at different pH values. This copolymer was used in
the self-assembling of a class of nanocarriers known as polymersomes (Madsen
et al. [2013]). Imaging in the WC also allows determination of the molecular
mechanisms of angiogenesis. Fukumura and co-workers, using this technique ob-
served that tumour cells induce production of Vascular Endothelial Growth Fac-
tor (VEGF) in stromal cells, which can represent up to 50% of the total VEGF
present (Fukumura et al. [1998]).
Cellular parameters The WC can be used to observe the establishment and
development of a tumour. A common strategy is to use genetically modified
tumour cells expressing fluorescent proteins, mostly Green Fluorescent Protein
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(GFP). This allows the visualisation of tumour growth, to establish the minimal
number of cells required for tumour growth and the visualisation of the tumour
metastasis cascade: cells leave the primary site, extravasate into the blood vessels,
reach a secondary site, extravasate into such location and finally establish as a
secondary tumour (Chambers et al. [1995], Reeves et al. [2009]).
Anatomical parameters Anatomical parameters include vascular density,
length, diameter and architecture. Such parameters are useful to describe the
tumour microenvironment and to establish readouts for therapy. For instance,
a decreased Micro Vessel Density (MVD) indicates the efficacy of an anti an-
giogenic agent, however MVD may not change if a reduction in vessel number
is followed by a reduction in tumour size. Another anatomical feature derived
from WC is pore-size cut-off, a critical aspect in nanocarrier therapy and imaging
(Hobbs et al. [1998]). Nanocarriers extravasate to the tumour site through gaps
between endothelial cells in the compromised vascular bed. To allow extrava-
sation, it is therefore essential that nanoparticles have smaller radius thn the
inter-cellular gap. In the cited work, Jain and co-worker demonstrated the mech-
anism of extravasation, and they showed that extravasation of small molecules
such as (' 7nm) is not affected in different tumours characterised by different
gap (pore-size cut off) size, but in the range 200nm-1.2µm. Opposite to albumin,
extravasation of nanocarriers (liposomes or latex microsphere with diameter rang-
ing from 250nm to 2.5µm)was highly dependent on tumour type and localisation,
with greater extravasation occurring in tumours with bigger gaps.
Functional parameters Functional parameters include hemodynamic vari-
ables such as red blood cell velocity, flow velocity and blood volume, vascular
permeability and interstitial diffusion(Samuel et al. [2013], Øye et al. [2008],
Dreher et al. [2006], Endrich et al. [1979], Reyes-Aldasoro et al. [2008]). Such
studies are conducted using size-specific macromolecules, useful to evaluate ex-
travasation and diffusion, or plasma markers such as the ones used in the study
conducted by Reeves and co-workers (Reeves et al. [2012]) These studies eluci-
dated not only the specific features of tumour vasculature compared to normal
vasculature but also provided information related to the tumour heterogeneous
blood supply and nanoparticle design to achieve better intra-tumour distribution.
DSC is also used in multi-modal imaging, normally combined with Magnetic
Resonance Imaging (MRI). This approach is useful to validate vascular param-
eters extrapolated from MRI by using IVM, even if errors are possible due to
different time acquisition points, a problem that could be overcome by simulta-
neous multi-modal data acquisition (Gaustad et al. [2008], Neeman et al. [2001],
102
5. In vivo imaging 5.1. INTRODUCTION
Lin et al. [2008]). Validation of MRI functional information is critical because
MRI is not quantitative, a correlation is required between contrast agent concen-
tration and signal strength. Furthermore MRI is widely used in clinical practice,
while WC cannot be used in this context. Multi-modal imaging can also provide
information which are complementary such as whole body drug biodistribution
(MRI) and cellular effect (DSC).
WC preparations can be analysed longitudinally, spatially and temporally and
multiple parameters can be extrapolated from the same animal. As a result, the
molecular, cellular, anatomical and functional parameters described above can be
obtained simultaneously. Perhaps the most cited example is the study conducted
by Fukumura and co-worker, in which they monitored gene expression, angiogen-
esis and physiological function of the tumour (Brown et al. [2001]). In another
study Tozer and co-workers investigated tumour response to Vascular Disrupting
Agent (VDA) combretastatin after implantation of fibrosarcoma cell-lines over-
expressing different iso-form of VEGF. They correlated response to treatment
with vessel length and density (anatomical parameter) and vasculature leakiness
(functional parameter) (Tozer et al. [2008]). Quantification of response to treat-
ment is another key application of WC. Classical therapy response is evaluated in
terms of tumour size. However tumour shrinkage is not the only possible outcome
of a therapy and in animal models is not always indicative of tumour response.
In response to treatment tumours may become quiescent, therefore there is no
change in size and no apparent response to the treatment. In both cases, changes
in tumour size are slow, and there is the need to understand if a therapy is ef-
fective in a certain time frame. WC can help to identify molecular markers that
respond rapidly to therapy which may help in predicting the outcome, or even
more interesting, they could help in designing a personalised therapy based on
prediction of outcome generated by the presence of such markers.
WC in mouse has many advantages: the multiple imaging of a single animal
limits the number of animals required to achieve statistical significance at any
given time-point. There is fast recovery from surgery and imaging analysis can
commence 48h after surgery. However its execution requires dedicated training
and skills. Furthermore the chamber is not always an orthoptic site for the tumour
of interest and this explains why chambers have been created to be implanted in
different parts of the body (e.g. cranial chamber and abdominal chamber(Coisne
et al. [2013], Ritsma et al. [2013])). Furthermore, tumour growth is visualised in
a time-frame of days/weeks, while human tumour development can take months
or even years. Finally, the 3D growth of the tumour is restricted by the coverslip
on at least one of the two sides of the frame, and this can cause artificially
increased intra-tumour pressure which affects vasculature permeability (Staton
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et al. [2009], Gaustad et al. [2008]). Despite this limitations, WC is a valuable
tool in angiogenesis and tumour biology research, being used to unravel tumour
angiogenic mechanisms at different levels.
Figure 5.1: Using a DSC it is possible to observe angiogenesis at different levels,
such as the anatomical level (i.e. micro-vascular density), the cellular level (i.e.
primary tumour growth and tumour metastasis), the functional level (i.e. quan-
tification of the red blood cell velocity) and the molecular level (i.e. feedback on
pO2 and pH of the tumour).
5.1.2 Vascular Endothelial Growth Factor
VEGF is a family of cytokines including four main members in humans:
VEGF-A, VEGF-B, VEGF-C and VEGF-D. The most important in cancer an-
giogenesis and the first one discovered was VEGF-A, which is a potent pro-
angiogenic factor and stimulates vasodilation and vessel permeability. VEGF-A
is also a mitogen and a chemoattractant (Shibuya [2013]). VEGF-A binds to two
receptors: VEGFR-1 and VEGFR-2. There is evidence that the binding affin-
ity to VEGFR-1 is higher than to VEGFR-2. In early angiogenesis binding to
VEGFR-2 is pro-angiogenic, whilst binding to VEGFR-1 suppress the angiogenic
response (Sawano et al. [1996], Fong et al. [1995]).
VEGF-A mRNA is transcribed from 8 exons alternatively sliced resulting in
different isoforms, the most common ones being VEGF120, VEGF164, VEGF188
in mouse, 1 amino acid longer in human. VEGF120 does not have a heparin bind-
ing site and is readily diffusible, VEGF188 has a heparin binding site, and binds
strongly to proteoglycans in the Extracellular Matrix (ECM) and cell membrane.
VEGF164 has intermediate properties (Ferrara [2004]). During development in
the mouse model, it has been shown that the presence of VEGF164 is sufficient
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to establish a functional vasculature, VEGF120 supports endothelial cell prolif-
eration, but the vessels formed are haemorrhagic. VEGF188 is essential for the
formation of a normal vasculature in 50% of animals (Stalmans et al. [2002]).
5.1.3 Single VEGF-A isoform producing tumours
Mouse fibrosarcoma cells expressing single isoforms of VEGF have been devel-
oped and tumours obtained from such cells have been analysed in a DSC. Tumour
growth rate is independent of the isoform used but dependent on VEGF concen-
tration (Yu et al. [2002]). Tumours expressing different specific isoforms of VEGF
have specific characteristics. VEGF120 tumours are less well-vascularised (CD31
staining) than VEGF188 or VEGF164 tumours, and VEGF188 tumours have
higher pericyte coverage (α-Smooth Muscle Actin (α-SMA) staining). VEGF120
tumours are more permeable to injected FITC-dextran 40KDa, and this is con-
sistent with lower pericyte coverage. In terms of tumour growth, VEGF120 tu-
mours shows dilation of pre-existing vessels which become highly haemorrhagic.
VEGF188 tumour growth have narrower non haemorrhagic vessels. VEGF120
established tumours are characterised by a vasculature limited to the periphery
while VEGF188 tumours are completely vascularised. Wild type (all isoform ex-
pression) and VEGF164 tumours had intermediate properties (Akerman et al.
[2013]).
5.1.4 Nanoparticles extravasation in tumour
Nanoparticles can extravasate and accumulate within tumours via the En-
hanced Permeation and Retention (EPR) effect (see 1.4.2). Once blood-borne
nanoparticles reach the tumour, extravasation and tissue penetration is a function
of nanoparticles size, shape, charge, vascular morphology and physical properties.
The effect of particle size and shape has been discussed in section 1.4.3. Here,
the role of vascular characteristics will be discussed.
The tumour vasculature is highly heterogeneous, characterised by vessels of
different diameter and anatomy, including capillaries, venules, arterioles, vascular
shunts, anastomosis and blood channels without endothelial cells (Jain [1988]).
Furthermore, the organisation of the vessels is not constant in space or time,
with heterogeneous flow rates (Dudley [2012]). In addition, tumours are often
characterised by a central necrotic area surrounded by a vascularised, growing
area. The first challenge is the homogeneous delivery of nanoparticles to tumour
via heterogeneous vasculature.
Once nanoparticles reach the tumour and distribute in the vasculature, the
intra-tumour penetration is a function of two main parameters: diffusion and
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convection. Diffusion D is a slow process and is dependent on surface area of the
vessel (S) and on the difference in concentration of the nanoparticles between the
plasma and the tumour stroma (CP −CS). Finally, convection is proportional to
blood leakage (and therefore to vessel surface area S), to the difference in osmotic
pressure between plasma and tumour (piP − piS) and the difference in hydrostatic
pressure (pP − pS) (Jain [2001]).
To be able to predict the intra-tumour distribution of nanoparticles is of great
interest as it would help to optimise the design of the nanoparticle to achieve
specific delivery via the EPR effect and higher tumour accumulation, which in
turn lead to an improved therapeutic outcome or improved signal-to-noise ratio
for an imaging application. In the last decade a great effort has been made to
model tumour vasculature and nanoparticle extravasation in silico (Frieboes et al.
[2013], Stylianopoulos et al. [2012], Chou et al. [2013], Sinek et al. [2004]).
Unfortunately, tumour in silico models are still far from perfect, due to the
difficulties relating to accurate modelling of events occurring simultaneously at
the vascular level (µm) and at the nanoparticle level (nm)and for the computa-
tional demand of running the simulation for biologically relevant time periods.
For this reasons a number of simplifications have been introduced in every model,
limiting their broader applicability to different scenarios (i.e. different tumour,
with different vasculature characteristics). Experimental data will assist in de-
veloping the critical parameters regulating extravasation and accumulation and
to perfect existing models.
5.1.5 Aim
DSC allows highly detailed visualisation of tumour pathophysiology in real
time in vivo. Fluorescent labelled polymersomes have been successfully used
in in vitro and in vivo imaging, however their use in a DSC chamber set-up
has not yet been reported. The aim of this work is to assess the suitability of
fluorescently labelled polymersomes for in vivo optical imaging using DSC. To do
so, PMPC-PDPA and POEGMA-PDPA rhodamine labelled polymersomes were
injected and their distribution in the tumour microenvironment was monitored
using fluorescence microscopy.
5.2 Results
Tumour growth after Mouse Fibrosarcoma Cells expressing VEGF188 isoform
(MFC188) spheroid implantation was monitored regularly to assess the extension
of vascularisation and animal well-being. A typical time-frame of tumour develop-
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ment for MFC188 is reported in figure 5.2. Tumour vasculature can be observed
starting at day 4 after surgery (4% of total chamber area), and it is fully estab-
lished around day 7 (70%). After this time the vasculature and tumour will start
to overgrow the chamber. Imaging sessions were performed when the tumour was
covering between 70% and 90% of the chamber, 8 days after surgery.
(a) 1 day (b) 4 days
(c) 5 days (d) 7 days
(e) No tumour growth (f) Tumour growth
Figure 5.2: MFC188 tumour development from 24h after surgery to 7 days after
surgery (d). Tumours are highlighted by the black dotted line. Picture (e) shows
a chamber with no tumour growing, picture (f) shows a chamber with tumour
established. Bar (a, b, c, d) 1.5mm; (e,f) 7mm.
Rhodamine labelled polymersomes were injected via the tail vein (Intra Ve-
nous (i.v.)) and a number of imaging sessions were conducted regularly from
immediately after injection up to 18h after injection. Imaging settings such as
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fluorescence intensity were defined before injection so that no background noise
was detected. Images were acquired using a confocal microscope equipped with a
10X objective. Under transmitted light, vessels are visible in black over a bright
tumour stroma. In the rhodamine channel, vessels are highlighted by polymer-
somes and are seen in bright over dark tumour stroma (fig. 5.3).
(a) Transmitted light, confocal, 10X (b) Rhodamine, confocal, 10X
Figure 5.3: DSC images, 10X confocal microscopy. Image acquired 5min after
i.v. injection of rhodamine labelled POEGMA-PDPA polymersomes. On the left
(a) transmitted light picture, on the right (b) fluorescence pictures. Rhodamine la-
belled POEGMA-PDPA can be seen localised inside the blood vessels. Bar 230µm.
Representative images for rhodamine labelled POEGMA-PDPA polymersomes
can be seen in figure 5.3. The images were acquired 5min after injection. A time-
lapse for the same polymersomes formulation is reported in figure 5.4. Transmit-
ted light images always show vessels as dark structures, acting as a reference
image. In the rhodamine channel it is visible that initially vessels are highlighted
as bright over dark stroma (2min, fig. 5.4-b), but at a later time point vessels ap-
peared in dark over brighter stroma (15h, fig. 5.4-f). This suggests polymersome
extravasation and accumulation within tumour.
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(a) Transmitted light, 10min (b) Rhodamine, 10min
(c) Transmitted light, 1h (d) Rhodamine, 1h
(e) Transmitted light, 24h (f) Rhodamine, 24h
Figure 5.4: MFC188 tumour microvasculature confocal images, 10X objective.
At earlier time point (a-d) the tumour stroma is darker than vessels in the rho-
damine channel (b, d), indicating circulating polymersomes. 24h after injection
the tumour stroma is brighter than the vessels (f), suggesting intra-tumour accu-
mulation. Bar 230µm.
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Rhodamine labelled POEGMA-PDPA and PMPC-PDPA polymersome locali-
sation were compared. At earlier time points, both PMPC-PDPA and POEGMA-
PDPA were localised in vessels. Interestingly, at later time points the PMPC-
PDPA signal was significantly weaker in the vasculature and the tumour stroma,
suggesting that the formulation was rapidly cleared from the circulatory system
(see fig. 5.5).
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(a) POEGMA-PDPA,10min (b) POEGMA-PDPA,1h (c) POEGMA-PDPA,24h
(d) PMPC-PDPA,10min (e) PMPC-PDPA,1h (f) PMPC-PDPA,24h
(g) POEGMA-PDPA,10min (h) POEGMA-PDPA,1h (i) POEGMA-PDPA,24h
(j) PMPC-PDPA,10min (k) PMPC-PDPA,1h (l) PMPC-PDPA,24h
Figure 5.5: Confocal imaging comparison of POEGMA-PDPA and PMPC-PDPA,
transmitted light (a-f) and rhodamine channels (g-l). 10min and 1h after injec-
tion both PMPC-PDPA and POEGMA-PDPA are localised in vessels (g, j, h,
k). At 24h, PMPC-PDPA (l) is almost not detectable, while POEGMA-PDPA is
clearly localised in tumour stroma (i). Bar 200µm.
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All images were analysed as described in section 3.6 and results are reported
in figure 5.6-5.7. Confocal image analysis confirmed the qualitative observation
of increased accumulation of POEGMA-PDPA compared to PMPC-PDPA poly-
mersomes (higher average intensity). Furthermore, for both formulations it was
observed that at early time points, blood vessels contribute to the overall im-
age intensity at a higher percentage than the tumour stroma, while at later time
points the contribution is reversed. Edges have intermediate contribution between
stroma and vessels. Thus, this analysis confirmed the qualitative observation of
extravasation (decreasing vessel contribution) and accumulation within tumour
(increasing stromal contribution).
Figure 5.6: PMPC-PDPA in vivo image analysis. Data are represented as overall
mean intensity of rhodamine signal in the tumour area (right axis) overlaid with
a break down of the relative contribution of vessels, edges and tumour stroma to
the signal intensity (left axis, coloured bars). The overall image intensity showed
a slight increase over time. Moving from t=1h to t=16h it was observed that poly-
mersomes relative distribution in the vessels Regions of interest (ROI) decreased,
while the intensity of the stroma ROI increased.
112
5. In vivo imaging 5.2. RESULTS
Figure 5.7: POEGMA-PDPA in vivo image analysis. Data are represented as
overall mean intensity of rhodamine signal in the tumour area (right axis) over-
laid with a break down of the relative contribution of vessels, edges and tumour
stroma to the signal intensity (left axis, coloured bars). The overall image inten-
sity showed a slight increase over time. Moving from t=1h to t=16h it was ob-
served that polymersomes relative distribution in the vessels ROI decreased, while
the intensity of the stroma ROI increased. At t=16h there was a clear inversion
between the two intensity distributions, evidence of the extravasation observed in
fig. 5.5.
Qualitative and quantitative confocal image analysis suggested polymersomes
extravasation and accumulation in tumours. Further image analysis was carried
out to gain insight into the dynamics of tumour extravasation. Confocal images
were segmented to correlate the amount of extravasation against the distance
travelled by the polymersomes and the diameter of the nearest vessel, here as-
sumed to be the origin of travel of polymersomes. The analysis is discussed in
section 3.6.2. The analysis revealed less extravasation of PMPC-PDPA com-
pared to POEGMA-PDPA, as was already anticipated by the previous analysis
(fig. 5.6-5.7). The analysis was performed also in pictures acquired with epifluo-
rescence microscope equipped with a 2.5X or a 20X magnification lenses, however
only confocal images analysis is reported here. This is due to the lack of spa-
tial resolution in epifluorescence microscopy compared to confocal microscopy:
masks identifying different ROI can potentially be less accurate. Furthermore,
in epifluorescence the transmitted light channel and the rhodamine channel were
not acquired simultaneously, therefore the translation of the mask created on
the transmitted light micrograph to the rhodamine one is less accurated as it
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is affected by mouse movements. Image analysis for epifluorescence pictures is
reported in annex section 9.3. Analysis of POEGMA-PDPA extravasation profile
interestingly reveals how extravasation is more intense at the level of bigger ves-
sels ('12µm), however higher distances are travelled from lower calibre vessels
('6µm) (see fig. 5.8-5.9).
Figure 5.8: Extravasation analysis of POEGMA-PDPA polymersomes. Over-
time (0min-16h) mapping of extravasation. For every pixel belonging to tumour
stroma, the distance to the closest vessel and the diameter of the closest vessels
were measured together with the rhodamine intensity. Data were then mashed to
obtain a heathmap were rhodamine intensity is colour coded from blue (low in-
tensity) to red (high intensity). Polymersomes extravasating from smaller vessels
(5-10µm) travelled the greatest distance ('15µm. Polymersomes extravasating
from larger vessels (10-15µm) travelled a shorter distance, however their accu-
mulation is greater (greater intensity).
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Figure 5.9: Extravasation analysis of PMPC-PDPA polymersomes. For every
pixel belonging to tumour stroma, the distance to the closest vessel and the di-
ameter of the closest vessels were measured together with the rhodamine inten-
sity. Data were then mashed to obtain a heathmap were rhodamine intensity is
colour coded from blue (low intensity) to red (high intensity). Polymersomes ex-
travasating from smaller vessels (5-10µm) travelled the greatest distance ('15µm.
Polymersomes extravasating from larger vessels (10-15µm) travelled a shorter dis-
tance, however their accumulation is greater (greater intensity).
5.3 Discussion
High resolution IVM of the tumour microenvironment has been made possible
by the use of a DSC. The DSC had the advantage of reducing the limitation of
poor tissue penetration of light characteristic of optical imaging techniques. DSC
models have the disadvantage of being usually non orthotopic and results can be
hindered by increased intra-tumour pressure, due to growth constraints by the
two glass cover slips of the chamber, however it is still a widely used model to
study angiogenesis and vascular response to therapy.
The tumour implanted within the chamber was a fibrosarcoma, derived from
Mouse Fibrosarcoma Cell (MFC) cell expressing VEGF188. This particular cell
type was chosen over the MFC wild type or cell-lines expressing VEGF120 or
VEGF164 because studies from our group reported that they are characterised
by a more vascularised tumour with higher pericyte coverage (Akerman et al.
[2013]). This is a more appropriate tumour to start developing polymersomes for
IVM imaging, compared to the MFC expressing VEGF120, where there is a poor
vasculature.
The results here discussed represent the outcome of a very limited number
of animals, not sufficient to draw conclusions based on solid statistic. Overall,
this part of the work should be considered a pilot experiment aimed to test the
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analysis methodology described in chapter 3 and to investigate possible corre-
lation between in vitro uptake discussed in chapter 4 and in vivo intra-tumour
distribution.
It was of interest to test both formulations in vivo to visualise any differen-
tial distributions within the tumour microenvironment. Because of the greater
uptake of PMPC-PDPA compared to POEGMA-PDPA polymersomes observed
From the in vitro, we expected to observe a shorter plasma half-life of PMPC-
PDPA compared to POEGMA-PDPA polymersomes. It was also hypothesised
that circulation time affects accumulation within the tumour and that the two
formulations may have different intra-tumour distribution due to the interactions
with different cell types in the tumour microenvironment.
Confocal microscopy allowed simultaneous acquisition from the rhodamine
and transmitted light channel. Simultaneous acquisition is critical to transfer
segmentation result from the transmitted light image to the rhodamine channel
avoiding offsets generated by mouse movement. Qualitative image observation
revealed gradual polymersomes extravasation and accumulation within tumour.
Qualitative comparison between POEGMA-PDPA and PMPC-PDPA polymer-
somes images revealed that accumulation of POEGMA-PDPA was higher than
PMPC-PDPA. This was confirmed by image analysis, performed using a specif-
ically developed segmentation and analysis algorithm (section 3.6). POEGMA-
PDPA distribution profile could be explained when considering the chemical
similarity between poly(oligo(ethylene glycol) methacrylate) (POEGMA) and
Polyethylene Oxide (PEO). PEGylated systems are known to have prolonged
plasma half-life (Pasut and Veronese [2012]) because of their ability to avoid
interaction with protein (non-fouling) and to escape the Reticuloendothelial Sys-
tem (RES) (stealth properties). POEGMA is likely to exhibit similar properties
to PEO.
Finally, we investigated polymersome extravasation, specifically the relation-
ship between distance travelled by the polymersomes over time with respect to the
diameter of the closest blood vessel, here assumed to be the origin of diffusion.
Despite having an overall different magnitude of accumulation, PMPC-PDPA
and POEGMA-PDPA polymersomes showed similar diffusion profiles. A peak
of extravasation can be observed at the level of largest vessels (>10µm), how-
ever the longest distance is travelled when extravasation occurs at the level of
smaller vessels (<10µm) (fig. 5.5). A similar irregular accumulation has been
reported by Yuan and co-workers for liposomes. Liposomes accumulated close
to larger vessels, and normally at the bifurcation points (Yuan et al. [1994]).
Higher accumulation around bigger vessels could be explained by the increased
superficial area of larger diameter vessels (therefore increasing both diffusion and
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convection), and perhaps increased hydrostatic pressure between larger vessels
and tumour stroma, compared to smaller vessels and tumour stroma. This could
be due to increased blood flow which in turn increases convection, which is a faster
phenomena compared to simple diffusion. Furthermore, local rheological proper-
ties of flow at bifurcation (i.e. increased turbulence) could affect extravasation.
Further development of the method should implement functional and cellular pa-
rameters. Functional parameters include hydrostatic and osmotic pressure and
flow velocity, cellular parameters include macrophage distribution, which could
be responsible for polymersomes uptake and local accumulation.
Overall, the findings suggest that PMPC-PDPA polymersomes rapidly inter-
act with other cells and organs, including the RES which is the usual body defence
mechanism against circulating non-self, such us the polymersomes. POEGMA-
PDPA polymersomes have reduced interactions with the RES and therefore have
prolonged half-life, resulting in the increased potential to extravasate into the
tumour via the EPR effect. These hypotheses are supported by unpublished
data from Prof. Battaglia, showing significantly shorter half-life of PMPC-PDPA
compared to POEGMA-PDPA in mouse model. The reduced plasma half-life of
PMPC-PDPA affects intra-tumour accumulation, which resulted in significantly
lower accumulation compared to POEGMA-PDPA polymersomes. Distribution
in other organs was not investigated in this work, however preliminary data ob-
tained from analysis of biodistribution of PMPC-PDPA and POEGMA-PDPA in
healthy SCID mouse were conducted previously by Prof. Battaglia group. For
both polymersom formulations it was found a profile of biodistribution typical
for nanoparticles, with significant accumulation in liver, spleen, lung and kidney.
Further work with tumour bearing animals should be performed to investigate the
overall intra-tumour accumulation compared to accumulation in other, off-target
organs.
A final remark should be made on the surgical procedure. The rate of success
proved to be poor, with major complications due to the tumour not vascularising
in the chamber or the chamber itself falling on the flank of the mouse a few
hours after surgery instead of staying on the top of the back. Some of these
complications are currently being addressed by standardising the cell spheroid
preparation or by changing some of the components of the chambers, such as the
spacers between the two frames. However, more work is required to improve the
outcome of the surgery, which has not only ethical implications, but is also vital
to obtain reliable information from in vivo experimentation.
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CHAPTER 6
PERIVASCULAR CELLS TARGETING
Abstract
In the previous chapters, methodologies for quantification of cellular uptake
of polymersomes have been developed. In this chapter the methodologies devel-
oped will be integrated in the context of further development of functionalised
polymersomes to target a specific cell type: perivascular cells. Perivascular cells
is a collective name identifying a group of cells, namely pericytes and Vascular
Smooth Muscle cells (vSMCs), in direct contact with endothelial cells on the outer
side of the blood vessel, hence the name perivascular. In tumour angiogenesis the
perivascular cells coverage is reduced and vasculature becomes unstable. The
ability to image perivascular cells in vivo and to monitor their response to anti-
angiogenic therapies may lead to an improved understanding of their role in an-
giogenesis. Active targeting of perivascular cells with polymersomes requires the
identification of a suitable specific marker. The first part of this chapter will focus
on the identification of such a marker in a in vitro cell model: 10T1/2 cells. The
expression of such markers in 10T1/2 and other tumour micronvironmental cells
will be compared: endothelial cells (Small Vessel Endothelial Cells (SVECs)) and
cancer cells (Mouse Fibrosarcoma Cells expressing VEGF188 isoform (MFC188)).
Finally, different synthetic strategies to functionalise polymersomes with a tar-
geting antibody will be investigated and the functionalised formulation will be
tested in vitro.
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6.1 Introduction
6.1.1 Perivascular cells
Blood vessels are formed by the endothelial cells and a number of supporting
cells collectively referred to as perivascular cells or mural cells. As the name
implies, perivascular cells are located outside the blood vessels and in contact
with the endothelial cells. The first report of perivascular cells was made by
Rouget in 1873 (Rouget [1873]). He described contractile cells located outside and
around small blood vessels (Rouget [1873]). Pericytes were initially called Rouget
cells. A few years later Zimmermann renamed the cells as pericytes due to their
perivascular location (Zimmermann [1923]). Since the discover of pericytes and
the improvement in phenotyping and microscopy techniques, other perivascular
cells have been reported, namely vSMCs. The main difference between the cell
type is in markers expression and location with respect of the vasculature bed.,
i.e in contact with capillaries, pre- or post- capillaries or larger vessels. However,
there is no clear differentiation between the cell types, to the point that the name
pericytes is often used as synonym for perivascular cells.
Perivascular cells are rounded cells with long primary cellular protrusions
running parallel to the blood vessel, from which small secondary processes per-
pendicular to the blood vessel are observed. Where the secondary processes are
in contact with the endothelial cell, a discontinuity of the basal membrane is ob-
served, suggesting direct contact between the two cell types through peg-socket
junctions and tight junctions. The ratio between the number of perivascular cells
and endothelial cells is known as pericyte coverage, the term reflecting the lack
of clear distinction between pericytes and other perivascular cells. Pericyte cov-
erage varies in different organs with specific tissue characteristics. Tissues with
high endothelial cell turnover have lower pericyte coverage and tissues subjected
to high orthostatic blood pressure have high pericyte coverage (Armulik et al.
[2011], Dı´az-Flores et al. [2009]).
Pericytes are traditionally restricted to a capillary and post-capillary location,
however other mural cells are found in the same area. Furthermore, it has been
reported that the pericyte embryological origin differs between organs. Pericytes
in the Central Nervous System (CNS) and cardiac tract vessels originate from the
neural crest (Creazzo et al. [1998], Ema et al. [2003]) while in the rest of the body
pericytes are mesenchymal in origin, with Transforming Growth Factor-β1 (TGF-
β1) responsible for their differentiation (Creazzo et al. [1998]). In adult tissues,
pericyte development is not well characterised. They have been reported to derive
from tissue derived stem cells including pericytes themselves and myofibroblasts
(Diaz-Flores et al. [1992]) but also from peripheral blood pluripotent stem cells
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Figure 6.1: A perivascular cell (P) in a capillary. Endothelial cells (EC) con-
stitute the capillary tube, one perivascular cell is directly in contact with many
endothelial cells and embedded within the basal membrane (MB). Red blood cells
are pictured as well (RBC).
(Rajantie et al. [2004], Ozerdem et al. [2005]). In fact pericytes are both de-
scendent and precursor cells and they have mesenchymal potential (Crisan et al.
[2008], Crisan et al. [2009]). Pericyte identification is made difficult by the lack of
a specific marker. Commonly pericytes are described asα-Smooth Muscle Actin
(α-SMA), Platelet Derived Growth Factor-B (PDGF-B) and Nerve Glial antigen
2 (NG2) positive (Bergers and Song [2005]). Furthermore, they can be identi-
fied by assessing their position with respect of blood vessel using techniques such
as Transmission Electron Microscopy (TEM) or Scanning Electron Microscopy
(SEM) imaging (Wagner and Hossler [1992], Hayden et al. [2007]).
Perivascular cells functions
Due to their important position and structural role in the vasculature, perivas-
cular cells contribute to the regulation of several homeostatic functions; includ-
ing regulation of blood flow, stabilisation of blood vessels, vascular permeability,
production of extracellular matrix and immune defence (Dı´az-Flores et al. [2009],
Bergers and Song [2005]).
Contractility Contractile properties of perivascular cells have been described
since the early original publications (Rouget [1873], Zimmermann [1923]) and are
now well documented (Kutcher et al. [2007], Peppiatt et al. [2006]). Endothelin 1
secreted by endothelial cells stimulates pericyte contraction (Rucker et al. [2000]),
whilst relaxation is induced by nitric oxide, atrial natriuretic peptide, adenosine,
lipopolysaccharide and reactive oxygen metabolites (Edelman et al. [2006a], Edel-
man et al. [2006b],). The contraction mechanism is supported by the expression
of the contractile protein α-SMA, a marker for both pericyte and vSMCs, which
can also be transferred to endothelial cells through adherent junctions (Hirschi
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and D’Amore [1996]). Contraction of perivascular cells in response to different
stimuli results in hemodynamic regulation at the microvascular level, with the
greatest impact observed in arterioles.
Capillary permeability regulation Perivascular cells regulate capillary per-
meability by two mechanisms: one physical and one chemical. Physical regula-
tion is a consequence of the pericyte coverage. The amount of pericyte coverage
on the albuminal side of endothelial cells correlates with capillary permeability
(Hellstroem et al. [2001], Wang et al. [2012]). Perivascular cells are also sensi-
tive to chemical signalling. In angiogenesis perivascular cells produce Vascular
Endothelial Growth Factor (VEGF), known to increase blood vessel permeabil-
ity (Reinmuth et al. [2001]). Although the mechanisms that regulate capillary
permeability are not fully characterised it is generally accepted that perivascular
modulate vascular permeability by modulating Endothelial cell (EC) signalling
pathways.
Vessel stabilisation Vessel stability is the result of functional endothelial cel-
l/endothelial cell, endothelial cell/perivascular cell and cell/Extracellular Matrix
(ECM) contacts. This is achieved by a balanced secretion of factors such as TGF-
β1, Platelet Derived Growth Factor (PDGF) and angiopoietin 1/angiopoietin 2
from both endothelial cells and perivascular cells (Armulik et al. [2005]).
TGF-β1 is a cytokine regulating cell proliferation and apoptosis modifying
angiogenesis in different ways (Mehta and Dhalla [2013]). It is a potent acti-
vator of endothelial cell proliferation and induces mural cell recruitment with
subsequent differentiation into pericytes. Mouse models with abnormal TGF-β1
signalling are embryonic lethal, demonstrating an unformed and non-functional
vasculature phenotype (Larsson et al. [2001], Dickson et al. [1995]). TGF-β1 re-
cruits and induces vSMCs differentiation which in turn promotes vessel stability.
In wound healing TGF-β1 interacts with endoglin, a part of the TGF-β1 recep-
tor complex expressed many proliferating and stem cells, in addition to promote
vSMCs/pericytes differentiation(Valluru et al. [2011]). TGF-β1 is secreted in a
latent form by both endothelial cells and perivascular cells, with contact between
the two cell types being reported to be essential for TGF-β1 activation (Hirschi
et al. [1997], Hirschi et al. [1998], Hirschi et al. [1999]). In the presence of TGF-
β1, perivascular cells increase the production of α-SMA, whereas absence results
in increased NG2 and desmin (Song et al. [2005]). Furthermore, TGF-β1 in con-
junction with angiopoietin 1 decreases the production of PDGF-B by endothelial
cells (Betsholtz [2004]).
The angiopoietin-Tie2 balance is another key regulator of vessel stability. An
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increase in angiopoietin 2 expression is a marker of tumour angiogenesis (Zhang
et al. [2003]), although neither the angiopoietin ligand or receptor expression is
correlated as a prognostic indicator (Staton et al. [2011]). Angiopoietin 1 is se-
creted by perivascular cells, with the receptor Tie2 expressed by endothelial cells
(Sundberg et al. [2002], Sato et al. [1995]). Angiopoietin 1 stabilises blood ves-
sels by inhibiting endothelial cell proliferation. Angiopoietin 1 or Tie2 negative
mice do not survive due to vascular abnormalities. It has also been hypothe-
sised that endothelial cell deficiency induced by the absence of angiopoietin 1
also negatively affects TGF-β1 expression (Suri et al. [1996]). Angiopoietin 2
is an antagonist of angiopoietin 1 secreted by perivascular cells. Angiopoietin 2
over-expression has been reported to mimic angiopoietin 1 deficiency (Gale et al.
[2002]). Angiopoietins require TGF-β1 to function. Angiopoietin 1 or angiopoi-
etin 2 have no effect on endothelial cell proliferation and tube formation in vitro
but angiopoietin 1 antagonises TGF-β1-induced tube disruption and angiopoietin
2 antagonises angiopoietin 1 (Ramsauer and D’Amore [2007]).
The PDGF-B/Platelet Derived Growth Factor Receptor-β (PDGFR-β) sys-
tem is also required for vessel stabilisation. In angiogenesis PDGF-B is secreted
by endothelial cells, particularly by the tip cell in a vessel sprout. The tip cell is
the endothelial cell leading the growth of the forming vessel in angiogenesis. It is
followed by other endothelial cells that will constitute the wall of the vessel and
by perivascular cells that stabilise the forming tubular structure. PDGF-B is a
chemotactic factor for perivascular cells (Bjarnegard et al. [2004]). Lack of PDGF-
B or PDGFR-β is lethal in knock-out mouse models. The phenotype is charac-
terised by reduced perivascular cells coverage which leads to a non-functional
vasculature (Leve´en et al. [1994], Soriano [1994]).
VEGF is probably the most potent pro-angiogenic factor modulating both
perivascular cells and endothelial function. It is responsible for direct stimulation
of perivascular cells proliferation and migration and also to indirect stimulation of
recruitment, by increasing NO production in endothelial cells. VEGF inhibition
has proven anti-angiogenic effects by increasing pericyte coverage (Tozer et al.
[2008]).
Perivascular cells in angiogenesis
Perivascular cells in the quiescent vasculature have different morphology, loca-
tion and protein expression when compared to those during active angiogenesis.
In the early stages of angiogenesis, perivascular cells bulge and the cytoplasmatic
processes become shorter (Baluk et al. [2003], Ozawa et al. [2005]). The basal
membrane is degraded, perivascular cells detach from endothelial cells and cov-
erage is decreased, a process mediated by VEGF (Dı´az-Flores et al. [2009]). In
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the sprouting phase of angiogenesis, endothelial cells migrate in the direction of
growth of the new vessels without perivascular cells recruitment(Reynolds et al.
[2000], Bjarnegard et al. [2004]). Perivascular cells are normally recruited soon
after and are among the first cells to colonise the new vascularised area. Other
studies have shown that perivascular cells can lead endothelial cells in the vessel
sprouting and have the ability to form functional tubes without endothelial cell
recruitment (Ozerdem and Stallcup [2003]). If angiogenesis resolves, endothelial
PDGF-B recruits perivascular cells thus increasing pericyte coverage. This is
a stabilising event, but pericyte coverage alone is not sufficient to protect ves-
sels from VEGF-induced degradation: endothelial cell/perivascular cell functional
contact must be established to ensure full vascular stability through the mecha-
nism previously described (see paragraph 6.1.1) (Hoffmann et al. [2005]). Finally,
perivascular cells have been reported to influence metastasis, with perivascular
cells function directly correlating to increased metastatic potential in a fibrosar-
coma model, which may be mediated by increasing vasculature permeability (Xian
et al. [2006]).
6.1.2 Perivascular cells in vitro models
Perivascular cells are an elusive cell population characterised by highly hetero-
geneous marker expression. Identification of perivascular cells in ex vivo studies
relies mostly on the description of their location with respect to blood vessels,
coupled with the expression of a panel of markers, none of which are expressed
only or by all perivascular cells. In vitro studies have shown similar limitations,
therefore there is not a unique model for perivascular cells in vitro. In some
studies perivascular cells have been extracted from in vivo tissues (Bryan and
D’Amore [2008]). Typically this is achieved in larger animals and examples in-
clude extraction from corpus luteum and the bovine retina (Beckman et al. [2006],
Dore-Duffy [2003]). Extraction from smaller animals has been reported, including
hamster skeletal muscle and stria vascularis of the mouse ear (Mogensen et al.
[2011], Neng et al. [2013]). There is a commercially available source of perivas-
cular cells extracted from normal fetal brain (Bagley et al. [2005]). Primary
perivascular cells present the advantage of demonstrating similar characteristics
to in vivo perivascular cells. However, extraction procedures are time consuming,
costly and require specific equipment and training, although improvements with
semi-automated systems and protocols are now available (i.e. gentleMACS from
Miltenyi Biotec). Alternatively, perivascular cells can be derived in vitro using a
stem cell precursor. Perhaps the most studied is C3H/10T1/2, Clone 8, commonly
referred to as 10T1/2. These cells were isolated in 1973 from C3H mouse embryos
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Figure 6.2: Pericytes in angiogenesis. A stable vessel is characterised by endothe-
lial cells (EC, red constituents of the tubes) associated with pericytes (PC, pink
perivascular cell) and the structure is enclosed in the basal membrane (ECM,
light blue layer). In response to pro-angiogenic signalling such as NO and VEGF
the membrane is degraded and vessels become more permeable. Angiopoietin 2
then causes the dissociation of pericytes from the endothelial cells and vascular
regression. PDGF-B signalling recruits pericytes which follow the tip endothelial
cell. If angiogenesis resolve pericytes are recruited and make contact with the
endothelial cell. Angiopoietin 1 stabilises the formed vessels. The deposition of a
new ECM is promoted by TGF-β1.
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(Reznikoff et al. [1973b]). In 1997 D’Amore and co-workers hypothesised the use
of 10T1/2 as perivascular cells precursors (Hirschi et al. [1997]) and in 1998 they
reported a more detailed characterisation of such a system (Hirschi et al. [1998]).
Cells responded in co-culture with endothelial cells, by directional migration fol-
lowing PDGF-B signalling, with co-culture increasing expression of the marker
α-SMA. In cell culture, TGF-β1 affected the phenotype of 10T1/2 and increased
the expression of α-SMA while decreasing the expression of NG2 (Darland and
D’Amore [2001]). Recently, 10T1/2 cells have been used to recreate the vascula-
ture not only in vitro, but also in vivo. A gel containing both endothelial cells
and 10T1/2 as supporting cells has been implanted into the mouse cranial win-
dow chamber and a functional vasculature was developed (Samuel et al. [2013]).
The panel of markers identified by D’Amore and co-workers does not describe
specifically pericytes or vSMCs cells. In fact, the authors referred to 10T1/2 as
both pericytes and vSMCs precursor. This is due in part to the fact that there is
no clear distinction between the two cell lines, at least regarding cellular marker
expression. If the only differentiation possible is based on location (capillaries for
pericytes, larger vessels for vSMCs), then of curse an in vitro model as the one
described above cannot distinguish between the two. In the work here presented,
10T1/2 were chosen as model for perivascular cells to investigate any selective
targeting against tumour cells or endothelial cells, without the specific need to
distinguish between pericyte or vSMCs.
6.1.3 TGF-β1 and perivascular cells
TGF-β1 has been reported to act as both a pro- and anti-angiogenic factor
in vivo (Pepper et al. [1993]). This dual role can be explained in terms of the
local concentration of TGF-β1. For example, specific concentrations (0.1ng/ml)
appear more efficient in stimulating Smooth muscle cells (SMC) proliferation
in vitro than lower (0.02ng/ml) or higher concentrations (1-5ng/ml) (Battegay
et al. [1990]). TGF-β1 response is dependent on the expression of the Activin
receptor-like kinase 1 (ALK-1), a receptor phosphorylated by TGF-β1 (Tallquist
et al. [2003]). TGF-β1 is secreted by both endothelial cells and perivascular cells
in an inactive form and the association between the two cell types is required for
TGF-β1 activation, mediated by a mechanism involving gap junctions (Antonelli-
Orlidge et al. [1989], Hirschi et al. [2003]). TGF-β1 also has the ability to modify
specific perivascular markers expression. α-SMA expression has been detected in
perivascular cells treated with TGF-β1 but not in untreated cells, which in turn
expressed NG2 and desmin.
The TGF-β1 response by 10T1/2 has mainly been studied in co-culture sys-
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tems with endothelial cells, with tubular structures characterised. Selective block-
ing of TGF-β1 receptor resulted in reduced formation of tubular structures, sug-
gesting a key role for TGF-β1 in recruitment and differentiation of 10T1/2 into
perivascular-like cells (Darland and D’Amore [2001]). In single cell culture it
has been reported that TGF-β1 increases the expression of α-SMA (Lien et al.
[2006]).
Perivascular cells markers
A number of markers have been used to identify perivascular cells. However,
none has been reported to be consistently expressed. Commonly used perivas-
cular cells markers include PDGFR-β, NG2, Regulator of G-protein Signalling
5 (RGS5), α-SMA, desmin, aminopeptidase A and N and the reporter XlacZ4.
Unfortunately the expression of such markers is highly heterogeneous. Variations
have been reported not only between species, but also within organs in the same
species. Furthermore, perivascular cells markers can be modified in pathological
states (Armulik et al. [2005], Armulik et al. [2011]). As an example, α-SMA ex-
pression is not detected in normal skin and the CNS, but it is highly expressed in
tumours implanted in these organs (Abramsson et al. [2002]). RGS5 expression
follows a similar pattern in a mouse model of pancreatic islet cell carcinogenesis
(Berger et al. [2005]).
α-SMA is part of the contractile apparatus of perivascular cells and is or-
ganised into cytoplasm microfilaments. α-SMA is expressed by perivascular cells
in pre and post capillary vessels, but not in mid-capillary vessels (Nehls and
Drenckhahn [1991]). α-SMA is not perivascular cells specific being expressed by
other cells, such as fibroblasts and keratinocytes (Hinz et al. [2001], Szentma´ry
et al. [2013]). In 10T1/2 α-SMA expression has been reported to be up-regulated
by exposure to TGF-β1 (Hirschi et al. [1998]). α-SMA expression is correlated
to contractile properties of perivascular cells and is the basis for the molecular
mechanisms regulating microvasculature flow and vessel diameter.
PDGFR-β is one isoform of the receptor for PDGF-B, secreted by endothelial
cells and some tumour cells and responsible for perivascular cells recruitment.
PDGFR-β is a tyrosine kinase transmembrane receptor and one of the members
of the Platelet Derived Growth Factor Receptor (PDGFR) family. PDGF exists
in 4 isoforms: A, B, C and D, which dimerise to PDGF-AA, PDGF-BB, PDGF-
CC and PDGF-DD. PDGFR exists in two isoforms: Platelet Derived Growth
Factor Receptor-α (PDGFR-α) and PDGFR-β, which dimerise after binding to
PDGFR-αα, PDGFR-ββ and PDGFR-αβ. The receptor is characterised by two
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intracellular domains responsible for the signal transduction of the signal and the
five extracellular domains (Shim et al. [2010]). Affinity of the different receptor
isoforms is reported in figure 6.3. PDGFR-β has been often reported to be ex-
pressed by 10T1/2 (Hirschi et al. [1997], Hirschi et al. [1998], Dı´az-Flores et al.
[2009]).
NG2 or High Molecular Weight Melanoma Associated Antigen (HMWMAA)
is a chondoitrin sulfate proteoglycan membrane receptor. NG2 was initially found
to be expressed by immature cells in the CNS that demonstrated the ability to
differentiate either into neurons or glial cells, thus the name nerve/glial antigen.
NG2 is expressed by several cell-types including mesenchymal stem cells and
perivascular cells, both in physiological and pathological angiogenesis (Ozerdem
et al. [2002], Ozerdem and Stallcup [2004]). NG2 has also been identified in some
cancer cells, such as melanomas and glioblastomas (Stallcup [2002]). NG2 con-
tributes to cell proliferation and motility. NG2 is an auxiliary receptor for growth
factors such as Fibroblast Growth Factor (FGF), Platelet Derived Growth Factor-
AA (PDGF-AA) and integrins (You et al. [2013]). As with other proteoglycans,
NG2 sequestrates the factors presenting them to their receptors. NG2 also binds
metalloprotease, which appears important in ECM degradation caused by tumour
cells. Cell motility is probably enhanced by binding with collagen VI (Stallcup
[2002]). NG2 has not been reported to be expressed by 10T1/2 cells.
6.1.4 Immunoglobulin of the class G (IgG) structure
The antibodies that will be used to functionalise the polymersomes are IgG.
An IgG is a protein with a molecular weight of '150Kda, and is the most
prevalent isoform of antibody. It is composed of two identical long (heavy)
chains (Molecular weight (MW)'50KDa) and two identical shorter (light) chains
(MW'25KDa). Disulfide bonds link together the heavy chains and the light
chains in the typical quaternary Y-shaped structure (see fig 6.4). There are also
functional distinctions. The non-binding region (Fc fragment) is a highly con-
served and glycosylated portion of the IgG. Ideally, any chemical modification
should occur in this area as it is not involved in the antigen recognition. The two
arms of the Y-shape (Fab fragment) includes the binding site. Knowing the exact
amino acid composition and 3D structure of an IgG is important to identify the
most probable binding site and the best binding strategy, to avoid compromising
the antigen recognition efficiency.
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Figure 6.3: (a) Affinity of the iso-form of PDGF for the PDGFR. Solid lines
indicate high affinity, dotted lines indicate low affinity. (b) Reconstruction of the
interaction of PDGF-BB dimer with the dimerised PDGFR-ββ. The two receptor
monomers are represented in red and green and the two PDGF monomers are
represented in blue and yellow. Protein Data Base (PDB) file obtained from
Shim et al. [2010].
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Figure 6.4: IgG Structure. The two heavy chains are visible in red and blue,
while the two light chains are coloured in green and yellow. Image obtained by
visualisation of PDB file 1IGT (Harris et al. [1997]).
6.1.5 Conjugation methods
Nanoparticles can accumulate in tumours by taking advantage of increased
leakiness and reduced lymphatic drainage (Enhanced Permeation and Retention
(EPR), sec. 1.4.2). Side effects are limited by delivering the cargo preferentially to
the tumour site, therefore increasing distribution volume and local concentration.
Passive targeting can be coupled with active targeting to a specific cell population.
Active targeting can be achieved by decorating the nanoparticle surface with
specific antibodies to recognise cell markers.
There is a vast literature available on conjugation of molecules with differ-
ential composition (peptides, antibodies, nucleic acid, small molecules, dyes and
more) to polymers. The process is called bio-conjugation and it has been devel-
oped mostly for polymer therapeutics. In 1975 Rigsdorf proposed a polymer-drug
model characterised by a polymeric backbone conjugated to a drug and a tar-
geting moiety (Ringsdorf [1975]). Over the years this model proved to efficiently
improve the pharmacokinetics and pharmacodynamic profile of the drug by lim-
iting side effects and improving drug efficacy due to the targeting moiety. Bio-
conjugation has resulted in a number of Food and Drugs Administration (FDA)
approved therapeutic agents, although mostly non actively targeted (Duncan
et al. [2006]).
One of the simplest approaches is complexation. This has been widely used
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Amino acid Conjugation strategy
N-terminal N-terminal
Glutamine TGase mediated
Cysteine Thiolation
Cysteine (2) Oxidation, bridging (2 cysteine required)
Threonine O-glycosilation
Lysine Amino-functionalisation
Asparagine N-glycosilation
Serine O-glycosialtion
C-terminal C-terminal functionalisation
Table 6.1: Sites of bioconjugation of proteins. Amino acid residuals offer a
number of sites available for bioconjugation using different chemical strategies.
Adapted from Pasut and Veronese [2012]).
to decorate polymers and liposomes with nucleic acids (Felnerova et al. [2004],
Grinstaff et al. [1997], Li and Szoka Jr [2007], Kataoka et al. [2013]). It is not a
direct chemical link and requires the interaction between anionic nucleic acids and
cationic lipids or polymers. The use of cationic polymers is a major drawback of
the system, due to rapid clearance and higher toxicity when compared to neutral
polymers. Another popular strategy for non-covalent binding involves the use of
biotin/streptavidin. Covalent binding offers a wide range of chemical strategies
depending on the structure of the two molecules. When considering proteins,
such as the IgG used in the present work, the main possibilities are listed in
table 6.1. Once a conjugation strategy has been chosen, for instance targeting
of primary amino groups with N-hydroxysuccinimide, it is helpful to assess the
availability of leucin in the protein and the location with respect to the active site
(see fig.6.5). Ideally the targeted amino group should be highly represented, but
not easily available for reaction near the functional site of the protein, to avoid a
potential reduction in target-recognition efficiency.
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(a) Cysteine (b) Leucine
Figure 6.5: Distribution of cystein (left) and leucine (right) in IgG. Amino acids
are highlighted in light blue. Note how leucine is more frequent and at more
accessible sites compared to cysteine.
During polymersome functionalisation for targeting purposes, the targeting
moiety is linked to the hydrophilic bock of the co-polymer to direct it towards
the exterior of the polymersome, where the target will be located. Functional-
isation of nanoparticles can be performed before or self-assembly, as described
for liposomes in the review published by Marques-Gallego (Marque´s-Gallego and
de Kroon [2014]). The considerations made for liposomes can be here extended
to polymersomes. Pre self-assembly functionalisation involves the synthesis of
the co-polymer-protein construct as a first step, followed by solubilisation of the
reaction product with pristine co-polymer and polymersome self-assembly. In
post self-assembly functionalisation, the pristine co-polymer is mixed with reac-
tive co-polymer, polymersomes are prepared and finally the polymersomes are
functionalised. Both techniques have advantages and disadvantages. In pre self-
assembly functionalisation, a percentage of the functionalised co-polymer will be
oriented towards the internal hydrophilic core, therefore it will not be useful for
targeting purposes. However, post self-assembly functionalisation can be difficult
due to of the steric hindrance generated by the packed hydrophilic brush. Further-
more, the non-fouling formulation will tend to repel proteins. Pre self-assembly
functionalisation is not affected by these limitations, however the solvent and the
reaction condition must not compromise protein stability (6.6).
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Figure 6.6: Polymersomes can be functionalised (A) before self-assembly or (B)
after self-assembly. The choice of best strategy depends on the self-assembly con-
ditions and ligand (IgG) stability.
Biotin/streptavidin conjugation Biotin is a small (244.31g · mol−1) water
soluble molecule. In bio-conjugation, more specifically biotinylation, the small
size is one of the advantages since it does not affect the properties of the molecule
to which it is linked. Biotinylated compounds bind strongly to avidin and strep-
tavidin (Kd '10−14mol · l−1). Streptavidin and avidin have a similar secondary
structure despite sharing only '30% of the amino acid sequence. They are large
tetramers ('53kg ·mol−1) binding up to four biotin moieties. Affinity for biotin
decreases at higher rate in avidin than in streptavidin after the first binding event.
Furthermore, avidin is glycosylated and positively charged. Streptavidin/biotin
functionalisation is used daily in laboratories, for instance in Immunohystochem-
istry (IHC) and Immunocytochemistry (ICC) to link biotinylated primary anti-
bodies to dyes conjugated with avidin or streptavidin. Using this non-covalent
binding strategy polymersomes have been functionalised to map their surface
via Atomic Force Microscopy (AFM) (Battaglia et al. [2011]), to mimic leukocyte
binding strategy through integrins or selectins (Hammer et al. [2008]) or to target
macrophages in vitro (Brozˇ et al. [2005]).
Maleimide conjugation Maleimide is traditionally used to functionalise thiol
groups via oxidation of the sulphur atom (Pasut and Veronese [2012]), typically
cysteine. At low pH (6.5-7.5) it is a specific reaction, however at pH>8 it can
undergo nucleophilic attack from primary amines (i.e. lysine), and this reaction
is favoured over thiol functionalisation (6.7)(Brewer and Riehm [1967]).
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Figure 6.7: Maleimide reactivity. At pH<8 maleimide oxidates thiol groups (cys-
teine), but at pH>8 it undergoes nucleophilic attack from primary amino groups
(leucine).
6.1.6 Aim
An interest application of the methodologies developed in the chapter 4 is
the active targeting of perivascular cells with rhodamine labelled polymersomes
for optical imaging in vivo. Targeting of perivascular cells is of interest because
of their role in vessel stabilisation, particularly in the context of tumour angio-
genesis. However, pericyte targeting is challenging because of the lack of specific
extracellular markers. In this chapter the expression of two of the most commonly
reported perivascular cells markers ex vivo(PDGFR-β and NG2) will be tested
in an in vitro perivascular cells model embryonic cells 10T1/2. The expression in
10T1/2 will be compared to the expression in SVECs and MFC188, with the aim
of identifying a marker expressed preferentially by the perivascular cells model,
therefore suitable for active targeting. Once the marker is identified, two different
conjugation strategies will be investigated in order to functionalise polymersomes
to target the perivascular cells. Finally, the targeting efficiency of the conjugate
will be tested in vitro.
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6.2 Results
6.2.1 ICC
ICC was used to assess the expression level of NG2, PDGFR-β and α-SMA in
10T1/2, MFC188 and SVECs. The aim of this analysis was to confirm expression
of perivascular cell markers on 10T1/2 cells and to identify a marker expressed
by 10T1/2 and not SVECs or MFC188. This is critical for the purpose of func-
tionalise polymersomes to selectively target perivascular cells. Transformation of
10T1/2 into perivascular cells was induced by exposure to TGF-β1, initially used
at 1ng/ml. The expression levels of NG2, PDGFR-β and α-SMA were assessed
after 24h, 48h and 72h of treatment (fig. 6.8). Image analysis showed a small
increase in expression of α-SMA after 48h compared to the 24h treatment. At
the 72h time point there was no further increase (p>0.05). PDGFR-β expression
was also increased after 48h compared to 24h, while at 72h the expression de-
creased compared to the control. NG2 ratio of expression at 24h was unchanged
with respect to the control, similar to α-SMA and PDGFR-β. However, NG2
expression decreased further at 48h and 72h compared to the control, while the
expression of PDGFR-β and α-SMA was increased (p> 0.05). The expression of
the markers was affected by exposure time to TGF-β1, and this first result sug-
gested an ideal treatment of 10T1/2 with 1ng/ml for 48h in order to maximise
expression of PDGFR-β and α-SMA without losing the expression of NG2.
Figure 6.8: Quantification of expression of α-SMA, NG2 and PDGFR-β in
10T1/2 cells treated with 1ng/ml of TGF-β1 for 24h, 48h or 72h. ICC mi-
crographs were analysed as reported in 3.3. Expression is compared to 10T1/2
cells not treated with TGF-β1 (*=statistical difference from untreated 10T1/2,
U-test, p<0.05).
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In a subsequent experiment the exposure to TGF-β1 was further optimised
by assessing the expression of the same markers in 10T1/2 after treatment with
a range of TGF-β1 concentration (1-10ng/ml). The exposure time was limited
to 24h and 48h as it was observed previously that 72h had no significant positive
effect on the expression of any of the markers (p>0.05). Results are reported
in figures 6.12-6.14. α-SMA expression was higher after 48h treatment at every
concentration used except 10ng/ml. At 24h exposure the highest expression was
measured when 10ng/ml were used, although the increase was not statistically
significant (p>0.05). At 48h a trend can be observed where the ratio of expres-
sion is on average decreasing with increasing TGF-β1 concentration, however
there is no statistical significant difference between the different concentrations
(p>0.05). PDGFR-β expression after 48h showed a remarked increase compared
to the 24h treatment (p<0.05), with the only exception of 10ng/ml treatment
as was observed for α-SMA. Another similarity to α-SMA expression is that at
24h the ratio is proportional with concentration, but in this case there was a
decrease at 2ng/ml. At 48h the maximal expression was measured at 2ng/ml.
NG2 expression showed a different pattern compared to α-SMA and PDGFR-β.
Expression ratio was ≤1, with the exception of 2ng/ml and 5ng/ml at 24h treat-
ment. At 1ng/ml for 48h showed a significant decrease in expression (p<0.05).
Increased concentrations of TGF-β1 restored the ratio to '1 (no significance
between treatment and control, p>0.05).
These results suggested that expression of perivascular markers in 10T1/2 in
better induced by treatment with 2ng/ml of TGF-β1 for 48h. At this concentra-
tion and time the expression of both α-SMA and PDGFR-β was at the maximum
observed, although the increase was not always significant, while the expression
of NG2 was retained at a similar level compared to the control.
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Figure 6.9: Representative images for staining of α-SMA for 10T1/2. (A, B)
10T1/2 cells. 10T1/2 cells were added with (B, G) 1ng/ml, (C, H) 2ng/ml, D,
I) 5ng/ml or (E, J) 10ng/ml of TGF-β1. Cells were grown for (B,C,D,E) 24h
or (F, G, H, I) 48h before imaging. Bar 18µm.
136
6. Perivascular Cells Targeting 6.2. RESULTS
Figure 6.10: Representative images for staining of PDGFR-β for 10T1/2. (A,
B) 10T1/2 cells. 10T1/2 cells were added with (B, G) 1ng/ml, (C, H) 2ng/ml,
(D, I) 5ng/ml or (E, J) 10ng/ml of TGF-β1. Cells were grown for (B,C,D,E)
24h or (F, G, H, I) 48h before imaging. Bar 18µm.
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Figure 6.11: Representative images for staining of NG2 for 10T1/2. (A, B)
10T1/2 cells. 10T1/2 cells were added with (B, G) 1ng/ml, (C, H) 2ng/ml, (D,
I) 5ng/ml or (E, J) 10ng/ml of TGF-β1. Cells were grown for (B,C,D,E) 24h
or (F, G, H, I) 48h before imaging. Bar 18µm.
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Figure 6.12: Quantification of expression of α-SMA in 10T1/2 cells treated with
1-10ng/ml of TGF-β1 for 24h or 48h. ICC micrographs were analysed as re-
ported in 3.3. Expression is compared to 10T1/2 cells not treated with TGF-β1
(*=statistical difference from untreated 10T1/2, U-test, p<0.05. N=3, ±SD).
Figure 6.13: Quantification of expression of PDGFR-β in 10T1/2 cells treated
with 1-10ng/ml of TGF-β1 for 24h or 48h. ICC micrographs were analysed as
reported in 3.3. Expression is compared to 10T1/2 cells not treated with TGF-β1
(*=statistical difference from untreated 10T1/2 U-test, p<0.05. N=3, ±SD).
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Figure 6.14: Quantification of expression of NG2 in 10T1/2 cells treated with
1-10ng/ml of TGF-β1 for 24h or 48h. ICC micrographs were analysed as re-
ported in 3.3. Expression is compared to 10T1/2 cells not treated with TGF-β1
(*=statistical difference from untreated 10T1/2, U-test, p<0.05. N=3, ±SD).
Additional experiments investigated the effect of growing condition on markers
expression. The expression of α-SMA because, despite being useful to confirm
the perivascular nature of 10T1/2 cells, it cannot be used for targeting purposes
as it is located inside the cell, therefore not accessible to polymersomes. In these
experiments TGF-β1 was added at 2ng/ml for 48h. The effects of culturing
10T1/2 in conditioned media from MFC188 or SVECs and fibronectin coating of
the well were assessed (fig. 6.17-6.16). In parallel to marker detection on 10T1/2,
MFC188 and SVECs were probed for the same markers (fig. 6.18-6.16). Data
quantification is reported in figure 6.19.
NG2 expression was significantly decreased in 10T1/2 cultured in MFC188
conditioned media (ratio 0.9, p< 0.05) compared to untreated 10T1/2 cells, but
there was no significant difference in any other culturing condition or in expression
on MFC188 cells, when compared t 10T1/2 cultured in standard conditions (Basal
medium eagle (BME), no TGF-β1 added). No expression of NG2 was detected
in SVECs cells. PDGFR-β expression did not showed any statistical difference
(p> 0.05) between 10T1/2 cultured in conditioned media and MFC188 or SVECs
compared to 10T1/2 cultured in standard condition. High levels of expression of
PDGFR-β was detected in NIH-3T3 cells, a positive control for the antibody used
(Santa Cruz SC-432).
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Figure 6.15: Representative images for staining of NG2 for 10T1/2. A) 10T1/2
cells, B) 10T1/2+2ng/ml TGF-β1, C) 10T1/2+2ng/ml TGF-β1 and fibronectin
coated well, D) 10T1/2 cells in MFC188 conditioned media, E) 10T1/2 in
MFC188 conditioned media and fibronectin coated well, F) 10T1/2 cells in SVECs
conditioned media, G) 10T1/2 in SVECs conditioned media and fibronectin coated
well. Bar 30µm.
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Figure 6.16: Representative images for staining of NG2 for 10T1/2, MFC188
and SVECs. A) 10T1/2 cells, B) 10T1/2+2ng/ml TGF-β1, C) MFC188, D)
SVECs. Bar 30µm.
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Figure 6.17: Representative images for staining of PDGFR-β for 10T1/2. A)
10T1/2 cells, B) 10T1/2+2ng/ml TGF-β1, C) 10T1/2+2ng/ml TGF-β1 and fi-
bronectin coated well, D) 10T1/2 cells in MFC188 conditioned media, E) 10T1/2
in MFC188 conditioned media and fibronectin coated well, F) 10T1/2 cells in
SVECs conditioned media, G) 10T1/2 in SVECs conditioned media and fi-
bronectin coated well. Bar 30µm.
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Figure 6.18: Representative images for staining of PDGFR-β for 10T1/2,
MFC188 and SVECs. A) 10T1/2 cells, B) 10T1/2+2ng/ml TGF-β1, C)
MFC188, D) SVECs, E) 3T3 cells. Bar 30µm.
144
6. Perivascular Cells Targeting 6.2. RESULTS
(a) NG2
(b) PDGFR-β
Figure 6.19: Quantification of markers expression (NG2 and PDGFR-β) in
10T1/2 cultured in different conditions and in MFC188, SVECs and NIH/3T3.
Expression was compared to 10T1/2 cells not treated with TGF-β1(*=statistical
difference from untreated 10T1/2, U-test, p<0.05. N=3, ±SD).
6.2.2 Western Blotting
Immunocytochemistry studies were complemented with western blot analysis
for confirmation. Traditional western blot on acrylamide gel and quantitative
western blot (ProteinSimple system) were used. In conventional western blot,
NG2 expression in 10T1/2 treated for 48h with 2ng/ml of TGF-β1 is reduced by
145
6. Perivascular Cells Targeting 6.2. RESULTS
50% when compared to the control, and no expression was detected in MFC188
or SVECs. Using the automated western blot equipment, different concentrations
of TGF-β1 with 10T1/2 were evaluated, and a reduced NG2 expression in the
presence of 5ng/ml and 10ng/ml (0.7 and 0.9 ratio) was observed, while with
2ng/ml there was a small increase in expression (1.05 ratio), although not signif-
icant (p>0.05). MFC188 and SVECs had very low expression ('0.1). PDGFR-β
detection was also different in the two methods. In traditional western blot there
is a slight decrease in expression in 10T1/2 treated with 2ng/ml of TGF-β1
for 48h compared to the control (ratio 0.9). MFC188 has significant (p<0.05)
reduced expression (ration 0.4) and no expression was detected in SVECs. Au-
tomated western blot detected an increase in PDGFR-β expression from all the
10T1/2 TGF-β1 treated cells, while the receptor was found to be expressed at
significantly (p<0.05) lower levels in MFC188 and SVECs (ratio 0.35 and 0.15)
(see fig. 6.20-6.21). These results suggested that both antibodies can be used
to target the perivascular cells as they are expressed only (NG2) or at greater
level (PDGFR-β) by 10T1/2 compared to SVECs or MFC188. Antibody against
PDGFR-β will be the first one tested in polymersomes functionalisation using
biotin/streptavidin chemistry.
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Figure 6.20: Traditional western blot results for PDGFR-β and NG2. Expression
was assessed in 10T1/2, 10T1/2 treated with TGF-β1 2ng/ml for 48h, MFC188
and SVECs.
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(a) Traditional western blot
(b) Quantitative automated western blot
Figure 6.21: Western blot results for the traditional method (top) on acrylamide
gel and the quantitative automated method (bottom). All results expressed as
ratio with respect of the band intensity or signal intensity measured in the control
(10T1/2 cells not treated with TGF-β1)(*=statistical difference from untreated
10T1/2, U-test, p<0.05. N=3, ±SD).
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(a) PDGFR-β
(b) NG2
Figure 6.22: Quantitative western blot chromatograms. A) PDGFR-β and B)
NG2 detection. Expression was assessed in 10T1/2, 10T1/2 treated with in-
creasing concentration of TGF-β1 (2-10ng/ml) for 48h, MFC188 and SVECs.
Expression is proportional to the area of the peak.
6.2.3 Biotin/streptavidin conjugation
To test the control over the conjugation ratio we conjugated different for-
mulations obtained using different molar ratios (0, 0.5, 3 and 5%) of Poly(2 -
methacryloxyethyl-phosphorylcholine)-poly( 2 -(diisopropylamino)ethyl methacry-
late) (PMPC-PDPA)-biotin with the same amount of streptavidin and biotiny-
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lated Texas-Red (equivalent to 2/1 molar ratio with the highest concentration of
PMPC-PDPA-biotin). The amount of dye linked to the polymersomes after pu-
rification was quantified (see figure 6.23). Results are expressed as fluorescence
intensity normalised by the amount of PMPC-PDPA detected. It can be ob-
served that when no PMPC-PDPA-biotin was used, no Texas-red was detected,
and that the concentration of Texas-red increased linearly with the concentration
of PMPC-PDPA-biotin detected, in the range 0.5%-5% molar.
Figure 6.23: Polymersome biotinylation. Formulations containing 0%, 0.5%, 3%
and 5% of PMPC-PDPA-biotin were reacted with streptavidin and Texas-Red-
biotin (1:1 molar ratio with biotinylated co-polymer). After purification, sam-
ples were analysed by Reverse Phase-High Pressure Liquid Chromatography (RP-
HPLC) and results are expressed by fluorescence intensity, proportional to Texas
red concentration, normalised by the total amount of PMPC-PDPA detected in
the UV channel at 220nm. N=3, ±SD.
The antibody against PDGFR-β used in polymersome functionalisation was
purchased biotinylated and it was different from the one used to evaluate marker
expression. The use of this new antibody was validated using the positive control
NIH-3T3 cells. In this experiment the biotinylated antibody to PDGFR-β was
added to living NIH-3T3 cells and FITC-avidin was used to detect the biotiny-
lated antibody. The average intensity was measured against a control, which was
3T3 cells treated with FITC-avidin, but not with the biotinylated antibody (fig-
ure 6.24). A clear increase in signal intensity was recorded, confirming that the
antibody chosen is suitable to target living cells expressing PDGFR-β.
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Figure 6.24: Biotinylated antibody to PDGFR-β testing. Living NIH-3T3 cells
were treated with biotinylated antibody to PDGFR-β (right) and FITC-avidin as
a control (left). Bar 30µm.
Polymersome functionalisation
Biotinylated polymersomes were functionalised with antibody to PDGFR-β,
The antibody was purchased already biotinylated and linked to the polymersomes
via a streptavidin bridge. The reaction mixture was purified by Gel Permeation
Chromatography (GPC) and characterised by TEM, Dynamic Light Scattering
(DLS) and RP-HPLC, as described in sections 2.1.3-2.1.4. TEM and DLS data
showed that spherical size and size distribution was not altered by the synthetic
protocol. A slight increase in the peak of size distribution recorded by DLS (from
'90nm to '110nm) suggesting successful conjugation which cause increase in
hydrodynamic diameter of polymersomes (see fig. 6.25). RP-HPLC results indi-
cated a molar ratio antibody/co-polymer of 2.1±1.2pmol/1mmol, demonstrating
the presence of both co-polymer and antibody in the purified sample, therefore
proving successful conjugation (see fig. 6.26).
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(a) TEM, PMPC-PDPA (b) TEM, PMPC-PDPA-IgG
(c) DLS
Figure 6.25: (a, b) TEM and (c) DLS of polymersomes functionalised with biot-
in/streptavidin. Pristine polymersomes (red) are compared to 10% functionalised
polymersomes (blue). Polymersomes retained spherical shape, however the hydro-
dynamic diameter was '20nm after conjugation, indicating surface modification.
152
6. Perivascular Cells Targeting 6.2. RESULTS
Figure 6.26: RP-HPLC analysis for biotin/streptavidin functionalised polymer-
somes. Polymersomes peak at '7min, the antibody peaks at '28min, the purified
conjugate polymersome-antibody showed both peaks ('7min an '28min).
Flow cytometry
Uptake of functionalised formulations was evaluated byFluorescence Activated
Cell Sorting (FACS). The formulations tested with 10T1/2 cells were pristine
Polyethylen Oxide-poly(2-(diisopropylamino)ethyl methacrylate) (PEO-PDPA),
1% functionalised PEO-PDPA, pristine PMPC-PDPA and 1% functionalised
PMPC-PDPA. In this section of the work PEO-PDPA was used as a polymeric
analogue of POEGMA-PDPA, which was not available in the laboratory at the
time the experiments were performed. With MFC188 the pristine formulations of
PEO-PDPA and PMPC-PDPA were tested. In 10T1/2 there was a small increase
of functionalised PMPC-PDPA formulations uptake at 6h (+10%) and at 24h for
functionalised PEO-PDPA formulations (+5%). However, the uptake was lower
than that of the pristine formulations at the same time points from MFC188 (fig.
6.27).
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Figure 6.27: Uptake of functionalised polymersomes. Polymersomes were func-
tionalised with 1% molar of antibody to PDGFR-β. Functionalised formulation
did not show significant improvement in kinetic of uptake compared to the non-
functionalised counterpart. N=3, ±SD.
6.2.4 Maleimide conjugation
Maleimide reaction was performed using a generic rabbit IgG instead of a
specific antibody to PDGFR-β or NG2. This choice was justified considering
the early developing stage of the functionalisation protocol and the consequent
need forsignificant amount of material. A generic rabbit IgG represented a sig-
nificantly cheaper alternative to specific antibodies. Maleimide reactivity can
be shifted from thiol to primary amino groups by controlling the reaction pH
(section 6.1.5) Considering the differences in amino acid abundance between cys-
teine and leucine in an IgG (fig. 6.5) the reaction was conducted at pH=7.5
(thiol groups, cysteine) and pH=8.5 (primary amino groups (leucine). TEM data
showed spherical vesicles suggesting that the functionalisation protocol did not
affect polymersomes stability. DLS data showed a small shift of size distribution
from '90nm to '100nm, suggesting possible conjugation (fig. 6.28). RP-HPLC
chromatograms were characterised by the presence of both peaks for polymer
(fig. 6.29a) and the antibody (fig. 6.29b). However, the ratio between the two
peaks was constant, indicating that there was no significant difference (p>0.05)
between the two reaction yield and that the degree of functionalisation was the
same (antibody/co-polymer 0.5±1.2pmol/1mmol).
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(a) TEM, PMPC-PDPA (b) TEM, PMPC-PDPA-IgG
pH=7.4
(c) TEM, PMPC-PDPA-IgG
pH=8.5
(d) DLS
Figure 6.28: (a, b, c) TEM and (d) DLS of polymersomes functionalised with
maleimide. Pristine polymersomes (red) are compared to 10% functionalised poly-
mersomes at pH 7.4 (blue) and pH 8.5 (black). Polymersomes retained spherical
shape, however the hydrodynamic diameter was '20nm after conjugation, indi-
cating surface modification.
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(a) UV, 220nm: Co-polymer
(b) EX/EM 270/340: IgG
Figure 6.29: Maleimide reaction optimisation, RP-HPLC analysis. (a) Co-
polymer peaked at t'12.75min. (b) IgG peaked at t'27.25min. Representative
RP-HPLC chromatograms for N=3 experiment. Peakes were integrated and the
amount of IgG per polymersomes was calculated after normalising the area of the
IgG against the area of the polymer.
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6.3 Discussion
A fundamental requirement in targeted delivery is the identification of a spe-
cific marker selectively expressed in the cell to target. We choose to investigate
the possibility to target perivascular cells. This choice was justified by the need of
a better understanding the role of perivascular cells in angiogenesis and their re-
sponse to anti-angiogenic or Vascular Disrupting Agent (VDA) treatments. Prof.
Tozer’s group developed a an in vivo tumour model of MFC188, and they char-
acterised its perivascular cell coverage ex vivo. Polymersomes can allow direct, in
vivo and real-time monitoring of perivascular cells in response to combretastatin.
This is of great importance in order to assess the exact mechanism of response
to the treatment and vasculature normalisation. Furthermore, it has potential
beneficial ethical impact as it real-time observation is not an end-point procedure,
therefore one animal can be used to acquired multiple time points, as opposed to
ex vivo examination.
In the current chapter we investigated the expression of a number of proposed
perivascular cells markers in 10T1/2 cells treated with TGF-β1, a cytokine re-
ported to induce differentiation of perivascular cells (Hirschi et al. [1998]). Differ-
ent concentrations and exposure times of TGF-β1 were tested, as well as different
growing conditions. Furthermore we compared the expression of the markers in
10T1/2 cells, tumour and endothelial cells. This is of particular importance be-
cause the marker to be targeted is required to be expressed by the target cells,
but not by other cell types such as tumour or endothelial cells; the aim of the
study being to target perivascular cells in the tumour microenvironment.
The expression of three perivascular cells markers was assessed: α-SMA,
PDGFR-β and NG2. α-SMA was included in the panel because it is characteris-
tic of perivascular cells. However, it should be noted that it is located internally,
therefore it cannot be used for targeting purposes. PDGFR-β and NG2 present
extracellular epitopes that can be targeted (Shim et al. [2010], Stallcup [2002]).
Overall, ICC and Western Blot (WB) showed no significant effect of TGF-β1
or tissue culturing conditions on 10T1/2 expression of PDGFR-β, NG2 or α-SMA.
It is also interesting to observe that some combinations of TGF-β1 exposure such
as 1ng/ml for 48h or 72h caused an increased expression of α-SMA and decreased
expression of NG2, which reflects a the phenotype of SMC surrounding veins (α-
SMA+, NG2+/−) rather then capillary pericytes (α-SMA−, NG2+) (Armulik et al.
[2011]).
Our results suggest that the pathway for differentiation of 10T1/2 in perivas-
cular cells is likely to be dependent on other factors rather than only TGF-β1.
Differentiation could be affected also by contact with endothelial cells (Hirschi
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et al. [1998], Hirschi et al. [2003]), cell-signalling (TGF-β1-PDGF-B, 6.1.1), stiff-
ness of the growth support (i.e. extracellular matrix, tubular shaped in vivo vs
plastic well plate) unreported for 10T1/2, but well known for other stem cells
systems (Park et al. [2011], Vincent et al. [2013]). Furthermore, it has been sug-
gested that 10T1/2 might not fully differentiate into pericytes or vSMCs, but
rather into myofibroblast with inconsistent markers expression (Brunelli et al.
[2004], Yoshida and Owens [2005]). These conflicting reports have been explain-
ing considering differences in protocols adopted by different laboratories (Xie et al.
[2011]). Another possible explanation could be in the lack of a clear definition of
pericytes and other perivascular cells, as most of the cited works referred to the
differentiation of 10T1/2 in pericytesvSMCs, rather than specifically in pericytes.
A major limitation of the in vitro model is the lack of direct transferability to in
vivo, as it is not possible to predict the expression of perivascular cells markers in
the animal mode, as it would be inaccurate to assume that the endothelial cells
of blood vessels found in the tumour growing in the Dorsal Skinfold Chamber
(DSC) express the same markers as the SVECs used here. A better model to be
adopted in future development of the targeting system would be to use histolog-
ical samples from the animals. These samples have benn already characterised
for α-SMA and other markers expression by Prof. Tozer group, and targeting
effect could be validated ex vivo using functionalised polymerosmes instead of
the primary antibody normally used in histology.
The aim of this part of the work was not to elucidate the mechanism of
differentiation of 10T1/2 into pericyets or vSMCs, but to assess if expression of
perivascular cell markers by 10T1/2 was higher compared to the expression of the
same marker in MFC188 or SVECs. With this respect, ICC showed no significant
difference in expression of PDGFR-β or NG2 between the three cell types. WB,
both the traditional acrylamide gel based and the quantitative Simon methods,
showed significant reduced of expression of PDGFR-β and NG2 in MFC188 and
SVECs compared to 10T1/2. The difference between the two techniques could
be explained by a better sensitivity of WB method compared to ICC. Consid-
ering these results it was chosen to functionalise polymersomes with both both
antibodies against PDGFR-β and NG2, however only the first one was used in
preliminary in vitro screening, while a cheaper generic IgG was preferred as a
model of antibody in further optimisation of the conjugation method.
In principle, the functionalisation can be achieved before or after polymer-
somes formation. When performed before formation, the single chain of co-
polymer is reacted with the desired moiety and the purified product is mixed
with pristine copolymer in the second, separate step of polymersomes forma-
tion. This approach has the advantage of being easier to control and to facilitate
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the reaction between the copolymer and the functionalising molecule. However,
the reaction requires the co-polymers to not aggregate, and this often involves
non-biocompatible chemical solvents that will need to be purified form the fi-
nal product. Furthermore, when the functionalised copolymer is mixed with the
pristine copolymer during polymersome formation, statistically, half the func-
tionalised chains will be exposed to the inner aqueous core of the polymersomes
rather than the outer surface. Such positioning is useless for functionalisation
and will result in lowering the yield of reaction by about 50%. The second ap-
proach is to functionalise polymersomes after their formation. In this way only
the reactive chains on the outer surface of the vesicles will react. This has the
advantage of reducing the waste of functionalising reagent. However, such an
approach presents increased steric hindrance from the polymersomes which could
affect reaction yield. In this work, functionalisation was performed following
polymersome self-assembly.
We tested two different reaction methods. The first reaction exploited the
strong non-covalent binding between biotin and the multivalent streptavidin to
link biotinylated copolymers with biotinylated antibody to PDGFR-β using a
bridge of streptavidin. We showed that the conjugation can be controlled by
changing the amount of biotinylated copolymer included in the polymersomes
formulation, and that the antibody used is effective in recognising PDGFR-β.
facs analysis showed increase of uptake by 10T1/2 for both PEO-PDPA and
PMPC-PDPA functionalised formulations compared to the pristine formulations.
However, the increased uptake was still not significantly (p>0.05) higher com-
pared to the pristine formulations by MFC188. This can be explained by low effi-
ciency of functionalisation and because PDGFR-β is also expressed by MFC188.
Biotin/streptavidin polymersomes functionalisation required 3 steps: poly-
mersomes self-assembly, streptavidin binding, biotinylated antibody binding. It
will also involved several purification steps to eliminate intermediate unreacted
reagents. These requirements have a negative impact on the cost of the produc-
tion method and on the yield. To overcome these limitations we investigated
the possibility using copolymers functionalised with maleimide to link directly
thiol groups in the antibody (cysteine). This approach will allow to eliminate
one reaction and purification step, and also to avoid the use of streptavidin, a
vary large protein that could potentially interfere with polymersomes stability,
mechanism of reaction or antibody/antigen recognition. The generic maleimide
reaction is reported in figure 2.6. Considering the high cost of the reaction due
to the amount of antibody required, the method was developed using a non spe-
cific rabbit IgG. RP-HPLC analysis showed successful conjugation of the IgG,
however at a very low yield (antibody/co-polymer ratio: 0.5±1.2pmol/1mmol).
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Investigation of cysteine availability on IgG showed that the amino acid is poorly
represented and generally not available, for instance because thiol groups are
already engaged in S-S bridges. This could explain the low yield of reaction.
Leucine is a more common amino acid and it has a reactive primary amino-
group. Maleimide reactivity can be shifted to primary amino groups at higher
(pH>8). The effect on reaction yield was tested by performing the reaction at
pH=8.5. Results did not show improvement on the yield of reaction. This can
be explained considering that Poly(2 - methacryloxyethyl - phosphorylcholine)
(PMPC) is a non-fouling polymers, therefore it is possible that repulsive forces
between polymersomes and IgG negatively affected the reaction kinetic. This can
also explain the low reaction yield obtained from biotin/streptavidin approach.
Further development of the should investigate the possibility of performing the
reaction before polymersomes self-assembly.
Overall, we could not prove efficient in vitro targeting of perivascular cells.
One of the major challenges associated with the project was the lack of a specific,
highly expressed pericyte marker. 10T1/2 screening identified PDGFR-β and
NG2 as possible markers, however they are not expressed only by 10T1/2, but
also by tumour cells (MFC188), limiting their applicability in targeting. Further-
more, there is no proof that the marker will be expressed by tumour perivascular
cells if the technology has to be translated to in vivo applications. Another prob-
lem was polymersomes-antibody conjugation strategy. When performed after
polymersomes self-assembly, the reaction was characterised by low yield, most
likely because of the steric hindrance generated by the non-fouling PMPC and
Polyethylene Oxide (PEO) polymers.
Despite being negative for targeting purposes, the methods used identified the
key steps in development of polymersomes for targeting: target identification,
functionalisation and in vitro screening. The choice of alternative target (i.e.
tumour cells via folic acid or RGD) and pre self-assembly conjugation can be
tested in further development of the method.
A final consideration should be made on the choice of the targeting moiety.
In this work we choose to work with a full IgG. This choice was made consid-
ering the commercial availability of biotinylated antibody to PDGFR-β and the
possibility to optimise the conjugation with a generic rabbit IgG. However, to
respect the stoichiometric ratio 1/1 between reactive co-polymer and antibody, it
was necessary to use high mass of high molecular weight IgG ('65KDa). Con-
sidering the cost of the biotinylated antibody, a single reaction with 10% reactive
co-polymer can be estimated to require '40,000£in consumable and reagents to
obtain enough material for an in vitro uptake study. Furthermore, functionalisa-
tion with big molecules can compromise the stealth properties of polymersomes,
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facilitating opsonisation and recognition by phagocytic cells. In future studies,
IgG fragments (i.e. Fab) or smaller peptides should be considered instead of full
IgG.
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CHAPTER 7
SUMMARY
7.1 General discussion
In this work, polymersomes based on co-polymers Poly(2 - methacryloxyethyl-
phosphorylcholine)-poly( 2 -(diisopropylamino)ethyl methacrylate) (PMPC-PDPA)
and poly(oligo(ethylene glycol) methacrylate)-poly( 2 -(diisopropylamino)ethyl
methacrylate) (POEGMA-PDPA) have been used in conjunction with the Dorsal
Skinfold Chamber (DSC) to image the tumour microenvironment. The develop-
ment of vesicles started with the study of uptake in vitro. Live cell imaging was
used as a quantitative method, its results being supported by Reverse Phase-High
Pressure Liquid Chromatography (RP-HPLC) and Fluorescence Activated Cell
Sorting (FACS) analysis (4.1). Because of the importance of blood flow in the
dynamic of polymersomes recognition and internalisation by cells, the in vitro
system was integrated with the development of a flow bio-incubator dedicated
to quantification of uptake studies via FACS and live cell imaging (fig. 4.8).
Uptake studies were performed on three cell types relevant to the tumour mi-
croenvironment: tumour cells (Mouse Fibrosarcoma Cells expressing VEGF188
isoform (MFC188)), endothelial cells (Small Vessel Endothelial Cells (SVECs))
and a perivascular cell model (10T1/2). Results showed a faster uptake of PMPC-
PDPA polymersomes compared to POEGMA-PDPA by all cell types, and partic-
ularly by tumour cells (fig. 4.2). In flow conditions, the differences between all cell
types and polymersome formulations were significantly reduced (fig. 4.11). Differ-
ences between PMPC-PDPA and POEGMA-PDPA could be surprising consider-
ing that both poly(oligo(ethylene glycol) methacrylate) (POEGMA) and Poly(2
- methacryloxyethyl - phosphorylcholine) (PMPC) are not fouling, therefore they
will not interact with circulating proteins which leads to opsonisation and rapid
blood clearance. However, it has been reported that PMPC-PDPA polymersomes
162
7. Summary 7.1. GENERAL DISCUSSION
uptake is mediated by scavenger receptor SR-B1 (Colley et al. [2014])). Reduced
uptake in flow to a level similar to POEGMA-PDPA suggests that flow interferes
with the recognition of PMPC-PDPA polymersomes by the receptors, therefore
the uptake kinetic becomes similar to POEGMA-PDPA. Further development of
the analysis in flow took advantage of the unique capability of imaging to focus in
real time to different areas of the well. Because the device developed did not de-
liver perfect homogeneous flow at the cell level, the local differences were used to
correlate shear stress and velocity magnitude to cellular uptake (fig. 4.12-4.14).
Results suggested that shear stress had lower impact on cell uptake compared
to vertical velocity. This suggests that the effect of flow on speed of the parti-
cles (therefore kinetics of ligand/receptor recognition) is higher than the effect
of shear stress, which is likely to affect cell phenotype by inducing mechanical
stress (Khan and Sefton [2011]), rather than ligand/receptor kinetics. Further
studies are required to elucidate the effect of flow on distribution of SR-B1 at the
cellular surface. Furthermore, uptake studies at this developmental stage were
performed in cell media. This is a Newtonian fluid, very different to blood. It
will be of interest to modify viscosity of the media to perform uptake studies
in blood-like fluid. Overall, the in vitro findings suggested that PMPC-PDPA
and POEGMA-PDPA formulations will have significantly different behaviour in
vivo. PMPC-PDPA are expected to be cleared rapidly, while POEGMA-PDPA
should have longer circulation time, which in turn will be reflected in improved
accumulation within tumour.
In in vivo testing, the tumour vasculature was imaged in DSC using a con-
focal microscope equipped with a 10X objective. The tumour was implanted as
a spheroid of MFC188. This particular model was chosen because it has been
reported to be characterised by more vascularised tumours with a higher pericyte
coverage compared to tumours obtained form Mouse Fibrosarcoma Cell (MFC)
cells expressing Vascular Endothelial Growth Factor isoform 120 (VEGF120) or
Vascular Endothelial Growth Factor isoform 164 (VEGF164) (Tozer et al. [2008],
Akerman et al. [2013]). This tumour model was ideal to develop an imaging plat-
form targeted to the tumour microenvironment. Image analysis was performed
using a specifically developed algorithm. Both polymersome formulations were
found to initially localise to the tumour vasculature, then gradually extravasate
and accumulate within tumours. However, the analysis also confirmed the antic-
ipated differences between PMPC-PDPA and POEGMA-PDPA polymersomes.
POEGMA-PDPA accumulated within tumours to a greater extent compared to
PMPC-PDPA polymersomes. After 16h from the injection, POEGMA-PDPA
polymersomes were clearly localised in tumour stroma, with vessels visible in
dark over the brighter stroma, while PMPC-PDPA polymersomes were hardly
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detected in either the vessels or the stroma at the same time point (fig. 5.5, 5.6-
5.6). This suggested faster clearance of PMPC-PDPA, which therefore was less
efficient in accumulating within the tumour. These observation are in agreement
with unpublished data from Prof. Battaglia showing longer circulating half life of
POEGMA-PDPA compared to PMPC-PDPA polymersomes, which quickly ac-
cumulate in liver and spleen, organs primarily involved in nanoparticle clearance
from blood. Finally, we implemented the analysis with a method to correlate the
distance travelled by the polymersomes with the diameter of the source vessel.
From the results it was observed that there was greater polymersomes accumu-
lation around higher calibre vessels, however the furthest distance travelled is
recorded from smaller vessels (fig. 5.8-5.9). The accumulation around bigger
calibre vessels, and specifically near vessels branches, has been already reported
for liposomes (Yuan et al. [1994]). A possible explanation could be that in those
areas there is a higher local density of tumour macrophages up-taking and accu-
mulating polymersomes. At smaller vessel level extravasated polymersomes are
less likely to be sequestrated by phagocytic cells, therefore they can travel longer
distances. This working hypothesis needs to be tested, ideally by macrophage
labelling in vivo in the DSC followed by co-localisation study. Another possible
explanation could be in the presence of bigger fenestrations in bigger calibre ves-
sels, and local flow turbulence at the branching level facilitating polymersomes
extrapolation.
The method of tumour targeting described is known as passive targeting. Poly-
mersomes reach the tumour and accumulate within the stroma via Enhanced
Permeation and Retention (EPR) effect. It is also possible to undertake active
targeting to any specific tumour cell. Active targeting can be achieved by func-
tionalising polymersomes with a moiety to recognise a specific cell marker. In the
final part of the work an attempt at active targeting was introduced. The chosen
target was perivascular cells. This cell type was chosen because of its key role in
angiogenesis and vessels stabilisation, and the implication in development of peri-
cyte targeted therapies. Targeting pericytes is challenging as there is no reported
cellular marker specific of pericytes and uniquely expressed by pericytes. Further-
more, pericytes are not a well defined cell type. Restricting their definition to
peri-capillary cells, there is still significant variation in reported markers depend-
ing on species, body location and activation status (Dı´az-Flores et al. [2009]). For
the in vitro work the embryo cell 10T1/2 was used a precursor of pericyte, as it
has been reported that they can differentiate into perivascular cells in response to
treatment with Transforming Growth Factor-β1 (TGF-β1) (Hirschi et al. [1998]).
Adopting this model, the first part of the development was focused on assessing
the expression of commonly accepted pericytes markers Platelet Derived Growth
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Factor Receptor-β (PDGFR-β) and Nerve Glial antigen 2 (NG2) in 10T1/2 when
treated with different concentrations of TGF-β1, and most importantly with re-
spect to the expression of the same markers in MFC188 and SVECs. Ideally, the
marker should be expressed only by 10T1/2 to facilitate active targeting. Results
indicated that 10T1/2 expression of PDGFR-β and NG2 was not significantly
affected by treatment with TGF-β1 alone, suggesting a more complex activation
pathway, perhaps involving direct contact with endothelial cells in a co-culture
system, as suggested by results reported by D’Amore and Hirschi (Hirschi et al.
[1998], Hirschi et al. [1999]). However, expression of both markers, and particu-
larly NG2, was found to be significantly higher in 10T1/2 compared to MFC188
and SVECs (fig. 6.12-6.21).
There is a vast library of chemistry available for polymer functionalisation.
In this work we tested two different synthetic approaches that can be performed
after polymersomes formation. The first approach is based on biotin/streptavidin
chemistry, the second on on maleimide reaction. In biotin/streptavidin approach
a percentage of biotinylated co-polymer was included in the formulation and after
polymersomes self assembly a biotinylated antibody against PDGFR-β was linked
via a bridge of streptavidin. Maleimide is commonly used to functionalise thiol
groups (cysteine in proteins), however at slightly higher pH it can also undergo
nucleophilic attack from primary amino groups (leucine). Both strategies were
tested. RP-HPLC characterisation (fig. 6.26, 6.29) showed successful conjugation
for both strategies. Biotin/streptavidin conjugate was tested in vitro (fig. 6.27).
At 6h a slight increased uptake of PMPC-PDPA functionalised formulation was
observed in 10T1/2 cells, however the uptake was still lower compared to up-
take of pristine PMPC-PDPA by MFC188. A similar pattern was observed for
Polyethylen Oxide-poly(2-(diisopropylamino)ethyl methacrylate) (PEO-PDPA)
functionalised polymersomes at the 24h time point.
Overall, results obtained in this work represent a collection of methods devel-
oped to screen polymersomes uptake in vitro, also taking into account the com-
plexity of flow mediated particles delivery. Furthermore, dedicated in vivo analyt-
ical methods were developed to characterise accumulation of polymersomes within
tumours. Results suggested that longer circulating POEGMA-PDPA polymer-
somes have better chance to accumulate intra-tumour and to provide increased
signal-to-noise ratio compared to PMPC-PDPA. Furthermore POEGMA-PDPA
are less likely to be up-taken preferentially by tumour cells by scavenger recep-
tors. However, PMPC-PDPA can still be considered especially for short term
imaging and perhaps active targeting of cells located close to the vessels, where
no significant intra-tumour accumulation is required.
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7.2 Future directions
The work presented generated some interesting questions that can be ad-
dressed in future developments.
In flow studies suggested a strong effect of flow on cellular uptake, and per-
haps a more significant effect of velocity magnitude compared to shear stress.
Further studies could complement the observations made by correlating uptake
with topological cellular distribution of receptor involved in uptake pathways such
as scavenger receptors. This is critical especially for endothelial cells, which are
known to polarise receptors expression in relation to the vascular or avascular
side. Formulations with receptor mediated uptake such as PMPC-PDPA could
be affected by a polarisation of the receptor expression. Furthermore, it would be
interesting to analyse polymersomes uptake not only as a function of the shear
stress or the fluid velocity but also according to local polymersomes velocity or
concentration, both quantifiable with appropriate in silico simulation. Polymer-
somes velocity is likely to be strongly correlated to fluid velocity, and to be very
low at the boundaries (i.e. cell surface). Local polymersomes at the cellular level,
however, is likely to be significantly higher at the inlet and outlet level compared
to the rest of the well. This is because the inlet and outlet are two small points
were all particles are forced to pass, while they can spread across a much big-
ger surface in the rest of the well. Furthermore, polymersomes concentration at
the cellular level is probably very low because they are mostly quickly dragged
away from the cell surface by the fluid, which has greater velocity away from the
boundaries. If in silico simulations shows a significant effect on polymersomes
drag, the device should probably be re-designed in favour of a greater surface to
volume ratio compared to the current design. Finally, the introduction of a more
viscous, blood-like fluid will improve the reproduction of physiological capillary
flow.
Active targeting attempt was not successful. Targeting of perivascular cell
is made difficult by the lack of a well characterised marker and the difficulty
of translating in vitro models to in vivo models. Further work could introduce
the screening on ex vivo samples obtained from animal models bearing the same
MFC188 tumour model used in this work. More work can also be done in the
conjugation of a targeting moiety to the polymersomes surface. In this work
we choose to functionalise pre-formed polymersomes, however the formualations
used are non-fouling, and this is likely to reduce the reaction yield as they will
interact poorly with the Immunoglobulin of the class G (IgG) chosen as function-
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alising molecule. Performing the reaction before the self-assembly could improve
the reaction yield by reducing the steric hindrance. Furthermore, the use of a
full antibody is not advisable for both stability and synthetic costs reasons. A
full antibody has a relatively large hydrodynamic radius which could potentially
destabilise the polymersome construct. Full antibodies could also be more easily
recognised by the Reticuloendothelial System (RES) or opsonising proteins be-
cause of their large volume. Finally, the use of specific, full antibodies is costly, as
it is necessary to use a significant amount of molecules, therefore of antibody, to
perform the reaction in the ideal condition of antibody excess. The use of smaller
molecules such as peptides or antibody fragments could address all the discussed
issues.
Finally, in vivo image analysis has proved to be potentially useful in analyse a
number of parameters related with polymersomes extravasation and intra-tumour
accumulation. More work can be done to fully automate the masking process,
which at the moment relies on the user judgement at least on the choice of the
masking parameters such as intensity threshold or Difference of gaussians (DoG)
kernel size. More animals are also required to draw significant conclusions from
the analysis, as only a total of 5 animals divided across different formulations
and imaging techniques were used. With respect to this, the surgical procedure
necessary to implant the DSC proved to have poor outcome, with major com-
plications arising a few hours after surgery. Some of the complication have been
addressed already by changing some of the parts of the chamber, most impor-
tantly the spacers between the two frames. However, more work should be done
to assure more reliable outcome, which has implication on both the ethics of the
work and data quality from in vivo experimentation.
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CHAPTER 8
LIST OF MATERIAL USED
8.1 General in vitro laboratory equipment and
reagents
Consumables
Item Supplier
1.2ml cryogenic vials Nalge Company, Rochester, NY, USA
0.5ml, 2.0ml eppendorf tubes Starstedt, Ak & Co, Germany
25cm2, 75cm2 tissue culture flasks Nunc-Life Technologies Ltd, UK
3M autoclave tape Rexam Medical Packaging, UK
5ml, 10ml and 25ml pipettes Corning Incorporated, USA
70% (v/v) IMS Adams Healthcare Ecolab, UK
Trigene Medimark Scientific, UK
96, 24 well plates Nunc-Life Technologies Ltd, UK
96 wells imaging plates Becton, Dickinson and Company, NJ,
USA
24 wells imaging plates ibidi, Martinsried, Germany
Gilson pipette tips Starsted Laboratory Supplies Ltd, UK
Latex examination gloves Kimberly Clarke Ltd, UK
P2, P10, P20, P200, P1000 pipettes Gilson Inc, USA
Paper tissue Kimberly Clarke, USA
Presept tablets Johnson & Johnson, UK
Sterile universal tubes Scientific Laboratory Supplies Ltd, UK
Bijoux Scientific Laboratory Supplies Ltd, UK
Glass vials Scientific Laboratory Supplies Ltd, UK
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1ml, 2ml, 5ml syringes Becton Dickinson Ltd, UK
1ml insulin syringe Becton Dickinson Ltd, UK
25G, 27G and 29G needles Becton Dickinson Ltd
4 well slides Nunc-Life Technologies Ltd, UK
Microscope glass slides Fisher Scientific, UK
Coverslip Fisher Scientific, UK
PVDF membrane EMD Millipore Corporation, Billerica,
MA, USA
Photographic film GE Healthcare, UK
Marprene tubing Watson-Marlow Pumps Group, UK
Elbow Luer Connector ibidi, Martinsried, Germany
Carbon coated TEM Grids Elektron Technology Ltd, UK
Cell scraper Corning, NY, USA
Simon ProteinSimple consumables ProteinSimple, Santa Clara, CA, USA
Table 8.1: In vitro consumables.
Equipment
Item Supplier
5% CO2 incubator Sanyo, UK
Autoclave Prestige Medical Ltd, UK
Centrifuge (tissue culture) Eppendorf 5702R
Microcentrifuge Eppedorf 5425
Ice machine Scotsman Ice System, UK
pH meter Hanna Instruments, Rhode Island,
USA
Plate reader
Fluorescence microscope Pathway 855
Microscope: Becton Dickinson Ltd, UK
Camera: Hammamatsu
Fluorescence microscope Leica TCS SP8
Microscope: Leica, Wetzlar, Germany
Camera:CRI NuanceFX, Quorum
Technologies, CA, USA
Brightfield microscope Medline Scientific Ltd, UK
Spectrofluorometer Jasco Inc, USA
Sterile safety cabinets/hoods Walker Safety Cabinets Ltd, UK
Temperature control water bath Fisher Scientific, UK
Vortex Whirlimixer, Fisher Scientific, UK
Analytical weighting scale Sartorius, D
Technical weighting scale Sartorius, D
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Western blot equipment Bio-Rad Laboratories, CA, UK
Western Blot semi-dry membrane
transfer
Bio-Rad Laboratories, CA, UK
FACS CellArray Becton Dickinson Ltd, UK
TEM microscope
Microscope: Fei Tecnica Spirit
Camera: Gatan1K MS600CW CCD
Glow discharger Quorum Technologies Ltd, UK
Peristaltic pump Watson-Marlow Pumps Group, UK
Simon ProteinSimple ProteinSimple, Santa Clara, CA, USA
RP-HPLC Ultimate 3000 Thermo Scientific Dionex, Waltham,
Massachusetts, USA
RP-HPLC column Phenomenex, CA, USA
Table 8.2: In vitro equipment.
Reagents
Item Supplier
Streptavidin Vector Laboratories, USA
Hydrochloric acid Sigma-Adrich, MI, USA
Sodium hydroxide Sigma-Adrich, MI, USA
Liquid Nitrogen BOC, UK
Gaseous Nitrogen BOC, UK
Phosphotungstenic acid Sigma-Adrich, MI, USA
DMEM Lonza, Switzerland
BME Invitrogen, CA, USA
Penicillin/streptomycin Sigma-Adrich, MI, USA
Fungizone Life Technologies, CA, USA
Methanol Sigma-Adrich, MI, USA
Choloroform Sigma-Adrich, MI, USA
Trifluoroacetic acid Sigma-Adrich, MI, USA
PBS Fisher Scientific, UK
FCS Biosera, UK
Trypsin/EDTA Sigma-Adrich, MI, USA
FACS cleaning buffer Becton Dickinson Ltd, UK
FACS running buffer Becton Dickinson Ltd, UK
RIPA Buffer Thermo Scientific, MA, USA
BSA Sigma-Adrich, MI, USA
Photographic fixative Eastman Kodak Company, NY, USA
Photographic developer Eastman Kodak Company, NY, USA
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Simon ProteinSimple reagents ProteinSimple, Santa Clara, CA, USA
Fibronectin Sigma-Adrich, MI, USA
HEPES buffer Sigma-Adrich, MI, USA
Acetone Sigma-Adrich, MI, USA
Ethanol Sigma-Adrich, MI, USA
ABC Vector Laboratories, USA
DAB Vector Laboratories, USA
DPX Sigma-Adrich, MI, USA
Haematoxylin Sigma-Adrich, MI, USA
Xylene Sigma-Adrich, MI, USA
Hydrogen peroxide Sigma-Adrich, MI, USA
Rabbit IgG Sigma-Adrich, MI, USA
Texas red-avidin Invitrogen, CA, USA
FITC-avidin Invitrogen, CA, USA
Streptavidin Vector Laboratories, USA
Normal Horse Serum Vector Laboratories, USA
DAPI Vector Laboratories, USA
TGF-β1 R&D Systems Inc, USA
Table 8.3: In vitro reagents.
Antibody Code Supplier
RGS5 sc-28492 Santa Cruz
Desmin ab15200 Abcam
α-SMA A2547 Sigma-Aldrich
PDGFR-β sc-432 Santa Cruz
PDGFR-β-Biotin ab93533 Abcam
NG2 ab5320 Millipore
NG2 4235 Cell Signaling
NG2-Alexa488 ab5320A4 Millipore
CD31-FITC 102406 Bio Legend
DyLight-649 406406 Bio Legend
DyLight-488 406404 Bio Legend
Table 8.4: List of all the antibodies used in vitro.
Consumables
Item Supplier
Syringes Becton Dickinson Ltd, UK
2.0ml eppendorf tubes Sarsted AG & Co, Germany
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25G and 27G needles Becton Dickinson Ltd, UK
4/0 Ethilon Ethicon Ltd, UK
5/0 mersilk non-adsorbable suture Ethicon Ltd, UK
5/0 PDS II suture Ethicon Ltd, UK
Latex examination gloves Kimberly Clarke Ltd, UK
Microscope slides Fisher Scientific, UK
Paper tissue Kimberly Clarke Ltd, UK
Petri dish Corning Inc, UK
Size 15 scalpel blade Swann Morton, UK
Sterile Biogel gloves Regent Medical Ltd, UK
Cotton swabs Shermond Surgical Supply Ltd, UK
Table 8.5: In vivo consumables.
Equipment
Item Supplier
C-clamp Medical Workshop, University of
Sheffield, UK
Chamber pieces Medical Workshop, University of
Sheffield, UK
Confocal Microscope Zeiss LSM510 NLO Upright
Epiluorescence Microscope Nikon Eclipse E600FN
Restrainer (model 84) IITC Life Science, USA
Incubator Brinsea Products Ltd, UK
Sensitive warming pad Cole-Palmer Ltd, UK
Surgical instruments Fine Science Tools, USA
Table 8.6: IVM equipment.
Reagents
Item Supplier
70% IMS Adams Healthcare Ecolab, UK
Betadine surgical scrub Seton Healthcare Group plc, UK
Trigene disinfectant concentrate Medichem International, UK
Table 8.7: In vivo reagents.
Lysis buffer
Reagent Final Concentration
Tris-HCl 50mM
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NaCl(150mM) 150mM
Sodium azide 0.02% (w/v)
SDS 0.1% (w/v)
Igepal CA-630 or Nonidet P-40 1%
Sodium deoxycholate 0.5%
Protease inhibitor 1 tablet for 10ml of buffer
Final pH 8.8
Running buffer 10X
Reagent Final Concentration
Tris base 25mM
Glycin 0.192M
SDS 0.1% (w/v)
Final pH 8.3
Transfer buffer
Reagent Final Concentration
Tris base 3.03g
Glycin 14.10g
SDS 2.5g
dH2O 900ml
Methanol 100ml
Final pH 8.3
SDS 2.5g
Stacking gel
Reagent Final Concentration
dH2O 3ml
tris-HCl pH 8.8 1.25ml
30% acrylamide 650µl
10% APS 50µl
TEMED 5µl
Running gel
Reagent Final Concentration
dH2O 4.85ml
tris-HCl pH 8.8 2.5ml
30% acrylamide 2.5ml
10% APS 50µl
TEMED 5µl
Table 8.8: Western blot reagents composition.
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Formulation as referred to in
the text
Copolymer Amount
[mg]
PMPC-PDPA
PMPC25-PDPA70 18
Rhd-PMPC25-PDPA70 2
PEO-PDPA
PEO113-PDPA70 18
Rhd-PEO113-PDPA70 2
POEGMA-PDPA
POEGMA-PDPA 18
Rhd-POEGMA-PDPA 2
Biotin-PMPC-PDPA
PMPC25-PDPA70 16
Rhd-PMPC25-PDPA70 2
Biotin-PMPC25-PDPA70 2
Maleimide-PMPC-PDPA
PMPC25-PDPA70 16
Rhd-PMPC25-PDPA70 2
Maleimide-PMPC25-PDPA70 2
Maleimide-POEGMA-PDPA
POEGMA25-PDPA70 16
Rhd-POEGMA-PDPA 2
Maleimide-PMPC25-PDPA70 2
Table 8.9: Composition of the different polymersomes formulations use. The
amounts reported are intented for the reparation of 2ml of polymeromses in film
hydration or to be dissolved in 2ml of Phosphate Buffer Saline pH 2 (PBS2) using
pH switch technique.
174
CHAPTER 9
ANNEX
9.1 Binding efficiency (BE)
Binding efficiency (BE) was defined as the amount of polymersomes up-taken
by the cells in the unit of time. BE was calculated by combining data from
Reverse Phase-High Pressure Liquid Chromatography (RP-HPLC) (amount of
polymersomes) and Fluorescence Activated Cell Sorting (FACS) (sorting of cell
population positive for polymersomes) analysis. The work flow for the analysis
is reported in figure 9.1.
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x'=ln(x)
FACS
values
FACS
values
RP-HPLC values,
x in logarithmic scale
Figure 9.1: Binding efficiency calculation. FACS results were plotted in logarith-
mic scale and the time-point at which the plateau of maximal uptake was reached
(tp) was graphically extrapolated. The number of vesicles per cell internalised was
derived from RP-HPLC data at t = tp.
RP-HPLC and FACS analysis were performed comparing 10% rhodamine
labelled Polyethylen Oxide-poly(2-(diisopropylamino)ethyl methacrylate) (PEO-
PDPA) and
Poly(2 - methacryloxyethyl-phosphorylcholine)-poly( 2 -(diisopropylamino)ethyl
methacrylate) (PMPC-PDPA) polymersomes. Cells used were Mouse Fibrosar-
coma Cells expressing VEGF120 isoform (MFC120), Mouse Fibrosarcoma Cells
expressing VEGF188 isoform (MFC188) and 10T1/2. Results are reported in fig-
ure 9.2-9.3. Consistently with the reported profile of uptake described in section
4, PMPC-PDPA polymersomes were up-taken faster than PEO-PDPA polymer-
somes. It was also confirmed higher uptake from Mouse Fibrosarcoma Cell (MFC)
compared to 10T1/2. There was no significant difference between MFC120 and
MFC188 (p>0.05).
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Figure 9.2: RP-HPLC uptake results. PMPC-PDPA (solid lines) is up-takes
faster than PEO-PDPA, with no significant difference (p>0.05) between MFC188
(red lines) and MFC120 (black lines). 10T1/2 (blue lines) have very low uptake of
PEO-PDPA, and the uptake of PMPC-PDPA is higher than PEO-PDPA, however
it is lower than the uptake of the same formulation in MFC cell lines. N=3, ±SD.
Figure 9.3: FACS uptake results. PMPC-PDPA (solid lines) is up-takes faster
than PEO-PDPA, with no significant difference (p>0.05) between MFC188 (red
lines), MFC120 (black lines) and 10T1/2 (blue lines). Uptake of PEO-PDPA has
no significant difference (p>0.05) between the three cell lines up to 6h, however
at 24h there is a significant difference (p<0.05) between MFC cell lines (higher
uptake) and 10T1/2. N=3, ±SD.
To calculate BE, it was critical to reach a plateau of uptake. with PEO-PDPA
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this was not achieved in the time limit of the analysis. The value of maximal up-
take can be mathematically extrapolated, however this would introduce inaccu-
racy. For this reason the calculation of BE was limited to the two MFC cell types.
BE of PMPC-PDPA was significantly higher (p>0.05) than BE of PEO-PDPA
polymersomes, and there was no significant difference (p>0.05) between MFC120
and MFC188 (9.4). The method provided a useful absolute term of comparison
between uptake of different formulations form different cell types. However the
technique was not developed further as it required to perform both FACS and
RP-HPLC for any given combination of polymersome formulation and cell type.
This was not advisable in fast, high throughput screening.
Figure 9.4: Binding efficiency for PEO-PDPA and PMPC-PDPA in MFC188
and MFC120. PMPC-PDPA had greater BE compared to PEO-PDPA, while
there was no significant difference between MFC120 and MFC188. N=3, ±SD.
9.2 FACS for in flow uptake
In section 4 FACS results were reported as fluorescence intensity variation
over time. This was useful to compare imaging and FACS results. However,
FACS results can also be expressed as variation of percentage of cells positive
for polymersomes over time. In this case there is no information on magnitude
of uptake, but only on the percentage of cells that are up-taking polymersomes
at a higher rate than a fixed threshold. For this reasons the two plots can be
different, as it is possible that all cells are up-taking polymersomes, therefore the
percentage of population is high, however the uptake could be slow, resulting in
low magnitude of uptake. This can be observed in the plots here reported (9.5-
9.7) when compared to plots 4.11, especially for cell types with low uptake (Small
Vessel Endothelial Cells (SVECs) and 10T1/2). Furthermore, it can be observed
how FACS uptake curves expressed as percentage of population reached a plateau
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for PMPC-PDPA and MFC188 and SVECs, but no plateau was observed in
curves expressed as variation of intensity. This suggested that for fast uptake
polymersomes all cells became positive for polymersomes, and vesicles continued
to accumulate within the cells increasing the intensity of the fluorescence signal.
Figure 9.5: Uptake of PMPC-PDPA and poly(oligo(ethylene glycol)
methacrylate)-poly( 2 -(diisopropylamino)ethyl methacrylate) (POEGMA-
PDPA) rhodamine labelled polymersomes by MFC188. FACS data expressed as
percentage of cells positive for rhodamine labelled polymersomes. N=3, ±SD.
Figure 9.6: Uptake of PMPC-PDPA and POEGMA-PDPA rhodamine labelled
polymersomes by SVECs. FACS data expressed as percentage of cells positive for
rhodamine labelled polymersomes. N=3, ±SD.
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Figure 9.7: Uptake of PMPC-PDPA and POEGMA-PDPA rhodamine labelled
polymersomes by 10T1/2. FACS data expressed as percentage of cells positive for
rhodamine labelled polymersomes. N=3, ±SD.
9.3 In vivo epifluorescence imaging
The epifluorescence microscope routinely used to asses tumour establishment
in Dorsal Skinfold Chamber (DSC) was also used to acquire fluorescence image
of injected polymersomes and for image analysis. Representative images acquired
equipping the microscope with a 2.5X objective and a 20X objective are reported
in figure 9.8. Images were acquired 5min after the injection of rhodamine labelled
POEGMA-PDPA polymersomes. In 2.5X and 20X transmitted light images (9.8-
a,c) vessels can be observed in dark over brighter stroma, however in 20X images
the contrast was significantly reduced. As was observed in confocal images (5.3),
at 5min after injection vessel in rhodamine channel are highlighted in bright over
dark background.
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(a) Transmitted light, epifluorescence, 2.5X (b) Rhodamine, epifluorescence, 2.5X
(c) Transmitted light, epifluorescence, 20X (d) Rhodamine, epifluorescence, 20X
Figure 9.8: DSC images obtained with different magnification, epifluorescence
microscopy. All images were acquired 5min after Intra Venous (i.v.) injection
of rhodamine labelled POEGMA-PDPA polymersomes. On the left (a, c) trans-
mitted light pictures, on the right (b, d) fluorescence pictures. Images (a, b) were
acquired with a epifluorescence microscope equipped with a 2.5X objective, images
(c, d) using the same microscope equipped with a 20X objective. Note how, in the
rhodamine channel, vessels appeared bright over darker tumour stroma. Bar(a,
b) 710µm; (c, d) 90µm.
A time lapse of both formulations is reported in figure 9.9-9.10 for 2.5X and
20X magnification respectively. In both cases it was observed that at early time
points vessels were highlighted by polymersomes in the rhodamine channel, how-
ever at later time points vessels appeared in dark over brighter background. This
supported confocal analysis results and suggested polymersomes extravasation
and accumulation within tumour via Enhanced Permeation and Retention (EPR)
effect.
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(a) Transmitted light, 2min (b) Rhodamine, 2min
(c) Transmitted light, 30min (d) Rhodamine, 30min
(e) Transmitted light, 15h (f) Rhodamine, 15h
Figure 9.9: MFC188 tumour microvasculature imaged in epifluorescence, 2.5X
objective. Note how between 2min and 30min after injection the tumour vascu-
lature gradually became brighter and the contrast increased, while at 15h vessels
appeared dark over brighter stroma. Tumour region of the image was manually
masked using the image analysis software developed (sec. 3.6). Bar 710µm.
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(a) TL, 2min (b) Rhodamine, 2min
(c) TL, 30min (d) Rhodamine, 30min
(e) TL, 15h (f) Rhodamine, 15h
Figure 9.10: MFC188 tumour microvasculature imaged in epifluorescence, 20X
objective. Note how between 2min and 30min after injection the tumour vascu-
lature gradually became brighter and the contrast increased, while at 15h vessels
appeared dark over brighter stroma. Tumour region of the image was manually
masked using the image analysis software developed (sec. 3.6). Bar 90µm.
Images were analysed using the algorithm described in section 3.6 to assess
polymersomes intra-tumour distribution. Results for both 2.5X and 20X magni-
fication confirmed what observed in confocal microscopy: at early time points the
vessels have higher contribute to fluorescence signal strength compared to tumour
stroma, while at later time point the relative contribution was reversed. However,
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epifluorescence imaging was affected by out-of-focus light, limiting sensitivity and
accuracy of the analysis (see 5.6-5.7 compared to 9.11-9.12).
Figure 9.11: POEGMA-PDPA in vivo image analysis. Data are represented as
overall mean intensity of rhodamine signal in the tumour area (right axis) overlaid
with a break down of the relative contribution of vessels, edges and tumour stroma
to the signal intensity (left axis, coloured bars). Epifluorescence microscopy, 2.5X
objective. N=2.
184
9. Annex 9.3. IN VIVO EPIFLUORESCENCE IMAGING
Figure 9.12: POEGMA-PDPA in vivo image analysis. Data are represented as
overall mean intensity of rhodamine signal in the tumour area (right axis) overlaid
with a break down of the relative contribution of vessels, edges and tumour stroma
to the signal intensity (left axis, coloured bars). Epifluorescence microscopy, 20X
objective. N=2.
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